Ligand source activities (1 row/activity)



Get vendors


Ligands Receptor Assay information Chemical information
Sel. page Common
name		 GPCRdb ID #Vendors Reference
ligand		 Fold selectivity
(Potency)		 # tested GPCRs
(Potency)		 Species p-value
(-log)		 Type Activity
Relation		 Activity
Value		 Assay Type Assay Description Source Mol
weight		 Rot
Bonds		 H don H acc LogP Smiles DOI
44354055 114710 0 None - 1 Human 8.0 pEC50 = 8 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL 1041 20 8 8 2.8 COc1c(I)cc(C[C@H](NC(=O)[C@H](Cc2ccc(Cl)c(Cl)c2)NC(=O)[C@H](C)N)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)cc1I 10.1021/jm00020a029
CHEMBL334510 114710 0 None - 1 Human 8.0 pEC50 = 8 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL 1041 20 8 8 2.8 COc1c(I)cc(C[C@H](NC(=O)[C@H](Cc2ccc(Cl)c(Cl)c2)NC(=O)[C@H](C)N)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)cc1I 10.1021/jm00020a029
CHEMBL1556461 207060 0 None - 1 Human 8.0 pEC50 = 8 Functional
Evaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None C[C@H](N)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CCCCN=C(N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O 10.1021/jm00020a029
11803290 106167 0 None - 1 Human 7.0 pEC50 = 7 Functional
Concentration of compound required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration of compound required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 765 20 10 8 0.8 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cccs1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143277 106167 0 None - 1 Human 7.0 pEC50 = 7 Functional
Concentration of compound required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration of compound required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 765 20 10 8 0.8 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cccs1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
9962227 99182 0 None - 1 Human 6.0 pEC50 = 6 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 763 18 9 8 2.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccc3ccccc23)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL284285 99182 0 None - 1 Human 6.0 pEC50 = 6 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 763 18 9 8 2.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccc3ccccc23)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280767 114086 0 None - 1 Human 6.0 pEC50 = 6 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 577 15 9 8 -1.3 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33377 114086 0 None - 1 Human 6.0 pEC50 = 6 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 577 15 9 8 -1.3 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
9960837 115034 0 None - 1 Human 6.0 pEC50 = 6 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 629 15 7 7 1.7 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cnc2ccccc2n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33532 115034 0 None - 1 Human 6.0 pEC50 = 6 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 629 15 7 7 1.7 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cnc2ccccc2n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL115543 206761 16 None - 1 Human 6.0 pEC50 = 6 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
CHEMBL407378 210911 0 None - 1 Human 5.0 pEC50 = 5.0 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O 10.1021/jm00020a029
44281172 99213 0 None - 1 Human 5.0 pEC50 = 5.0 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 589 15 9 9 -0.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1cccs1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL284474 99213 0 None - 1 Human 5.0 pEC50 = 5.0 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 589 15 9 9 -0.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1cccs1)C(N)=O 10.1016/s0960-894x(99)00197-3
9875337 98790 0 None - 1 Human 6.0 pEC50 = 6.0 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 747 18 9 8 2.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccccc2Cl)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL281753 98790 0 None - 1 Human 6.0 pEC50 = 6.0 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 747 18 9 8 2.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccccc2Cl)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
10461499 23824 0 None - 1 Human 4.9 pEC50 = 4.9 Functional
Effective concentration for stimulation of platelet aggregationEffective concentration for stimulation of platelet aggregation
ChEMBL 617 20 8 7 -0.9 CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CCN)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL133808 23824 0 None - 1 Human 4.9 pEC50 = 4.9 Functional
Effective concentration for stimulation of platelet aggregationEffective concentration for stimulation of platelet aggregation
ChEMBL 617 20 8 7 -0.9 CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CCN)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL337126 209846 0 None - 1 Human 6.9 pEC50 = 6.9 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCCN=C(N)N)C(N)=O 10.1021/jm00020a029
44280949 102241 0 None - 1 Human 5.9 pEC50 = 5.9 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 651 15 7 5 3.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc2c(c1)-c1ccccc1-2)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL30484 102241 0 None - 1 Human 5.9 pEC50 = 5.9 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 651 15 7 5 3.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc2c(c1)-c1ccccc1-2)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
9851501 116721 0 None - 1 Human 5.9 pEC50 = 5.9 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 593 15 8 7 0.7 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc(N)nc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33946 116721 0 None - 1 Human 5.9 pEC50 = 5.9 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 593 15 8 7 0.7 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc(N)nc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL336623 209839 1 None - 1 Human 5.9 pEC50 = 5.9 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CN)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
44280660 99416 0 None - 1 Human 4.9 pEC50 = 4.9 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 617 15 7 6 2.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc2ccccc2o1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL285915 99416 0 None - 1 Human 4.9 pEC50 = 4.9 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 617 15 7 6 2.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc2ccccc2o1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL131912 206955 0 None - 1 Human 6.9 pEC50 = 6.9 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
44280685 99290 0 None - 1 Human 5.9 pEC50 = 5.9 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 585 15 7 8 0.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1csnn1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL285018 99290 0 None - 1 Human 5.9 pEC50 = 5.9 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 585 15 7 8 0.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1csnn1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL132849 206969 0 None - 1 Human 5.9 pEC50 = 5.9 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
CHEMBL132292 206959 0 None - 1 Human 6.9 pEC50 = 6.9 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@H](C)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
44280899 114287 0 None - 1 Human 4.9 pEC50 = 4.9 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 578 15 7 6 1.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccccn1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33394 114287 0 None - 1 Human 4.9 pEC50 = 4.9 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 578 15 7 6 1.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccccn1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44281047 167264 0 None - 1 Human 4.9 pEC50 = 4.9 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 752 18 10 8 2.0 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2c[nH]c3ccccc23)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL430734 167264 0 None - 1 Human 4.9 pEC50 = 4.9 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 752 18 10 8 2.0 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2c[nH]c3ccccc23)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44354285 22497 0 None - 1 Human 6.8 pEC50 = 6.8 Functional
Evaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregation
ChEMBL 1147 26 12 10 0.3 C[C@H](N)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CCCCN=C(N)N)C(=O)NC(Cc1cc(I)c(O)c(I)c1)C(N)=O 10.1021/jm00020a029
CHEMBL132734 22497 0 None - 1 Human 6.8 pEC50 = 6.8 Functional
Evaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregation
ChEMBL 1147 26 12 10 0.3 C[C@H](N)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CCCCN=C(N)N)C(=O)NC(Cc1cc(I)c(O)c(I)c1)C(N)=O 10.1021/jm00020a029
44354055 114710 0 None - 1 Human 5.8 pEC50 = 5.8 Functional
Evaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregation
ChEMBL 1041 20 8 8 2.8 COc1c(I)cc(C[C@H](NC(=O)[C@H](Cc2ccc(Cl)c(Cl)c2)NC(=O)[C@H](C)N)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)cc1I 10.1021/jm00020a029
CHEMBL334510 114710 0 None - 1 Human 5.8 pEC50 = 5.8 Functional
Evaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregation
ChEMBL 1041 20 8 8 2.8 COc1c(I)cc(C[C@H](NC(=O)[C@H](Cc2ccc(Cl)c(Cl)c2)NC(=O)[C@H](C)N)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)cc1I 10.1021/jm00020a029
CHEMBL130147 206943 0 None - 1 Human 4.8 pEC50 = 4.8 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
CHEMBL1556461 207060 0 None - 1 Human 6.8 pEC50 = 6.8 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None C[C@H](N)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CCCCN=C(N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O 10.1021/jm00020a029
44280608 99641 0 None - 1 Human 5.8 pEC50 = 5.8 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 731 18 9 8 1.8 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C(F)=C/c2ccccc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL287468 99641 0 None - 1 Human 5.8 pEC50 = 5.8 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 731 18 9 8 1.8 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C(F)=C/c2ccccc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL2431718 208717 0 None 44 2 Human 6.8 pEC50 = 6.8 Functional
Agonist activity at human PAR1 expressed in African green monkey COS7 cells assessed as stimulation of inositol triphosphate productionAgonist activity at human PAR1 expressed in African green monkey COS7 cells assessed as stimulation of inositol triphosphate production
ChEMBL None None None CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C 10.1021/jm400638v
10747898 106217 0 None - 1 Human 5.8 pEC50 = 5.8 Functional
Effective concentration for stimulation of platelet aggregationEffective concentration for stimulation of platelet aggregation
ChEMBL 798 20 11 7 1.2 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc2ccccc2[nH]1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143683 106217 0 None - 1 Human 5.8 pEC50 = 5.8 Functional
Effective concentration for stimulation of platelet aggregationEffective concentration for stimulation of platelet aggregation
ChEMBL 798 20 11 7 1.2 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc2ccccc2[nH]1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44826172 99526 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 758 19 9 10 1.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccc([N+](=O)[O-])c2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL286648 99526 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 758 19 9 10 1.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccc([N+](=O)[O-])c2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44826171 116366 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 758 19 9 10 1.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccccc2[N+](=O)[O-])n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33818 116366 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 758 19 9 10 1.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccccc2[N+](=O)[O-])n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL134081 206983 0 None - 1 Human 4.7 pEC50 = 4.7 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
CHEMBL33473 209654 18 None - 1 Human 6.7 pEC50 = 6.7 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O 10.1021/jm00020a029
CHEMBL335845 209820 0 None - 1 Human 6.7 pEC50 = 6.7 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
44280804 99216 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 578 15 7 6 1.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cccnc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL284498 99216 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 578 15 7 6 1.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cccnc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL263369 208826 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(N)=O 10.1021/jm00020a029
44280877 116371 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 589 15 9 8 0.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](CC1CCCCC1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33820 116371 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 589 15 9 8 0.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](CC1CCCCC1)C(N)=O 10.1016/s0960-894x(99)00197-3
9875040 113925 0 None - 1 Human 4.7 pEC50 = 4.7 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 713 18 9 8 1.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccccc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33318 113925 0 None - 1 Human 4.7 pEC50 = 4.7 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 713 18 9 8 1.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccccc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL337502 209851 0 None - 1 Human 4.7 pEC50 = 4.7 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None COc1ccc(C[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)cc1 10.1021/jm00020a029
44280935 99627 0 None - 1 Human 5.6 pEC50 = 5.6 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 747 18 9 8 2.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccc(Cl)c2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL287368 99627 0 None - 1 Human 5.6 pEC50 = 5.6 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 747 18 9 8 2.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccc(Cl)c2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL133789 206980 0 None - 1 Human 4.6 pEC50 = 4.6 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(N)=O 10.1021/jm00020a029
44281237 116229 0 None - 1 Human 5.6 pEC50 = 5.6 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 604 16 7 6 1.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)/C=C/c1cccnc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33742 116229 0 None - 1 Human 5.6 pEC50 = 5.6 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 604 16 7 6 1.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)/C=C/c1cccnc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
90663359 106188 0 None - 1 Human 6.6 pEC50 = 6.6 Functional
Effective concentration for stimulation of platelet aggregationEffective concentration for stimulation of platelet aggregation
ChEMBL 761 21 8 7 0.8 CC(=O)NCCC(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143325 106188 0 None - 1 Human 6.6 pEC50 = 6.6 Functional
Effective concentration for stimulation of platelet aggregationEffective concentration for stimulation of platelet aggregation
ChEMBL 761 21 8 7 0.8 CC(=O)NCCC(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL334746 209655 0 None - 1 Human 6.6 pEC50 = 6.6 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(Cl)c(Cl)c1)NC(=O)[C@H](C)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
CHEMBL33473 209654 18 None - 1 Human 6.6 pEC50 = 6.6 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O 10.1016/s0960-894x(99)00197-3
44280607 167288 0 None - 1 Human 4.6 pEC50 = 4.6 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 789 19 9 8 3.0 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C(=C/c2ccccc2)c2ccccc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL430930 167288 0 None - 1 Human 4.6 pEC50 = 4.6 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 789 19 9 8 3.0 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C(=C/c2ccccc2)c2ccccc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL130930 206948 0 None - 1 Human 4.6 pEC50 = 4.6 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
9810477 98321 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 719 18 9 9 1.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccs2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL278216 98321 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 719 18 9 9 1.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccs2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44281081 119198 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 592 15 8 6 1.3 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cccc(N)c1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL34738 119198 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 592 15 8 6 1.3 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cccc(N)c1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44354323 24079 0 None - 1 Human 7.5 pEC50 = 7.5 Functional
Evaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregation
ChEMBL 1021 26 12 10 -0.4 C[C@H](N)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CCCCN=C(N)N)C(=O)NC(Cc1ccc(O)c(I)c1)C(N)=O 10.1021/jm00020a029
CHEMBL134036 24079 0 None - 1 Human 7.5 pEC50 = 7.5 Functional
Evaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregation
ChEMBL 1021 26 12 10 -0.4 C[C@H](N)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CCCCN=C(N)N)C(=O)NC(Cc1ccc(O)c(I)c1)C(N)=O 10.1021/jm00020a029
CHEMBL334746 209655 0 None - 1 Human 6.5 pEC50 = 6.5 Functional
Evaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activity of Radio-ligand Peptides upon the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(Cl)c(Cl)c1)NC(=O)[C@H](C)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
44280768 116672 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 569 14 9 8 -0.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@H](C(N)=O)c1ccccc1 10.1016/s0960-894x(99)00197-3
CHEMBL33940 116672 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 569 14 9 8 -0.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@H](C(N)=O)c1ccccc1 10.1016/s0960-894x(99)00197-3
CHEMBL434623 211911 0 None - 1 Human 4.5 pEC50 = 4.5 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
CHEMBL264249 208865 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(N)=O 10.1021/jm00020a029
CHEMBL3143260 209401 0 None - 1 Human 4.5 pEC50 = 4.5 Functional
Effective concentration for stimulation of platelet aggregationEffective concentration for stimulation of platelet aggregation
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
10461499 23824 0 None - 1 Human 4.5 pEC50 = 4.5 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL 617 20 8 7 -0.9 CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CCN)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
CHEMBL133808 23824 0 None - 1 Human 4.5 pEC50 = 4.5 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL 617 20 8 7 -0.9 CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CCN)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
11803426 106216 0 None - 1 Human 5.4 pEC50 = 5.4 Functional
Effective concentration for stimulation of platelet aggregationEffective concentration for stimulation of platelet aggregation
ChEMBL 793 20 10 7 1.4 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1ccc(Cl)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143682 106216 0 None - 1 Human 5.4 pEC50 = 5.4 Functional
Effective concentration for stimulation of platelet aggregationEffective concentration for stimulation of platelet aggregation
ChEMBL 793 20 10 7 1.4 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1ccc(Cl)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
9937578 99495 0 None - 1 Human 5.4 pEC50 = 5.4 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 555 15 7 8 0.3 NCCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL286430 99495 0 None - 1 Human 5.4 pEC50 = 5.4 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 555 15 7 8 0.3 NCCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL133837 206981 0 None - 1 Human 6.4 pEC50 = 6.4 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
CHEMBL263319 208822 0 None - 1 Human 4.4 pEC50 = 4.4 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
44280822 116045 0 None - 1 Human 5.4 pEC50 = 5.4 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 594 15 8 8 0.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1nccnc1N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33629 116045 0 None - 1 Human 5.4 pEC50 = 5.4 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 594 15 8 8 0.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1nccnc1N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
9895920 99558 0 None - 1 Human 6.3 pEC50 = 6.3 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 656 15 7 6 1.9 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cncc(Br)c1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL286837 99558 0 None - 1 Human 6.3 pEC50 = 6.3 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 656 15 7 6 1.9 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cncc(Br)c1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44281079 116717 0 None - 1 Human 5.3 pEC50 = 5.3 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 612 15 7 6 1.8 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc(Cl)nc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33945 116717 0 None - 1 Human 5.3 pEC50 = 5.3 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 612 15 7 6 1.8 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc(Cl)nc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280955 118787 0 None - 1 Human 5.3 pEC50 = 5.3 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 611 15 8 6 0.9 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccc2[nH]cnc2c1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL34387 118787 0 None - 1 Human 5.3 pEC50 = 5.3 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 611 15 8 6 0.9 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccc2[nH]cnc2c1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL2370701 208172 0 None - 1 Human 6.3 pEC50 = 6.3 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(N)=O 10.1021/jm00020a029
CHEMBL337490 209850 0 None - 1 Human 6.3 pEC50 = 6.3 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(Cl)c(Cl)c1)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
44280651 114934 0 None - 1 Human 5.3 pEC50 = 5.3 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 781 18 9 8 2.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccc(C(F)(F)F)cc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33506 114934 0 None - 1 Human 5.3 pEC50 = 5.3 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 781 18 9 8 2.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccc(C(F)(F)F)cc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
9961058 99489 0 None - 1 Human 6.3 pEC50 = 6.3 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 645 15 7 7 1.8 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc(=O)c2ccccc2o1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL286382 99489 0 None - 1 Human 6.3 pEC50 = 6.3 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 645 15 7 7 1.8 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc(=O)c2ccccc2o1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280650 114621 0 None - 1 Human 4.3 pEC50 = 4.3 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 747 18 9 8 2.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccc(Cl)cc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33435 114621 0 None - 1 Human 4.3 pEC50 = 4.3 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 747 18 9 8 2.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccc(Cl)cc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280649 112160 0 None - 1 Human 5.3 pEC50 = 5.3 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 743 19 8 9 1.3 COc1ccc(/C=C/C(=O)Nc2n[nH]c(C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc3ccccc3)C(N)=O)n2)cc1 10.1016/s0960-894x(99)00197-3
CHEMBL33033 112160 0 None - 1 Human 5.3 pEC50 = 5.3 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 743 19 8 9 1.3 COc1ccc(/C=C/C(=O)Nc2n[nH]c(C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc3ccccc3)C(N)=O)n2)cc1 10.1016/s0960-894x(99)00197-3
44280667 102473 0 None - 1 Human 5.2 pEC50 = 5.2 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 738 18 9 9 1.4 N#Cc1ccc(/C=C/C(=O)Nc2nc(C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc3ccccc3)C(N)=O)n[nH]2)cc1 10.1016/s0960-894x(99)00197-3
CHEMBL30635 102473 0 None - 1 Human 5.2 pEC50 = 5.2 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 738 18 9 9 1.4 N#Cc1ccc(/C=C/C(=O)Nc2nc(C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc3ccccc3)C(N)=O)n[nH]2)cc1 10.1016/s0960-894x(99)00197-3
CHEMBL3143259 209400 0 None - 1 Human 4.2 pEC50 = 4.2 Functional
Effective concentration for stimulation of platelet aggregationEffective concentration for stimulation of platelet aggregation
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
90663347 106185 0 None - 1 Human 4.2 pEC50 = 4.2 Functional
Effective concentration for stimulation of platelet aggregationEffective concentration for stimulation of platelet aggregation
ChEMBL 781 21 8 9 0.9 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)NC(=O)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)O 10.1021/jm960455s
CHEMBL3143312 106185 0 None - 1 Human 4.2 pEC50 = 4.2 Functional
Effective concentration for stimulation of platelet aggregationEffective concentration for stimulation of platelet aggregation
ChEMBL 781 21 8 9 0.9 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)NC(=O)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)O 10.1021/jm960455s
CHEMBL133449 206977 0 None - 1 Human 6.2 pEC50 = 6.2 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(Cl)cc1)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
CHEMBL130058 206942 1 None - 1 Human 4.2 pEC50 = 4.2 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](C)C(N)=O 10.1021/jm00020a029
CHEMBL2370948 208220 0 None - 1 Human 6.1 pEC50 = 6.1 Functional
Effective concentration for stimulation of platelet aggregationEffective concentration for stimulation of platelet aggregation
ChEMBL None None None COc1ccc(C[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)cc1 10.1021/jm960455s
9808447 102442 0 None - 1 Human 6.1 pEC50 = 6.1 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 583 15 9 8 -0.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL30612 102442 0 None - 1 Human 6.1 pEC50 = 6.1 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 583 15 9 8 -0.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280585 116478 0 None - 1 Human 6.1 pEC50 = 6.1 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 727 18 8 8 1.7 C/C(=C\c1ccccc1)C(=O)Nc1n[nH]c(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)n1 10.1016/s0960-894x(99)00197-3
CHEMBL33873 116478 0 None - 1 Human 6.1 pEC50 = 6.1 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 727 18 8 8 1.7 C/C(=C\c1ccccc1)C(=O)Nc1n[nH]c(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)n1 10.1016/s0960-894x(99)00197-3
44280936 116020 0 None - 1 Human 5.1 pEC50 = 5.1 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 731 18 9 8 1.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccc(F)cc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33617 116020 0 None - 1 Human 5.1 pEC50 = 5.1 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 731 18 9 8 1.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccc(F)cc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL337875 209853 1 None - 1 Human 6.1 pEC50 = 6.1 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm00020a029
44280683 98946 0 None - 1 Human 5.1 pEC50 = 5.1 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 593 15 8 7 0.7 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cccnc1N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL282733 98946 0 None - 1 Human 5.1 pEC50 = 5.1 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 593 15 8 7 0.7 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cccnc1N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL268064 208993 0 None - 1 Human 5.1 pEC50 = 5.1 Functional
Evaluated for the activation of human thrombin receptor measured by platelet aggregationEvaluated for the activation of human thrombin receptor measured by platelet aggregation
ChEMBL None None None None 10.1021/jm00020a029
44281070 111856 0 None - 1 Human 5.1 pEC50 = 5.1 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 633 15 7 6 2.9 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc2ccccc2s1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL32941 111856 0 None - 1 Human 5.1 pEC50 = 5.1 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 633 15 7 6 2.9 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc2ccccc2s1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL3143248 209396 0 None - 1 Human 5.1 pEC50 = 5.1 Functional
Concentration of compound required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration of compound required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)CCCN)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44281289 118057 0 None - 1 Human 5.0 pEC50 = 5.0 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 599 15 10 9 -0.9 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL34156 118057 0 None - 1 Human 5.0 pEC50 = 5.0 Functional
Activation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombinActivation of human platelet aggregation (gel-filtered platelets) induced by alpha thrombin
ChEMBL 599 15 10 9 -0.9 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O 10.1016/s0960-894x(99)00197-3
121469330 148092 0 None - 1 Human 9.0 pIC50 = 9 Functional
Antagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assayAntagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assay
ChEMBL 474 4 1 5 5.1 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2cc[nH]n2)CC1(F)F 10.1021/acsmedchemlett.6b00327
CHEMBL3939323 148092 0 None - 1 Human 9.0 pIC50 = 9 Functional
Antagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assayAntagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assay
ChEMBL 474 4 1 5 5.1 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2cc[nH]n2)CC1(F)F 10.1021/acsmedchemlett.6b00327
155526775 170616 0 None - 1 Human 8.0 pIC50 = 8 Functional
Antagonist activity at PAR1 in human MDA-MB-231 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human MDA-MB-231 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 1309 45 6 19 5.6 NCCOCCOCCOCCOCCOCCOCCOCCOCCn1cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc2ccc(F)c(F)c2)NC(=O)Nc2ccc3c(CN4CCCC4)nn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)NCc2ccccc2)nn1 10.1021/acsmedchemlett.8b00538
CHEMBL4459024 170616 0 None - 1 Human 8.0 pIC50 = 8 Functional
Antagonist activity at PAR1 in human MDA-MB-231 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human MDA-MB-231 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 1309 45 6 19 5.6 NCCOCCOCCOCCOCCOCCOCCOCCOCCn1cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc2ccc(F)c(F)c2)NC(=O)Nc2ccc3c(CN4CCCC4)nn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)NCc2ccccc2)nn1 10.1021/acsmedchemlett.8b00538
44306762 201411 0 None - 1 Human 7.0 pIC50 = 7 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 817 17 5 6 7.5 NCCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL63966 201411 0 None - 1 Human 7.0 pIC50 = 7 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 817 17 5 6 7.5 NCCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
44306599 201958 0 None - 1 Human 7.0 pIC50 = 7 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 803 16 5 6 7.1 NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL67308 201958 0 None - 1 Human 7.0 pIC50 = 7 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 803 16 5 6 7.1 NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
51003683 75301 0 None - 1 Human 6.0 pIC50 = 6 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 346 6 2 2 4.9 CCCCNc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
CHEMBL2047297 75301 0 None - 1 Human 6.0 pIC50 = 6 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 346 6 2 2 4.9 CCCCNc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
CHEMBL4227548 75301 0 None - 1 Human 6.0 pIC50 = 6 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 346 6 2 2 4.9 CCCCNc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
44338917 161373 0 None - 1 Human 6.0 pIC50 = 6 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 409 8 0 4 5.9 Clc1cccc(CN(CCCN2CCCCC2)c2cc(-c3ccccc3)no2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL415325 161373 0 None - 1 Human 6.0 pIC50 = 6 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 409 8 0 4 5.9 Clc1cccc(CN(CCCN2CCCCC2)c2cc(-c3ccccc3)no2)c1 10.1016/s0960-894x(01)00745-4
44306903 101782 0 None - 1 Human 6.0 pIC50 = 6 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 809 18 6 7 5.8 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL303157 101782 0 None - 1 Human 6.0 pIC50 = 6 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 809 18 6 7 5.8 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
44306404 201219 0 None - 1 Human 6.0 pIC50 = 6 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 813 20 6 7 5.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccccc4C)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL62775 201219 0 None - 1 Human 6.0 pIC50 = 6 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 813 20 6 7 5.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccccc4C)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
44316184 103677 0 None - 1 Human 6.0 pIC50 = 6 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 397 8 3 6 0.1 COC(=O)C(CC(=O)O)NC(=O)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL309531 103677 0 None - 1 Human 6.0 pIC50 = 6 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 397 8 3 6 0.1 COC(=O)C(CC(=O)O)NC(=O)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
51003683 75301 0 None - 1 Human 6.0 pIC50 = 6 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 346 6 2 2 4.9 CCCCNc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
CHEMBL2047297 75301 0 None - 1 Human 6.0 pIC50 = 6 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 346 6 2 2 4.9 CCCCNc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
CHEMBL4227548 75301 0 None - 1 Human 6.0 pIC50 = 6 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 346 6 2 2 4.9 CCCCNc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
137655130 158102 0 None - 1 Human 5.0 pIC50 = 5 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 489 5 2 4 5.7 C[C@@]12CC[C@@H](O)[C@@](C)(CO)[C@H]1CC[C@@]1(CO1)[C@H]2CCc1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1021/acs.jmedchem.7b00951
CHEMBL4092540 158102 0 None - 1 Human 5.0 pIC50 = 5 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 489 5 2 4 5.7 C[C@@]12CC[C@@H](O)[C@@](C)(CO)[C@H]1CC[C@@]1(CO1)[C@H]2CCc1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1021/acs.jmedchem.7b00951
145971090 164483 0 None - 1 Human 4.0 pIC50 = 4 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 323 6 2 3 4.6 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2N=[N+]=[N-])c1 10.1016/j.bmc.2018.04.016
CHEMBL4226195 164483 0 None - 1 Human 4.0 pIC50 = 4 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 323 6 2 3 4.6 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2N=[N+]=[N-])c1 10.1016/j.bmc.2018.04.016
145967675 164544 0 None - 1 Human 4.0 pIC50 = 4 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 370 5 2 2 4.1 C#CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
CHEMBL4227184 164544 0 None - 1 Human 4.0 pIC50 = 4 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 370 5 2 2 4.1 C#CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
44306659 102299 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 820 16 4 6 8.2 CSCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL305188 102299 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 820 16 4 6 8.2 CSCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
137661486 158929 0 None - 1 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 407 3 1 2 6.8 C[C@H]1CC[C@@H]2C(C)(C)[C@H](O)CC[C@@]2(C)[C@@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
CHEMBL4101591 158929 0 None - 1 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 407 3 1 2 6.8 C[C@H]1CC[C@@H]2C(C)(C)[C@H](O)CC[C@@]2(C)[C@@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
145386428 176523 0 None - 1 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assayAntagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assay
ChEMBL 478 6 2 5 4.7 C[C@H]1OC(=O)[C@]2(NCC(=O)O)C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1016/j.bmcl.2020.127046
CHEMBL4633243 176523 0 None - 1 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assayAntagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assay
ChEMBL 478 6 2 5 4.7 C[C@H]1OC(=O)[C@]2(NCC(=O)O)C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1016/j.bmcl.2020.127046
44316560 104297 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 375 7 3 5 0.0 O=C(NCCS(=O)(=O)O)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL310859 104297 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 375 7 3 5 0.0 O=C(NCCS(=O)(=O)O)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
44306660 202126 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 797 20 6 7 5.6 CCN(CC)Cc1cn(Cc2ccc(F)cc2)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC3CCCCC3)ccc12 10.1016/s0960-894x(01)00378-x
CHEMBL68458 202126 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 797 20 6 7 5.6 CCN(CC)Cc1cn(Cc2ccc(F)cc2)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC3CCCCC3)ccc12 10.1016/s0960-894x(01)00378-x
CHEMBL3143271 209408 0 None - 1 Human 6.0 pIC50 = 6.0 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306894 102239 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 806 18 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4cccc(C)c4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL304829 102239 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 806 18 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4cccc(C)c4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
12018762 109146 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 451 8 0 6 5.5 Fc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL322282 109146 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 451 8 0 6 5.5 Fc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
90663563 106218 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 829 22 9 8 2.0 CCC(=O)c1cccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)c1 10.1021/jm960455s
CHEMBL3143684 106218 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 829 22 9 8 2.0 CCC(=O)c1cccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)c1 10.1021/jm960455s
44339029 109204 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 447 8 0 6 5.7 Cc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL322763 109204 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 447 8 0 6 5.7 Cc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
44338929 5768 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 493 10 0 8 5.4 COc1cc(OC)cc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL107919 5768 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 493 10 0 8 5.4 COc1cc(OC)cc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
137632193 156121 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 478 4 1 5 5.4 C[C@@]1(/C=C/c2ccc(-c3cccc(F)c3)cn2)[C@H]2CC[C@@H]3COC(=O)[C@H]3[C@]2(C)CC[C@H]1OC(N)=O 10.1021/acs.jmedchem.7b00951
CHEMBL4069486 156121 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 478 4 1 5 5.4 C[C@@]1(/C=C/c2ccc(-c3cccc(F)c3)cn2)[C@H]2CC[C@@H]3COC(=O)[C@H]3[C@]2(C)CC[C@H]1OC(N)=O 10.1021/acs.jmedchem.7b00951
44339060 9332 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 323 5 2 3 3.5 CC(C)N(CC(O)c1ccc(C#N)cc1)C(=O)Nc1ccccc1 10.1016/s0960-894x(01)00745-4
CHEMBL111689 9332 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 323 5 2 3 3.5 CC(C)N(CC(O)c1ccc(C#N)cc1)C(=O)Nc1ccccc1 10.1016/s0960-894x(01)00745-4
12018759 110711 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 467 8 0 6 6.0 Clc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL326456 110711 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 467 8 0 6 6.0 Clc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
155564785 174947 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 1786 52 6 24 9.3 CC(C)c1cc(-c2ccc(F)cc2)nn2cc(C(=O)N3CCN(C(=O)CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn4cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc5ccc(F)c(F)c5)NC(=O)Nc5ccc6c(CN7CCCC7)nn(Cc7c(Cl)cccc7Cl)c6c5)C(=O)NCc5ccccc5)nn4)CC3(C)C)nc12 10.1021/acsmedchemlett.8b00538
CHEMBL4578092 174947 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 1786 52 6 24 9.3 CC(C)c1cc(-c2ccc(F)cc2)nn2cc(C(=O)N3CCN(C(=O)CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn4cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc5ccc(F)c(F)c5)NC(=O)Nc5ccc6c(CN7CCCC7)nn(Cc7c(Cl)cccc7Cl)c6c5)C(=O)NCc5ccccc5)nn4)CC3(C)C)nc12 10.1021/acsmedchemlett.8b00538
44338929 5768 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 493 10 0 8 5.4 COc1cc(OC)cc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL107919 5768 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 493 10 0 8 5.4 COc1cc(OC)cc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
44339173 8140 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 463 9 0 7 5.4 COc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL109226 8140 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 463 9 0 7 5.4 COc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
10276545 9057 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 463 9 0 7 5.4 COc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL110024 9057 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 463 9 0 7 5.4 COc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
44306349 102129 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 804 18 7 8 5.1 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc([N+](=O)[O-])cc1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3ccc(F)cc3)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL304120 102129 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 804 18 7 8 5.1 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc([N+](=O)[O-])cc1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3ccc(F)cc3)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
44306337 96389 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 800 18 6 8 5.1 Cc1ccccc1Cn1cc(CN2CCCC2)c2ccc(NC(=O)N[C@@H](Cc3ccc([N+](=O)[O-])cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc3ccccc3)cc21 10.1016/s0960-894x(01)00378-x
CHEMBL265227 96389 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 800 18 6 8 5.1 Cc1ccccc1Cn1cc(CN2CCCC2)c2ccc(NC(=O)N[C@@H](Cc3ccc([N+](=O)[O-])cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc3ccccc3)cc21 10.1016/s0960-894x(01)00378-x
44306499 201654 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 815 22 6 7 5.9 CCN(CC)Cc1cn(Cc2cccc(C)c2)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc3ccccc3)ccc12 10.1016/s0960-894x(01)00378-x
CHEMBL65004 201654 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 815 22 6 7 5.9 CCN(CC)Cc1cn(Cc2cccc(C)c2)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc3ccccc3)ccc12 10.1016/s0960-894x(01)00378-x
44328342 206353 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 881 21 8 7 5.2 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)N[C@@H](Cc1ccc(C(=O)c2ccccc2)cc1)C(=O)O 10.1016/s0960-894x(98)00730-6
CHEMBL97780 206353 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 881 21 8 7 5.2 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)N[C@@H](Cc1ccc(C(=O)c2ccccc2)cc1)C(=O)O 10.1016/s0960-894x(98)00730-6
44339157 109267 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 451 8 0 6 5.5 Fc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL323054 109267 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 451 8 0 6 5.5 Fc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL5085826 213220 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysisAntagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysis
ChEMBL None None None CC1=NO[C@@]2(C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@@H](c1ccc(-c3cccc(F)c3)cn1)[C@@H]2C 10.1021/acs.jmedchem.1c02048
CHEMBL5077710 212740 0 None - 1 Human 7.9 pIC50 = 7.9 Functional
Antagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysisAntagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysis
ChEMBL None None None C[C@@H]1[C@@H](C)[C@@H]2CNC[C@@]23C(=O)O[C@H](C)[C@H]3[C@H]1/C=C/c1ccc(-c2ccccc2C#N)cn1 10.1021/acs.jmedchem.1c02048
155549751 173346 0 None 16 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at PAR1 in human MDA-MB-231 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human MDA-MB-231 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 2446 97 6 39 9.5 CC(C)c1cc(-c2ccc(F)cc2)nn2cc(C(=O)N3CCN(C(=O)CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCn4cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc5ccc(F)c(F)c5)NC(=O)Nc5ccc6c(CN7CCCC7)nn(Cc7c(Cl)cccc7Cl)c6c5)C(=O)NCc5ccccc5)nn4)CC3(C)C)nc12 10.1021/acsmedchemlett.8b00538
CHEMBL4540591 173346 0 None 16 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at PAR1 in human MDA-MB-231 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human MDA-MB-231 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 2446 97 6 39 9.5 CC(C)c1cc(-c2ccc(F)cc2)nn2cc(C(=O)N3CCN(C(=O)CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCn4cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc5ccc(F)c(F)c5)NC(=O)Nc5ccc6c(CN7CCCC7)nn(Cc7c(Cl)cccc7Cl)c6c5)C(=O)NCc5ccccc5)nn4)CC3(C)C)nc12 10.1021/acsmedchemlett.8b00538
44339002 9260 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 447 8 0 6 5.7 Cc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL111258 9260 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 447 8 0 6 5.7 Cc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
12018762 109146 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 451 8 0 6 5.5 Fc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL322282 109146 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 451 8 0 6 5.5 Fc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
44306500 167353 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 833 20 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccccc4Cl)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL431369 167353 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 833 20 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccccc4Cl)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
137637794 155473 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 451 5 1 4 5.5 CO[C@@H]1CC[C@@]2(C)[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@@]3(CC[C@@H]2[C@]1(C)CO)CO3 10.1021/acs.jmedchem.7b00951
CHEMBL4062114 155473 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 451 5 1 4 5.5 CO[C@@H]1CC[C@@]2(C)[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@@]3(CC[C@@H]2[C@]1(C)CO)CO3 10.1021/acs.jmedchem.7b00951
137653750 158182 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 439 5 2 4 4.8 C[C@@]12CC[C@@H](O)[C@@](C)(CO)[C@H]1CC[C@@]1(CO1)[C@H]2CCc1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
CHEMBL4093491 158182 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 439 5 2 4 4.8 C[C@@]12CC[C@@H](O)[C@@](C)(CO)[C@H]1CC[C@@]1(CO1)[C@H]2CCc1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
44306337 96389 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 800 18 6 8 5.1 Cc1ccccc1Cn1cc(CN2CCCC2)c2ccc(NC(=O)N[C@@H](Cc3ccc([N+](=O)[O-])cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc3ccccc3)cc21 10.1016/s0960-894x(01)00378-x
CHEMBL265227 96389 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 800 18 6 8 5.1 Cc1ccccc1Cn1cc(CN2CCCC2)c2ccc(NC(=O)N[C@@H](Cc3ccc([N+](=O)[O-])cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc3ccccc3)cc21 10.1016/s0960-894x(01)00378-x
137645208 157423 0 None - 1 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 421 4 1 3 5.9 C[C@H]1CC[C@H]2[C@@](C)(CC[C@@H](O)[C@@]2(C)C=O)[C@@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
CHEMBL4084812 157423 0 None - 1 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 421 4 1 3 5.9 C[C@H]1CC[C@H]2[C@@](C)(CC[C@@H](O)[C@@]2(C)C=O)[C@@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
44306761 168343 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 789 15 5 6 6.8 NCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL438551 168343 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 789 15 5 6 6.8 NCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
44338885 7418 0 None - 1 Human 5.8 pIC50 = 5.8 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 405 9 0 5 5.2 COc1cccc(CN(CCCN2CCCCC2)c2cc(-c3ccccc3)no2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL108716 7418 0 None - 1 Human 5.8 pIC50 = 5.8 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 405 9 0 5 5.2 COc1cccc(CN(CCCN2CCCCC2)c2cc(-c3ccccc3)no2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL3143270 209407 0 None - 1 Human 4.8 pIC50 = 4.8 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@H](CCCN=C(N(C)C)N(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143299 209420 0 None - 1 Human 5.8 pIC50 = 5.8 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccc(N)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
137661676 158805 0 None - 1 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 450 5 2 4 5.1 CNC[C@@]1(C)[C@H]2CC[C@@]3(CO3)[C@@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@]2(C)CC[C@H]1O 10.1021/acs.jmedchem.7b00951
CHEMBL4100310 158805 0 None - 1 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 450 5 2 4 5.1 CNC[C@@]1(C)[C@H]2CC[C@@]3(CO3)[C@@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@]2(C)CC[C@H]1O 10.1021/acs.jmedchem.7b00951
CHEMBL3143317 209429 0 None - 1 Human 4.8 pIC50 = 4.8 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143311 209425 0 None - 1 Human 5.8 pIC50 = 5.8 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL5078821 212816 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysisAntagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysis
ChEMBL None None None C[C@H]1OC(=O)[C@@H]2CC3(NC(=O)NC3=O)[C@@H](C)[C@H](c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/acs.jmedchem.1c02048
155549751 173346 0 None 16 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 2446 97 6 39 9.5 CC(C)c1cc(-c2ccc(F)cc2)nn2cc(C(=O)N3CCN(C(=O)CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCn4cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc5ccc(F)c(F)c5)NC(=O)Nc5ccc6c(CN7CCCC7)nn(Cc7c(Cl)cccc7Cl)c6c5)C(=O)NCc5ccccc5)nn4)CC3(C)C)nc12 10.1021/acsmedchemlett.8b00538
CHEMBL4540591 173346 0 None 16 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 2446 97 6 39 9.5 CC(C)c1cc(-c2ccc(F)cc2)nn2cc(C(=O)N3CCN(C(=O)CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCn4cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc5ccc(F)c(F)c5)NC(=O)Nc5ccc6c(CN7CCCC7)nn(Cc7c(Cl)cccc7Cl)c6c5)C(=O)NCc5ccccc5)nn4)CC3(C)C)nc12 10.1021/acsmedchemlett.8b00538
145386406 176946 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assayAntagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assay
ChEMBL 459 5 1 5 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](NCC#N)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1016/j.bmcl.2020.127046
CHEMBL4639789 176946 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assayAntagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assay
ChEMBL 459 5 1 5 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](NCC#N)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1016/j.bmcl.2020.127046
9919038 166175 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 845 17 7 6 6.7 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL428311 166175 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 845 17 7 6 6.7 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL3143290 209418 0 None - 1 Human 4.8 pIC50 = 4.8 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
9832212 203241 4 None - 1 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/j.bmc.2018.04.016
CHEMBL4226137 203241 4 None - 1 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/j.bmc.2018.04.016
CHEMBL7642 203241 4 None - 1 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/j.bmc.2018.04.016
CHEMBL3143254 209398 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN)C(N)=O 10.1021/jm960455s
44306697 102259 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 846 17 6 6 6.9 NC(=O)NCCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL304924 102259 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 846 17 6 6 6.9 NC(=O)NCCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
137638549 156323 0 None - 1 Human 4.7 pIC50 = 4.7 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 435 3 1 4 5.3 C[C@@]1(/C=C/c2ccc(-c3cccc(F)c3)cn2)[C@@H](O)CC[C@]2(C)[C@@H]1CC[C@@H]1COC(=O)[C@H]12 10.1021/acs.jmedchem.7b00951
CHEMBL4071756 156323 0 None - 1 Human 4.7 pIC50 = 4.7 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 435 3 1 4 5.3 C[C@@]1(/C=C/c2ccc(-c3cccc(F)c3)cn2)[C@@H](O)CC[C@]2(C)[C@@H]1CC[C@@H]1COC(=O)[C@H]12 10.1021/acs.jmedchem.7b00951
10161572 5476 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 458 8 0 7 5.2 N#Cc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL107667 5476 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 458 8 0 7 5.2 N#Cc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
1048267 32212 87 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 360 5 2 2 4.4 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
CHEMBL1411333 32212 87 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 360 5 2 2 4.4 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
17222599 169203 3 None - 1 Human 6.7 pIC50 = 6.7 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 360 5 2 2 3.8 CCCNC(=O)c1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
CHEMBL4438936 169203 3 None - 1 Human 6.7 pIC50 = 6.7 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 360 5 2 2 3.8 CCCNC(=O)c1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
CHEMBL5084411 213142 0 None - 1 Human 8.7 pIC50 = 8.7 Functional
Antagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysisAntagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysis
ChEMBL None None None C[C@H]1OC(=O)[C@]2(O)CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@H]12 10.1021/acs.jmedchem.1c02048
9832212 203241 4 None - 1 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1021/acsmedchemlett.8b00538
CHEMBL4226137 203241 4 None - 1 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1021/acsmedchemlett.8b00538
CHEMBL7642 203241 4 None - 1 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1021/acsmedchemlett.8b00538
9832212 203241 4 None - 1 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/j.bmc.2018.04.016
CHEMBL4226137 203241 4 None - 1 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/j.bmc.2018.04.016
CHEMBL7642 203241 4 None - 1 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/j.bmc.2018.04.016
9825804 203782 0 None - 1 Human 7.7 pIC50 = 7.7 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 466 8 3 5 2.9 O=C(O)C[C@H](NC(=O)[C@@H]1CCCN(C(=O)CCC2CCNCC2)C1)c1cnc2ccccc2c1 10.1016/0960-894X(96)00438-6
CHEMBL80623 203782 0 None - 1 Human 7.7 pIC50 = 7.7 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 466 8 3 5 2.9 O=C(O)C[C@H](NC(=O)[C@@H]1CCCN(C(=O)CCC2CCNCC2)C1)c1cnc2ccccc2c1 10.1016/0960-894X(96)00438-6
10095734 203820 0 None - 1 Human 7.7 pIC50 = 7.7 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 459 8 3 6 2.1 O=C(O)C[C@H](NC(=O)[C@@H]1CCCN(C(=O)CCC2CCNCC2)C1)c1ccc2c(c1)OCO2 10.1016/0960-894X(96)00438-6
CHEMBL80942 203820 0 None - 1 Human 7.7 pIC50 = 7.7 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 459 8 3 6 2.1 O=C(O)C[C@H](NC(=O)[C@@H]1CCCN(C(=O)CCC2CCNCC2)C1)c1ccc2c(c1)OCO2 10.1016/0960-894X(96)00438-6
CHEMBL3143272 209409 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306698 102238 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 826 15 5 6 7.4 O=C(Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)N[C@@H](Cc1ccc(F)c(F)c1)C(=O)NC(Cc1c[nH]cn1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL304827 102238 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 826 15 5 6 7.4 O=C(Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)N[C@@H](Cc1ccc(F)c(F)c1)C(=O)NC(Cc1c[nH]cn1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
44306404 201219 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 813 20 6 7 5.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccccc4C)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL62775 201219 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 813 20 6 7 5.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccccc4C)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
44338895 9215 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 425 8 0 4 6.4 c1ccc(-c2cc(N(CCCN3CCCCC3)Cc3ccc4ccccc4c3)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL110996 9215 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 425 8 0 4 6.4 c1ccc(-c2cc(N(CCCN3CCCCC3)Cc3ccc4ccccc4c3)on2)cc1 10.1016/s0960-894x(01)00745-4
10771636 106177 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 798 20 11 7 1.2 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1c[nH]c2ccccc12)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143298 106177 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 798 20 11 7 1.2 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1c[nH]c2ccccc12)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306696 101659 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 817 16 5 6 6.7 NC(=O)CCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL302433 101659 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 817 16 5 6 6.7 NC(=O)CCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
44316045 102634 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 353 7 2 4 0.9 CN1CCC(CCC(=O)N2CCCC(C(=O)NCCC(=O)O)C2)CC1 10.1016/0960-894X(96)00438-6
CHEMBL307684 102634 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 353 7 2 4 0.9 CN1CCC(CCC(=O)N2CCCC(C(=O)NCCC(=O)O)C2)CC1 10.1016/0960-894X(96)00438-6
22611792 104647 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 353 7 3 4 1.0 CC(CC(=O)O)NC(=O)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL311426 104647 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 353 7 3 4 1.0 CC(CC(=O)O)NC(=O)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
137639606 156360 0 None - 1 Human 4.7 pIC50 = 4.7 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 478 4 1 5 5.4 C[C@@]1(/C=C/c2ccc(-c3cccc(F)c3)cn2)[C@@H](OC(N)=O)CC[C@]2(C)[C@@H]1CC[C@@H]1COC(=O)[C@H]12 10.1021/acs.jmedchem.7b00951
CHEMBL4072202 156360 0 None - 1 Human 4.7 pIC50 = 4.7 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 478 4 1 5 5.4 C[C@@]1(/C=C/c2ccc(-c3cccc(F)c3)cn2)[C@@H](OC(N)=O)CC[C@]2(C)[C@@H]1CC[C@@H]1COC(=O)[C@H]12 10.1021/acs.jmedchem.7b00951
44315780 203367 0 None - 1 Human 4.7 pIC50 = 4.7 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 375 8 3 5 0.0 O=C(O)CCNC(=O)C1CCCN(S(=O)(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL77367 203367 0 None - 1 Human 4.7 pIC50 = 4.7 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 375 8 3 5 0.0 O=C(O)CCNC(=O)C1CCCN(S(=O)(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL3143291 209419 0 None - 1 Human 7.7 pIC50 = 7.7 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306499 201654 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 815 22 6 7 5.9 CCN(CC)Cc1cn(Cc2cccc(C)c2)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc3ccccc3)ccc12 10.1016/s0960-894x(01)00378-x
CHEMBL65004 201654 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 815 22 6 7 5.9 CCN(CC)Cc1cn(Cc2cccc(C)c2)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc3ccccc3)ccc12 10.1016/s0960-894x(01)00378-x
137654212 158131 0 None - 1 Human 4.7 pIC50 = 4.7 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 478 4 1 5 5.4 C[C@]1(/C=C/c2ccc(-c3cccc(F)c3)cn2)[C@H]2CC[C@@H]3COC(=O)[C@H]3[C@]2(C)CC[C@H]1OC(N)=O 10.1021/acs.jmedchem.7b00951
CHEMBL4092965 158131 0 None - 1 Human 4.7 pIC50 = 4.7 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 478 4 1 5 5.4 C[C@]1(/C=C/c2ccc(-c3cccc(F)c3)cn2)[C@H]2CC[C@@H]3COC(=O)[C@H]3[C@]2(C)CC[C@H]1OC(N)=O 10.1021/acs.jmedchem.7b00951
44338944 110893 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 481 9 0 7 5.5 COc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1F 10.1016/s0960-894x(01)00745-4
CHEMBL327117 110893 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 481 9 0 7 5.5 COc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1F 10.1016/s0960-894x(01)00745-4
90663337 106178 0 None - 1 Human 4.7 pIC50 = 4.7 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 869 20 9 10 1.1 CC(=O)N(C(=O)c1cc2ccccc2oc1=O)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143301 106178 0 None - 1 Human 4.7 pIC50 = 4.7 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 869 20 9 10 1.1 CC(=O)N(C(=O)c1cc2ccccc2oc1=O)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
17222599 169203 3 None - 1 Human 6.7 pIC50 = 6.7 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 360 5 2 2 3.8 CCCNC(=O)c1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
CHEMBL4438936 169203 3 None - 1 Human 6.7 pIC50 = 6.7 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 360 5 2 2 3.8 CCCNC(=O)c1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
44339001 109002 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 463 9 0 7 5.4 COc1ccccc1-c1cc(N(CCCN2CCCCCC2)Cc2ccc3c(c2)OCO3)on1 10.1016/s0960-894x(01)00745-4
CHEMBL322093 109002 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 463 9 0 7 5.4 COc1ccccc1-c1cc(N(CCCN2CCCCCC2)Cc2ccc3c(c2)OCO3)on1 10.1016/s0960-894x(01)00745-4
10276545 9057 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 463 9 0 7 5.4 COc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL110024 9057 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 463 9 0 7 5.4 COc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
44306403 201174 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 815 22 6 7 5.9 CCN(CC)Cc1cn(Cc2ccccc2C)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc3ccccc3)ccc12 10.1016/s0960-894x(01)00378-x
CHEMBL62584 201174 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 815 22 6 7 5.9 CCN(CC)Cc1cn(Cc2ccccc2C)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc3ccccc3)ccc12 10.1016/s0960-894x(01)00378-x
137647264 157321 0 None - 1 Human 4.6 pIC50 = 4.6 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 436 4 2 4 4.8 C[C@@]12CC[C@@H](O)[C@@](C)(CN)[C@H]1CC[C@@]1(CO1)[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
CHEMBL4083850 157321 0 None - 1 Human 4.6 pIC50 = 4.6 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 436 4 2 4 4.8 C[C@@]12CC[C@@H](O)[C@@](C)(CN)[C@H]1CC[C@@]1(CO1)[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
9853816 96888 0 None - 1 Human 5.6 pIC50 = 5.6 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 789 18 6 7 5.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL269345 96888 0 None - 1 Human 5.6 pIC50 = 5.6 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 789 18 6 7 5.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
44306903 101782 0 None - 1 Human 4.6 pIC50 = 4.6 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 809 18 6 7 5.8 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL303157 101782 0 None - 1 Human 4.6 pIC50 = 4.6 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 809 18 6 7 5.8 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
90663307 106163 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 861 21 9 8 2.1 CC(=O)N(C(=O)/C=C/c1ccc(Cl)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143267 106163 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 861 21 9 8 2.1 CC(=O)N(C(=O)/C=C/c1ccc(Cl)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44338787 6815 0 None - 1 Human 5.6 pIC50 = 5.6 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 469 8 0 6 5.6 Fc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1F 10.1016/s0960-894x(01)00745-4
CHEMBL108428 6815 0 None - 1 Human 5.6 pIC50 = 5.6 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 469 8 0 6 5.6 Fc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1F 10.1016/s0960-894x(01)00745-4
10077130 3944 49 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at PAR1 in human platelets assessed as inhibition of haTRAP-induced platelet aggregationAntagonist activity at PAR1 in human platelets assessed as inhibition of haTRAP-induced platelet aggregation
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
4047 3944 49 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at PAR1 in human platelets assessed as inhibition of haTRAP-induced platelet aggregationAntagonist activity at PAR1 in human platelets assessed as inhibition of haTRAP-induced platelet aggregation
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
4870 3944 49 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at PAR1 in human platelets assessed as inhibition of haTRAP-induced platelet aggregationAntagonist activity at PAR1 in human platelets assessed as inhibition of haTRAP-induced platelet aggregation
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
CHEMBL493982 3944 49 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at PAR1 in human platelets assessed as inhibition of haTRAP-induced platelet aggregationAntagonist activity at PAR1 in human platelets assessed as inhibition of haTRAP-induced platelet aggregation
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
DB09030 3944 49 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at PAR1 in human platelets assessed as inhibition of haTRAP-induced platelet aggregationAntagonist activity at PAR1 in human platelets assessed as inhibition of haTRAP-induced platelet aggregation
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
10077130 3944 49 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assayAntagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assay
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1016/j.bmcl.2020.127046
4047 3944 49 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assayAntagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assay
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1016/j.bmcl.2020.127046
4870 3944 49 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assayAntagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assay
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1016/j.bmcl.2020.127046
CHEMBL493982 3944 49 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assayAntagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assay
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1016/j.bmcl.2020.127046
DB09030 3944 49 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assayAntagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assay
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1016/j.bmcl.2020.127046
90663294 106157 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 827 22 8 9 2.1 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN)C(=O)CC(N)=O 10.1021/jm960455s
CHEMBL3143253 106157 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 827 22 8 9 2.1 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN)C(=O)CC(N)=O 10.1021/jm960455s
90663318 106169 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 986 28 12 10 0.5 CCC(=O)c1cccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)c1 10.1021/jm960455s
CHEMBL3143280 106169 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 986 28 12 10 0.5 CCC(=O)c1cccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)c1 10.1021/jm960455s
CHEMBL3143309 209423 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)COc1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306500 167353 0 None - 1 Human 5.6 pIC50 = 5.6 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 833 20 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccccc4Cl)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL431369 167353 0 None - 1 Human 5.6 pIC50 = 5.6 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 833 20 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccccc4Cl)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
12018758 9257 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 467 8 0 6 6.0 Clc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL111241 9257 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 467 8 0 6 6.0 Clc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
9853816 96888 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 789 18 6 7 5.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL269345 96888 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 789 18 6 7 5.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL3143321 209432 0 None - 1 Human 5.6 pIC50 = 5.6 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccc(O)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL5094099 213694 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysisAntagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysis
ChEMBL None None None C[C@@H]1[C@@H](C)[C@@H]2CN(C)C[C@@]23C(=O)O[C@H](C)[C@H]3[C@H]1/C=C/c1ccc(-c2ccccc2C#N)cn1 10.1021/acs.jmedchem.1c02048
117909194 151704 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assayAntagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assay
ChEMBL 485 4 1 6 4.4 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2n[nH]c(=O)o2)CC1(F)F 10.1021/acsmedchemlett.6b00327
CHEMBL3968866 151704 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assayAntagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assay
ChEMBL 485 4 1 6 4.4 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2n[nH]c(=O)o2)CC1(F)F 10.1021/acsmedchemlett.6b00327
CHEMBL3143246 209395 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC#Cc1ccccc1C(=O)N(C(C)=O)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
22611774 203726 0 None - 1 Human 4.6 pIC50 = 4.6 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 353 7 2 4 0.9 CN(CCC(=O)O)C(=O)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL80289 203726 0 None - 1 Human 4.6 pIC50 = 4.6 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 353 7 2 4 0.9 CN(CCC(=O)O)C(=O)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
145970191 164528 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 870 18 5 7 6.7 C#CCCC(=O)NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/j.bmc.2018.04.016
CHEMBL4226980 164528 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 870 18 5 7 6.7 C#CCCC(=O)NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/j.bmc.2018.04.016
90663334 106176 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 807 20 9 7 2.0 CC(=O)N(c1cccc(Cl)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143297 106176 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 807 20 9 7 2.0 CC(=O)N(c1cccc(Cl)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
137654568 158389 0 None - 1 Human 4.5 pIC50 = 4.5 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 451 4 2 4 4.9 C[C@]1(C(=O)O)[C@H]2CC[C@@]3(CO3)[C@@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@]2(C)CC[C@H]1O 10.1021/acs.jmedchem.7b00951
CHEMBL4095795 158389 0 None - 1 Human 4.5 pIC50 = 4.5 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 451 4 2 4 4.9 C[C@]1(C(=O)O)[C@H]2CC[C@@]3(CO3)[C@@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@]2(C)CC[C@H]1O 10.1021/acs.jmedchem.7b00951
12018757 108673 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 467 8 0 6 6.0 Clc1ccccc1-c1cc(N(CCCN2CCCCCC2)Cc2ccc3c(c2)OCO3)on1 10.1016/s0960-894x(01)00745-4
CHEMBL321437 108673 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 467 8 0 6 6.0 Clc1ccccc1-c1cc(N(CCCN2CCCCCC2)Cc2ccc3c(c2)OCO3)on1 10.1016/s0960-894x(01)00745-4
CHEMBL5085562 213200 1 None - 1 Human 8.5 pIC50 = 8.5 Functional
Antagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysisAntagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysis
ChEMBL None None None Cc1cccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@]4(O)CC(F)(F)[C@H]3C)nc2)c1C#N 10.1021/acs.jmedchem.1c02048
CHEMBL5091232 213524 0 None - 1 Human 8.5 pIC50 = 8.5 Functional
Antagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysisAntagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysis
ChEMBL None None None C[C@H]1[C@H](c2ccc(-c3cccc(F)c3)cn2)[C@@H]2[C@@H](C)OC(=O)[C@@H]2C[C@@H]1C 10.1021/acs.jmedchem.1c02048
117909768 146813 0 None - 1 Human 8.5 pIC50 = 8.5 Functional
Antagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assayAntagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assay
ChEMBL 491 4 1 8 4.4 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2nnc(N)o2)CC1(F)F 10.1021/acsmedchemlett.6b00327
CHEMBL3929336 146813 0 None - 1 Human 8.5 pIC50 = 8.5 Functional
Antagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assayAntagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assay
ChEMBL 491 4 1 8 4.4 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2nnc(N)o2)CC1(F)F 10.1021/acsmedchemlett.6b00327
155536026 171539 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 1698 46 6 22 9.3 CC(C)c1cc(-c2ccc(F)cc2)nn2cc(C(=O)N3CCN(C(=O)CCC(=O)NCCOCCOCCOCCOCCOCCOCCn4cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc5ccc(F)c(F)c5)NC(=O)Nc5ccc6c(CN7CCCC7)nn(Cc7c(Cl)cccc7Cl)c6c5)C(=O)NCc5ccccc5)nn4)CC3(C)C)nc12 10.1021/acsmedchemlett.8b00538
CHEMBL4472608 171539 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 1698 46 6 22 9.3 CC(C)c1cc(-c2ccc(F)cc2)nn2cc(C(=O)N3CCN(C(=O)CCC(=O)NCCOCCOCCOCCOCCOCCOCCn4cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc5ccc(F)c(F)c5)NC(=O)Nc5ccc6c(CN7CCCC7)nn(Cc7c(Cl)cccc7Cl)c6c5)C(=O)NCc5ccccc5)nn4)CC3(C)C)nc12 10.1021/acsmedchemlett.8b00538
10350886 178179 1 None - 1 Human 6.5 pIC50 = 6.5 Functional
Antagonist activity against PAR1 in human platelet rich plasma assessed as inhibition of tissue factor-induced platelet aggregation pre-incubated for 2 mins before Cacl2 and tissue factor addition by optical or impedance aggregometryAntagonist activity against PAR1 in human platelet rich plasma assessed as inhibition of tissue factor-induced platelet aggregation pre-incubated for 2 mins before Cacl2 and tissue factor addition by optical or impedance aggregometry
ChEMBL 942 27 13 9 -0.3 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O nan
CHEMBL46869 178179 1 None - 1 Human 6.5 pIC50 = 6.5 Functional
Antagonist activity against PAR1 in human platelet rich plasma assessed as inhibition of tissue factor-induced platelet aggregation pre-incubated for 2 mins before Cacl2 and tissue factor addition by optical or impedance aggregometryAntagonist activity against PAR1 in human platelet rich plasma assessed as inhibition of tissue factor-induced platelet aggregation pre-incubated for 2 mins before Cacl2 and tissue factor addition by optical or impedance aggregometry
ChEMBL 942 27 13 9 -0.3 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O nan
44328523 106153 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 786 21 10 7 1.8 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O 10.1016/s0960-894x(98)00730-6
CHEMBL314325 106153 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 786 21 10 7 1.8 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O 10.1016/s0960-894x(98)00730-6
44306697 102259 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 846 17 6 6 6.9 NC(=O)NCCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL304924 102259 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 846 17 6 6 6.9 NC(=O)NCCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
10819322 203205 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 839 18 7 7 6.4 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL7610 203205 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 839 18 7 7 6.4 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
44316522 203787 1 None - 1 Human 6.5 pIC50 = 6.5 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 339 7 3 4 0.6 O=C(O)CCNC(=O)[C@@H]1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL80672 203787 1 None - 1 Human 6.5 pIC50 = 6.5 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 339 7 3 4 0.6 O=C(O)CCNC(=O)[C@@H]1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
137632009 156114 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 435 4 1 4 5.1 C[C@]1(C=O)[C@H]2CC[C@@]3(CO3)[C@@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@]2(C)CC[C@H]1O 10.1021/acs.jmedchem.7b00951
CHEMBL4069403 156114 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 435 4 1 4 5.1 C[C@]1(C=O)[C@H]2CC[C@@]3(CO3)[C@@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@]2(C)CC[C@H]1O 10.1021/acs.jmedchem.7b00951
90663339 106180 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 883 21 9 8 3.1 CC(=O)N(C(=O)c1cccc(C2CCCCC2)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143303 106180 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 883 21 9 8 3.1 CC(=O)N(C(=O)c1cccc(C2CCCCC2)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306403 201174 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 815 22 6 7 5.9 CCN(CC)Cc1cn(Cc2ccccc2C)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc3ccccc3)ccc12 10.1016/s0960-894x(01)00378-x
CHEMBL62584 201174 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 815 22 6 7 5.9 CCN(CC)Cc1cn(Cc2ccccc2C)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc3ccccc3)ccc12 10.1016/s0960-894x(01)00378-x
44316532 203754 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 339 7 3 4 0.6 O=C(O)CCNC(=O)[C@H]1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL80455 203754 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 339 7 3 4 0.6 O=C(O)CCNC(=O)[C@H]1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
10459564 514 34 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC 10.1016/j.bmc.2018.04.016
4048 514 34 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC 10.1016/j.bmc.2018.04.016
CHEMBL2103856 514 34 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC 10.1016/j.bmc.2018.04.016
DB12046 514 34 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC 10.1016/j.bmc.2018.04.016
57892463 164504 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CCC2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmc.2018.04.016
CHEMBL4226439 164504 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CCC2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmc.2018.04.016
44306402 167645 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 827 20 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccccc4C)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL433499 167645 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 827 20 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccccc4C)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
44328340 96254 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 1095 30 12 10 3.0 CCC(=O)NCCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](Cc1ccc(C(=O)c2ccccc2)cc1)NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)O 10.1016/s0960-894x(98)00730-6
CHEMBL264099 96254 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 1095 30 12 10 3.0 CCC(=O)NCCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](Cc1ccc(C(=O)c2ccccc2)cc1)NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)O 10.1016/s0960-894x(98)00730-6
10328351 206297 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 892 24 10 8 2.9 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)CCc1ccc(C(=O)c2ccccc2)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O 10.1016/s0960-894x(98)00730-6
CHEMBL97498 206297 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 892 24 10 8 2.9 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)CCc1ccc(C(=O)c2ccccc2)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O 10.1016/s0960-894x(98)00730-6
145970191 164528 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 870 18 5 7 6.7 C#CCCC(=O)NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/j.bmc.2018.04.016
CHEMBL4226980 164528 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 870 18 5 7 6.7 C#CCCC(=O)NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/j.bmc.2018.04.016
3109060 170096 4 None - 1 Human 6.5 pIC50 = 6.5 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 384 4 2 3 4.5 O=C(Nc1cccc(NC(=O)c2ccccc2Br)c1)c1ccco1 10.1016/j.bmc.2019.06.043
CHEMBL4451525 170096 4 None - 1 Human 6.5 pIC50 = 6.5 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 384 4 2 3 4.5 O=C(Nc1cccc(NC(=O)c2ccccc2Br)c1)c1ccco1 10.1016/j.bmc.2019.06.043
50910548 75302 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 374 5 2 2 4.7 CC(C)CC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
CHEMBL2047299 75302 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 374 5 2 2 4.7 CC(C)CC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
877874 23121 16 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 346 4 2 2 4.1 CCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
CHEMBL1332325 23121 16 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 346 4 2 2 4.1 CCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
877874 23121 16 None - 1 Human 5.5 pIC50 = 5.5 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 346 4 2 2 4.1 CCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
CHEMBL1332325 23121 16 None - 1 Human 5.5 pIC50 = 5.5 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 346 4 2 2 4.1 CCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
57892463 164504 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CCC2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmc.2018.04.016
CHEMBL4226439 164504 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CCC2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmc.2018.04.016
3109060 170096 4 None - 1 Human 6.5 pIC50 = 6.5 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 384 4 2 3 4.5 O=C(Nc1cccc(NC(=O)c2ccccc2Br)c1)c1ccco1 10.1016/j.bmc.2019.06.043
CHEMBL4451525 170096 4 None - 1 Human 6.5 pIC50 = 6.5 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 384 4 2 3 4.5 O=C(Nc1cccc(NC(=O)c2ccccc2Br)c1)c1ccco1 10.1016/j.bmc.2019.06.043
10279248 108355 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 511 9 0 8 4.7 CS(=O)(=O)c1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL320990 108355 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 511 9 0 8 4.7 CS(=O)(=O)c1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
44339002 9260 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 447 8 0 6 5.7 Cc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL111258 9260 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 447 8 0 6 5.7 Cc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
137633371 155837 0 None - 1 Human 4.5 pIC50 = 4.5 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 450 4 1 3 6.9 C[C@H]1CC[C@@H]2C(C)(C)[C@H](OC(N)=O)CC[C@@]2(C)[C@@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
CHEMBL4066290 155837 0 None - 1 Human 4.5 pIC50 = 4.5 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 450 4 1 3 6.9 C[C@H]1CC[C@@H]2C(C)(C)[C@H](OC(N)=O)CC[C@@]2(C)[C@@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
90663297 106158 0 None - 1 Human 4.5 pIC50 = 4.5 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 779 20 9 8 1.4 CC(=O)N(c1cccs1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143256 106158 0 None - 1 Human 4.5 pIC50 = 4.5 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 779 20 9 8 1.4 CC(=O)N(c1cccs1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44339055 9233 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 447 8 0 6 5.7 Cc1ccccc1-c1cc(N(CCCN2CCCCCC2)Cc2ccc3c(c2)OCO3)on1 10.1016/s0960-894x(01)00745-4
CHEMBL111101 9233 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 447 8 0 6 5.7 Cc1ccccc1-c1cc(N(CCCN2CCCCCC2)Cc2ccc3c(c2)OCO3)on1 10.1016/s0960-894x(01)00745-4
10459564 514 34 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC 10.1016/j.bmc.2018.04.016
4048 514 34 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC 10.1016/j.bmc.2018.04.016
CHEMBL2103856 514 34 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC 10.1016/j.bmc.2018.04.016
DB12046 514 34 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC 10.1016/j.bmc.2018.04.016
877874 23121 16 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 346 4 2 2 4.1 CCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
CHEMBL1332325 23121 16 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 346 4 2 2 4.1 CCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
44338886 162750 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 391 9 0 5 4.8 COc1cccc(CN(CCCN2CCCC2)c2cc(-c3ccccc3)no2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL418815 162750 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 391 9 0 5 4.8 COc1cccc(CN(CCCN2CCCC2)c2cc(-c3ccccc3)no2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL3143288 209416 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@H](Cc1cccs1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306761 168343 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 789 15 5 6 6.8 NCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL438551 168343 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 789 15 5 6 6.8 NCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
44328381 97842 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 1265 34 15 12 3.5 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(C(=O)c2ccccc2)cc1)NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)N[C@@H](CCCNC(=O)CCCC[C@H]1SC[C@H]2NC(=O)N[C@H]21)C(=O)O 10.1016/s0960-894x(98)00730-6
CHEMBL274769 97842 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 1265 34 15 12 3.5 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(C(=O)c2ccccc2)cc1)NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)N[C@@H](CCCNC(=O)CCCC[C@H]1SC[C@H]2NC(=O)N[C@H]21)C(=O)O 10.1016/s0960-894x(98)00730-6
10161572 5476 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 458 8 0 7 5.2 N#Cc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL107667 5476 0 None - 1 Human 6.5 pIC50 = 6.5 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 458 8 0 7 5.2 N#Cc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
90663354 106186 0 None - 1 Human 4.5 pIC50 = 4.5 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 791 20 9 7 1.5 CC(=O)N(c1ccccc1F)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143319 106186 0 None - 1 Human 4.5 pIC50 = 4.5 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 791 20 9 7 1.5 CC(=O)N(c1ccccc1F)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
155549751 173346 0 None 16 2 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of thrombin-induced intracellular calcium mobilization preincubated for 15 mins followed by thrombin addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of thrombin-induced intracellular calcium mobilization preincubated for 15 mins followed by thrombin addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 2446 97 6 39 9.5 CC(C)c1cc(-c2ccc(F)cc2)nn2cc(C(=O)N3CCN(C(=O)CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCn4cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc5ccc(F)c(F)c5)NC(=O)Nc5ccc6c(CN7CCCC7)nn(Cc7c(Cl)cccc7Cl)c6c5)C(=O)NCc5ccccc5)nn4)CC3(C)C)nc12 10.1021/acsmedchemlett.8b00538
CHEMBL4540591 173346 0 None 16 2 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of thrombin-induced intracellular calcium mobilization preincubated for 15 mins followed by thrombin addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of thrombin-induced intracellular calcium mobilization preincubated for 15 mins followed by thrombin addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 2446 97 6 39 9.5 CC(C)c1cc(-c2ccc(F)cc2)nn2cc(C(=O)N3CCN(C(=O)CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCn4cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc5ccc(F)c(F)c5)NC(=O)Nc5ccc6c(CN7CCCC7)nn(Cc7c(Cl)cccc7Cl)c6c5)C(=O)NCc5ccccc5)nn4)CC3(C)C)nc12 10.1021/acsmedchemlett.8b00538
44338864 7211 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 439 8 0 4 6.8 c1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3cccc4ccccc34)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL108604 7211 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 439 8 0 4 6.8 c1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3cccc4ccccc34)on2)cc1 10.1016/s0960-894x(01)00745-4
44306612 101690 0 None - 1 Human 4.4 pIC50 = 4.4 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 875 19 6 8 6.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccc(OC(F)(F)F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL302603 101690 0 None - 1 Human 4.4 pIC50 = 4.4 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 875 19 6 8 6.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccc(OC(F)(F)F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
154688307 172279 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 385 4 2 4 3.9 O=C(Nc1cccc(NC(=O)c2ccccc2Br)c1)c1cnco1 10.1016/j.bmc.2019.06.043
CHEMBL4514779 172279 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 385 4 2 4 3.9 O=C(Nc1cccc(NC(=O)c2ccccc2Br)c1)c1cnco1 10.1016/j.bmc.2019.06.043
10278388 110510 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 495 9 0 7 5.1 C[S+]([O-])c1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL326247 110510 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 495 9 0 7 5.1 C[S+]([O-])c1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
155519325 169848 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 400 4 2 2 4.6 O=C(CC(F)(F)F)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
CHEMBL4448258 169848 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 400 4 2 2 4.6 O=C(CC(F)(F)F)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
90663343 106184 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 865 21 9 8 2.1 CC(=O)N(C(=O)Cc1cccc2ccccc12)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143308 106184 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 865 21 9 8 2.1 CC(=O)N(C(=O)Cc1cccc2ccccc12)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306658 101725 0 None - 1 Human 4.4 pIC50 = 4.4 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 835 19 6 9 5.0 COC(=O)c1ccc(Cn2cc(CN3CCCC3)c3ccc(NC(=O)N[C@@H](Cc4ccc(OC)cc4)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC4CCCCC4)cc32)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL302823 101725 0 None - 1 Human 4.4 pIC50 = 4.4 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 835 19 6 9 5.0 COC(=O)c1ccc(Cn2cc(CN3CCCC3)c3ccc(NC(=O)N[C@@H](Cc4ccc(OC)cc4)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC4CCCCC4)cc32)cc1 10.1016/s0960-894x(01)00378-x
90663292 106155 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 857 22 9 9 1.4 COc1ccc(/C=C/C(=O)N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)cc1 10.1021/jm960455s
CHEMBL3143251 106155 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 857 22 9 9 1.4 COc1ccc(/C=C/C(=O)N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)cc1 10.1021/jm960455s
90663333 106175 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 843 23 9 8 2.4 CCCC(=O)c1ccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)cc1 10.1021/jm960455s
CHEMBL3143296 106175 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 843 23 9 8 2.4 CCCC(=O)c1ccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)cc1 10.1021/jm960455s
155519325 169848 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 400 4 2 2 4.6 O=C(CC(F)(F)F)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
CHEMBL4448258 169848 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 400 4 2 2 4.6 O=C(CC(F)(F)F)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
154688304 175637 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 385 4 2 4 3.9 O=C(Nc1cccc(NC(=O)c2ccccc2Br)c1)c1cocn1 10.1016/j.bmc.2019.06.043
CHEMBL4594058 175637 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 385 4 2 4 3.9 O=C(Nc1cccc(NC(=O)c2ccccc2Br)c1)c1cocn1 10.1016/j.bmc.2019.06.043
CHEMBL5069528 212447 0 None - 1 Human 8.4 pIC50 = 8.4 Functional
Antagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysisAntagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysis
ChEMBL None None None CCOC(=O)N1C[C@H]2[C@H](C)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@]32C1 10.1021/acs.jmedchem.1c02048
117909666 148217 0 None - 1 Human 8.4 pIC50 = 8.4 Functional
Antagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assayAntagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assay
ChEMBL 492 4 1 7 4.1 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2n[nH]c(=O)o2)CC1(F)F 10.1021/acsmedchemlett.6b00327
CHEMBL3940415 148217 0 None - 1 Human 8.4 pIC50 = 8.4 Functional
Antagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assayAntagonist activity at PAR-1 in HEK293 cells incubated for 30 mins followed by Ala-parafluoroPhe-Arg-Cha-Cit-Try-NH2 substrate addition by calcium-5 dye based FLIPR assay
ChEMBL 492 4 1 7 4.1 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2n[nH]c(=O)o2)CC1(F)F 10.1021/acsmedchemlett.6b00327
155512671 169101 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 1874 58 6 26 9.3 CC(C)c1cc(-c2ccc(F)cc2)nn2cc(C(=O)N3CCN(C(=O)CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCn4cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc5ccc(F)c(F)c5)NC(=O)Nc5ccc6c(CN7CCCC7)nn(Cc7c(Cl)cccc7Cl)c6c5)C(=O)NCc5ccccc5)nn4)CC3(C)C)nc12 10.1021/acsmedchemlett.8b00538
CHEMBL4437508 169101 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 1874 58 6 26 9.3 CC(C)c1cc(-c2ccc(F)cc2)nn2cc(C(=O)N3CCN(C(=O)CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCn4cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc5ccc(F)c(F)c5)NC(=O)Nc5ccc6c(CN7CCCC7)nn(Cc7c(Cl)cccc7Cl)c6c5)C(=O)NCc5ccccc5)nn4)CC3(C)C)nc12 10.1021/acsmedchemlett.8b00538
90663313 106164 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 982 27 12 10 -0.3 C#CC(=O)c1cccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)c1 10.1021/jm960455s
CHEMBL3143273 106164 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 982 27 12 10 -0.3 C#CC(=O)c1cccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)c1 10.1021/jm960455s
90663314 106165 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 984 28 11 11 0.6 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN)C(=O)CC(N)=O 10.1021/jm960455s
CHEMBL3143274 106165 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 984 28 11 11 0.6 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN)C(=O)CC(N)=O 10.1021/jm960455s
44338946 9216 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 493 10 0 8 5.4 COc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1OC 10.1016/s0960-894x(01)00745-4
CHEMBL110998 9216 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 493 10 0 8 5.4 COc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1OC 10.1016/s0960-894x(01)00745-4
44306659 102299 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 820 16 4 6 8.2 CSCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL305188 102299 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 820 16 4 6 8.2 CSCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
44306611 201908 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 775 18 6 7 4.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL66958 201908 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 775 18 6 7 4.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
15887956 203721 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 415 8 3 4 2.3 O=C(O)CC(NC(=O)C1CCCN(C(=O)CCC2CCNCC2)C1)c1ccccc1 10.1016/0960-894X(96)00438-6
CHEMBL80232 203721 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 415 8 3 4 2.3 O=C(O)CC(NC(=O)C1CCCN(C(=O)CCC2CCNCC2)C1)c1ccccc1 10.1016/0960-894X(96)00438-6
44316106 203737 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 395 9 3 4 2.0 CC(C)CC(CC(=O)O)NC(=O)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL80343 203737 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 395 9 3 4 2.0 CC(C)CC(CC(=O)O)NC(=O)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
90663330 106172 0 None - 1 Human 4.4 pIC50 = 4.4 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 791 20 9 7 1.5 CC(=O)N(c1cccc(F)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143293 106172 0 None - 1 Human 4.4 pIC50 = 4.4 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 791 20 9 7 1.5 CC(=O)N(c1cccc(F)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
15887960 203821 0 None - 1 Human 4.4 pIC50 = 4.4 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 363 7 3 6 -0.1 O=C(NCCc1nnn[nH]1)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL80943 203821 0 None - 1 Human 4.4 pIC50 = 4.4 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 363 7 3 6 -0.1 O=C(NCCc1nnn[nH]1)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
44306657 101789 0 None - 1 Human 4.4 pIC50 = 4.4 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 861 19 6 8 6.2 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(OC(F)(F)F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL303187 101789 0 None - 1 Human 4.4 pIC50 = 4.4 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 861 19 6 8 6.2 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(OC(F)(F)F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL3143264 209403 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(N)=O 10.1021/jm960455s
154688304 175637 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 385 4 2 4 3.9 O=C(Nc1cccc(NC(=O)c2ccccc2Br)c1)c1cocn1 10.1016/j.bmc.2019.06.043
CHEMBL4594058 175637 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 385 4 2 4 3.9 O=C(Nc1cccc(NC(=O)c2ccccc2Br)c1)c1cocn1 10.1016/j.bmc.2019.06.043
12018759 110711 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 467 8 0 6 6.0 Clc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL326456 110711 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 467 8 0 6 6.0 Clc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL4764659 212285 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Affinity Phenotypic Cellular interaction (Inhibition of platelet aggregation (human plasma, TRAP-6)) EUB0000291b F2RAffinity Phenotypic Cellular interaction (Inhibition of platelet aggregation (human plasma, TRAP-6)) EUB0000291b F2R
ChEMBL None None None O=C(N1CCS(=O)(=O)CC1)N1C[C@@](S)(c2ccc(OC(F)(F)F)cc2)C[C@@](S)(c2nc(C3CC3)no2)C1 nan
10206026 9352 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 479 9 0 7 6.1 CSc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL111761 9352 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 479 9 0 7 6.1 CSc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
90663291 106154 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Concentration of compound required to inhibit agonist (SFFLRR-NH2, at 18 uM) induced platelet aggregation by 50%Concentration of compound required to inhibit agonist (SFFLRR-NH2, at 18 uM) induced platelet aggregation by 50%
ChEMBL 877 21 9 8 2.7 CC(=O)N(C(=O)c1ccc(-c2ccccc2)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143250 106154 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Concentration of compound required to inhibit agonist (SFFLRR-NH2, at 18 uM) induced platelet aggregation by 50%Concentration of compound required to inhibit agonist (SFFLRR-NH2, at 18 uM) induced platelet aggregation by 50%
ChEMBL 877 21 9 8 2.7 CC(=O)N(C(=O)c1ccc(-c2ccccc2)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306540 201347 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 795 18 6 7 5.4 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL63402 201347 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 795 18 6 7 5.4 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
10164471 9047 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 509 9 0 6 7.0 c1ccc(-c2ccc(-c3cc(N(CCCN4CCCCCC4)Cc4ccc5c(c4)OCO5)on3)cc2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL109946 9047 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 509 9 0 6 7.0 c1ccc(-c2ccc(-c3cc(N(CCCN4CCCCCC4)Cc4ccc5c(c4)OCO5)on3)cc2)cc1 10.1016/s0960-894x(01)00745-4
44306698 102238 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 826 15 5 6 7.4 O=C(Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)N[C@@H](Cc1ccc(F)c(F)c1)C(=O)NC(Cc1c[nH]cn1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL304827 102238 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 826 15 5 6 7.4 O=C(Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)N[C@@H](Cc1ccc(F)c(F)c1)C(=O)NC(Cc1c[nH]cn1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
90663332 106174 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 865 21 9 8 2.1 CC(=O)N(C(=O)Cc1ccc2ccccc2c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143295 106174 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 865 21 9 8 2.1 CC(=O)N(C(=O)Cc1ccc2ccccc2c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44338946 9216 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 493 10 0 8 5.4 COc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1OC 10.1016/s0960-894x(01)00745-4
CHEMBL110998 9216 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 493 10 0 8 5.4 COc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1OC 10.1016/s0960-894x(01)00745-4
10077130 3944 49 None - 1 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at PAR1 in human platelets assessed as inhibition of thrombin-induced platelet aggregationAntagonist activity at PAR1 in human platelets assessed as inhibition of thrombin-induced platelet aggregation
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
4047 3944 49 None - 1 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at PAR1 in human platelets assessed as inhibition of thrombin-induced platelet aggregationAntagonist activity at PAR1 in human platelets assessed as inhibition of thrombin-induced platelet aggregation
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
4870 3944 49 None - 1 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at PAR1 in human platelets assessed as inhibition of thrombin-induced platelet aggregationAntagonist activity at PAR1 in human platelets assessed as inhibition of thrombin-induced platelet aggregation
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
CHEMBL493982 3944 49 None - 1 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at PAR1 in human platelets assessed as inhibition of thrombin-induced platelet aggregationAntagonist activity at PAR1 in human platelets assessed as inhibition of thrombin-induced platelet aggregation
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
DB09030 3944 49 None - 1 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at PAR1 in human platelets assessed as inhibition of thrombin-induced platelet aggregationAntagonist activity at PAR1 in human platelets assessed as inhibition of thrombin-induced platelet aggregation
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
CHEMBL3143275 209410 0 None - 1 Human 7.3 pIC50 = 7.3 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN)C(N)=O 10.1021/jm960455s
90663360 106189 0 None - 1 Human 4.3 pIC50 = 4.3 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 795 21 9 9 1.2 CC(=O)N(Oc1cccs1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143326 106189 0 None - 1 Human 4.3 pIC50 = 4.3 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 795 21 9 9 1.2 CC(=O)N(Oc1cccs1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306501 102218 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 834 17 7 7 6.3 N#Cc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL304683 102218 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 834 17 7 7 6.3 N#Cc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
44306657 101789 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 861 19 6 8 6.2 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(OC(F)(F)F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL303187 101789 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 861 19 6 8 6.2 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(OC(F)(F)F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
44306402 167645 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 827 20 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccccc4C)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL433499 167645 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 827 20 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccccc4C)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
9832212 203241 4 None - 1 Human 8.3 pIC50 = 8.3 Functional
Antagonist activity at PAR1 in human MDA-MB-231 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human MDA-MB-231 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1021/acsmedchemlett.8b00538
CHEMBL4226137 203241 4 None - 1 Human 8.3 pIC50 = 8.3 Functional
Antagonist activity at PAR1 in human MDA-MB-231 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human MDA-MB-231 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1021/acsmedchemlett.8b00538
CHEMBL7642 203241 4 None - 1 Human 8.3 pIC50 = 8.3 Functional
Antagonist activity at PAR1 in human MDA-MB-231 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human MDA-MB-231 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1021/acsmedchemlett.8b00538
CHEMBL5077302 212721 0 None - 1 Human 8.3 pIC50 = 8.3 Functional
Antagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysisAntagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysis
ChEMBL None None None C[C@H]1OC(=O)[C@@H]2CC(F)(F)[C@@H](C)[C@H](c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/acs.jmedchem.1c02048
CHEMBL3143281 209412 0 None - 1 Human 7.3 pIC50 = 7.3 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccc(F)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44338787 6815 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 469 8 0 6 5.6 Fc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1F 10.1016/s0960-894x(01)00745-4
CHEMBL108428 6815 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 469 8 0 6 5.6 Fc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1F 10.1016/s0960-894x(01)00745-4
44338875 109290 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 413 9 0 5 5.6 COc1cccc(CN(CCCN2C=CC=CC=C2)c2cc(-c3ccccc3)no2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL323221 109290 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 413 9 0 5 5.6 COc1cccc(CN(CCCN2C=CC=CC=C2)c2cc(-c3ccccc3)no2)c1 10.1016/s0960-894x(01)00745-4
44339070 109843 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 425 8 0 4 6.4 c1ccc(-c2cc(N(CCCN3CCCCC3)Cc3cccc4ccccc34)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL323956 109843 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 425 8 0 4 6.4 c1ccc(-c2cc(N(CCCN3CCCCC3)Cc3cccc4ccccc34)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL3143284 209414 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@H](CCCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306732 102131 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 775 14 5 6 6.4 NCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL304128 102131 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 775 14 5 6 6.4 NCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
44339056 8597 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 453 9 0 4 7.2 c1ccc(-c2cc(N(CCCCN3CCCCCC3)Cc3cccc4ccccc34)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL109564 8597 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 453 9 0 4 7.2 c1ccc(-c2cc(N(CCCCN3CCCCCC3)Cc3cccc4ccccc34)on2)cc1 10.1016/s0960-894x(01)00745-4
44338865 108635 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 425 7 0 4 6.4 c1ccc(-c2cc(N(CCN3CCCCCC3)Cc3cccc4ccccc34)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL321380 108635 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 425 7 0 4 6.4 c1ccc(-c2cc(N(CCN3CCCCCC3)Cc3cccc4ccccc34)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL3143313 209426 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44315792 203346 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 341 6 3 5 0.4 O=C(O)CCNC(=O)C1CCCN(C(=O)OCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL77179 203346 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 341 6 3 5 0.4 O=C(O)CCNC(=O)C1CCCN(C(=O)OCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
154688307 172279 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 385 4 2 4 3.9 O=C(Nc1cccc(NC(=O)c2ccccc2Br)c1)c1cnco1 10.1016/j.bmc.2019.06.043
CHEMBL4514779 172279 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 385 4 2 4 3.9 O=C(Nc1cccc(NC(=O)c2ccccc2Br)c1)c1cnco1 10.1016/j.bmc.2019.06.043
9847494 5771 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 469 8 0 6 5.6 Fc1cc(F)cc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL107920 5771 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 469 8 0 6 5.6 Fc1cc(F)cc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL3143249 209397 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccc(F)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
90663299 106160 0 None - 1 Human 4.3 pIC50 = 4.3 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 812 20 10 7 1.9 CC(=O)N(c1c[nH]c2ccccc12)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143258 106160 0 None - 1 Human 4.3 pIC50 = 4.3 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 812 20 10 7 1.9 CC(=O)N(c1c[nH]c2ccccc12)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
145386419 176493 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assayAntagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assay
ChEMBL 474 5 1 5 5.5 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccn2)cc1 10.1016/j.bmcl.2020.127046
CHEMBL4632907 176493 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assayAntagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assay
ChEMBL 474 5 1 5 5.5 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccn2)cc1 10.1016/j.bmcl.2020.127046
137644873 157666 0 None - 1 Human 4.3 pIC50 = 4.3 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 439 4 3 4 4.8 C[C@]1(O)CC[C@H]2[C@@](C)(CC[C@@H](O)[C@@]2(C)CO)[C@@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
CHEMBL4088070 157666 0 None - 1 Human 4.3 pIC50 = 4.3 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 439 4 3 4 4.8 C[C@]1(O)CC[C@H]2[C@@](C)(CC[C@@H](O)[C@@]2(C)CO)[C@@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
9919038 166175 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 845 17 7 6 6.7 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL428311 166175 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 845 17 7 6 6.7 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
1048267 32212 87 None - 1 Human 6.2 pIC50 = 6.2 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 360 5 2 2 4.4 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
CHEMBL1411333 32212 87 None - 1 Human 6.2 pIC50 = 6.2 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 360 5 2 2 4.4 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
CHEMBL5081773 212995 0 None - 1 Human 8.2 pIC50 = 8.2 Functional
Antagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysisAntagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysis
ChEMBL None None None C[C@H]1NC(=O)[C@]2(N)CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@H]12 10.1021/acs.jmedchem.1c02048
90663316 106168 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 1002 28 11 11 0.7 CC(=O)N(C(=O)/C=C/c1ccc(F)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN)C(=O)CC(N)=O 10.1021/jm960455s
CHEMBL3143278 106168 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 1002 28 11 11 0.7 CC(=O)N(C(=O)/C=C/c1ccc(F)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN)C(=O)CC(N)=O 10.1021/jm960455s
44338882 5846 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 419 8 0 6 5.0 c1ccc(-c2cc(N(CCCN3CCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL107971 5846 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 419 8 0 6 5.0 c1ccc(-c2cc(N(CCCN3CCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
44306708 100443 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 817 20 6 7 5.5 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL293867 100443 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 817 20 6 7 5.5 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
44306336 201853 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 780 17 6 7 5.1 Cc1ccccc1Cn1cc(CN2CCCC2)c2ccc(NC(=O)N[C@@H](Cc3ccc(C#N)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc3ccccc3)cc21 10.1016/s0960-894x(01)00378-x
CHEMBL66585 201853 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 780 17 6 7 5.1 Cc1ccccc1Cn1cc(CN2CCCC2)c2ccc(NC(=O)N[C@@H](Cc3ccc(C#N)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc3ccccc3)cc21 10.1016/s0960-894x(01)00378-x
44306599 201958 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 803 16 5 6 7.1 NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL67308 201958 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 803 16 5 6 7.1 NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
44328562 167516 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 924 23 11 8 3.4 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(C(=O)c2ccccc2)cc1)NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)O 10.1016/s0960-894x(98)00730-6
CHEMBL432578 167516 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 924 23 11 8 3.4 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(C(=O)c2ccccc2)cc1)NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)O 10.1016/s0960-894x(98)00730-6
145386418 176560 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assayAntagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assay
ChEMBL 512 5 1 6 6.1 Cc1ccnc(N[C@@H]2CC[C@@H]3[C@@H](C2)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]3/C=C/c2ccc(-c3cccc(F)c3)cn2)n1 10.1016/j.bmcl.2020.127046
CHEMBL4633888 176560 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assayAntagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assay
ChEMBL 512 5 1 6 6.1 Cc1ccnc(N[C@@H]2CC[C@@H]3[C@@H](C2)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]3/C=C/c2ccc(-c3cccc(F)c3)cn2)n1 10.1016/j.bmcl.2020.127046
44306349 102129 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 804 18 7 8 5.1 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc([N+](=O)[O-])cc1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3ccc(F)cc3)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL304120 102129 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 804 18 7 8 5.1 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc([N+](=O)[O-])cc1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3ccc(F)cc3)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
44306336 201853 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 780 17 6 7 5.1 Cc1ccccc1Cn1cc(CN2CCCC2)c2ccc(NC(=O)N[C@@H](Cc3ccc(C#N)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc3ccccc3)cc21 10.1016/s0960-894x(01)00378-x
CHEMBL66585 201853 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 780 17 6 7 5.1 Cc1ccccc1Cn1cc(CN2CCCC2)c2ccc(NC(=O)N[C@@H](Cc3ccc(C#N)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc3ccccc3)cc21 10.1016/s0960-894x(01)00378-x
10077130 3944 49 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/acs.jmedchem.7b00951
4047 3944 49 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/acs.jmedchem.7b00951
4870 3944 49 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/acs.jmedchem.7b00951
CHEMBL493982 3944 49 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/acs.jmedchem.7b00951
DB09030 3944 49 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/acs.jmedchem.7b00951
44306540 201347 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 795 18 6 7 5.4 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL63402 201347 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 795 18 6 7 5.4 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
44306612 101690 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 875 19 6 8 6.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccc(OC(F)(F)F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL302603 101690 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 875 19 6 8 6.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccc(OC(F)(F)F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
90663305 106162 0 None - 1 Human 4.2 pIC50 = 4.2 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 558 11 5 5 2.3 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(N)=O 10.1021/jm960455s
CHEMBL3143265 106162 0 None - 1 Human 4.2 pIC50 = 4.2 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 558 11 5 5 2.3 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(N)=O 10.1021/jm960455s
44339030 9326 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 509 9 0 6 7.0 c1ccc(-c2cccc(-c3cc(N(CCCN4CCCCCC4)Cc4ccc5c(c4)OCO5)on3)c2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL111653 9326 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 509 9 0 6 7.0 c1ccc(-c2cccc(-c3cc(N(CCCN4CCCCCC4)Cc4ccc5c(c4)OCO5)on3)c2)cc1 10.1016/s0960-894x(01)00745-4
15887958 104818 0 None - 1 Human 4.2 pIC50 = 4.2 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 393 5 2 5 0.5 O=C(O)C1CN(C(=O)C2CCCN(C(=O)CCC3CCNCC3)C2)CCC1=O 10.1016/0960-894X(96)00438-6
CHEMBL311554 104818 0 None - 1 Human 4.2 pIC50 = 4.2 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 393 5 2 5 0.5 O=C(O)C1CN(C(=O)C2CCCN(C(=O)CCC3CCNCC3)C2)CCC1=O 10.1016/0960-894X(96)00438-6
90663358 106187 0 None - 1 Human 4.2 pIC50 = 4.2 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 903 22 9 8 3.1 CC(=O)N(C(=O)/C=C/c1ccc(-c2ccccc2)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143324 106187 0 None - 1 Human 4.2 pIC50 = 4.2 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 903 22 9 8 3.1 CC(=O)N(C(=O)/C=C/c1ccc(-c2ccccc2)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
90663341 106182 0 None - 1 Human 4.2 pIC50 = 4.2 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 791 20 9 7 1.5 CC(=O)N(c1ccc(F)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143306 106182 0 None - 1 Human 4.2 pIC50 = 4.2 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 791 20 9 7 1.5 CC(=O)N(c1ccc(F)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3144093 209436 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)CSc1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL5081315 212969 1 None - 1 Human 8.2 pIC50 = 8.2 Functional
Antagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysisAntagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysis
ChEMBL None None None C[C@H]1OC(=O)[C@]2(N)CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@H]12 10.1021/acs.jmedchem.1c02048
CHEMBL5088392 213383 2 None - 1 Human 8.2 pIC50 = 8.2 Functional
Antagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysisAntagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysis
ChEMBL None None None CCNC(=O)N1C[C@H]2[C@H](C)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@]32C1 10.1021/acs.jmedchem.1c02048
CHEMBL5094869 213740 0 None - 1 Human 8.2 pIC50 = 8.2 Functional
Antagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysisAntagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysis
ChEMBL None None None CNC(=O)N1C[C@H]2[C@H](C)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@]32C1 10.1021/acs.jmedchem.1c02048
44338944 110893 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 481 9 0 7 5.5 COc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1F 10.1016/s0960-894x(01)00745-4
CHEMBL327117 110893 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 481 9 0 7 5.5 COc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1F 10.1016/s0960-894x(01)00745-4
44306501 102218 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 834 17 7 7 6.3 N#Cc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL304683 102218 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 834 17 7 7 6.3 N#Cc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
44306762 201411 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 817 17 5 6 7.5 NCCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL63966 201411 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 817 17 5 6 7.5 NCCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
9801767 99866 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 339 7 3 4 0.6 O=C(O)CCNC(=O)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL289432 99866 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 339 7 3 4 0.6 O=C(O)CCNC(=O)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
137649563 156808 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 465 4 1 5 5.0 COC(=O)[C@@]1(C)[C@H]2CC[C@@]3(CO3)[C@@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@]2(C)CC[C@H]1O 10.1021/acs.jmedchem.7b00951
CHEMBL4077763 156808 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 465 4 1 5 5.0 COC(=O)[C@@]1(C)[C@H]2CC[C@@]3(CO3)[C@@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@]2(C)CC[C@H]1O 10.1021/acs.jmedchem.7b00951
44315793 203279 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 340 6 4 4 -0.0 O=C(O)CCNC(=O)C1CCCN(C(=O)NCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL76641 203279 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 340 6 4 4 -0.0 O=C(O)CCNC(=O)C1CCCN(C(=O)NCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
44316059 203827 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 325 7 3 4 0.2 O=C(O)CCNC(=O)C1CCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL80975 203827 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 325 7 3 4 0.2 O=C(O)CCNC(=O)C1CCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
90663340 106181 0 None - 1 Human 4.1 pIC50 = 4.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 779 20 9 8 1.4 CC(=O)N(c1ccsc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143304 106181 0 None - 1 Human 4.1 pIC50 = 4.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 779 20 9 8 1.4 CC(=O)N(c1ccsc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
145386426 176938 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assayAntagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assay
ChEMBL 459 5 1 5 5.1 C[C@H]1OC(=O)[C@]2(NCC#N)C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1016/j.bmcl.2020.127046
CHEMBL4639680 176938 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assayAntagonist activity at human PAR1 expressed in KNRK cells assessed as inhibition of agonist-induced intracellular calcium mobilization by fluorimetric assay
ChEMBL 459 5 1 5 5.1 C[C@H]1OC(=O)[C@]2(NCC#N)C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1016/j.bmcl.2020.127046
CHEMBL3143268 209405 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CCCCC/C=C/CC(=O)N(C(C)=O)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306696 101659 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 817 16 5 6 6.7 NC(=O)CCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL302433 101659 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 817 16 5 6 6.7 NC(=O)CCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
1048267 32212 87 None - 1 Human 6.1 pIC50 = 6.1 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 360 5 2 2 4.4 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
CHEMBL1411333 32212 87 None - 1 Human 6.1 pIC50 = 6.1 Functional
Negative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayNegative allosteric modulation of PAR1 in human EAhy926 cells assessed as reduction in TFLLRN-NH2-induced intracellular calcium mobilization incubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 360 5 2 2 4.4 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2019.06.043
CHEMBL5093637 213660 0 None - 1 Human 8.1 pIC50 = 8.1 Functional
Antagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysisAntagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysis
ChEMBL None None None C[C@H]1OC(=O)[C@]2(O)CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/acs.jmedchem.1c02048
CHEMBL5094241 213707 0 None - 1 Human 8.1 pIC50 = 8.1 Functional
Antagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysisAntagonist activity at human PAR-1 expressed in HEK293 cells assessed as reduction in TRAP induced calcium signal at 3 uM by FLIPR analysis
ChEMBL None None None CC[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(O)CC1(F)F 10.1021/acs.jmedchem.1c02048
90663298 106159 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Concentration of compound required to inhibit agonist (SFFLRR-NH2, at 120 uM) induced platelet aggregation by 50%Concentration of compound required to inhibit agonist (SFFLRR-NH2, at 120 uM) induced platelet aggregation by 50%
ChEMBL 861 21 9 8 2.1 CC(=O)N(C(=O)/C=C/c1cccc(Cl)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143257 106159 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Concentration of compound required to inhibit agonist (SFFLRR-NH2, at 120 uM) induced platelet aggregation by 50%Concentration of compound required to inhibit agonist (SFFLRR-NH2, at 120 uM) induced platelet aggregation by 50%
ChEMBL 861 21 9 8 2.1 CC(=O)N(C(=O)/C=C/c1cccc(Cl)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
10741717 102560 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 439 7 3 4 2.0 O=C(O)C[C@@H](C#Cc1ccccc1)NC(=O)[C@@H]1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL307065 102560 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 439 7 3 4 2.0 O=C(O)C[C@@H](C#Cc1ccccc1)NC(=O)[C@@H]1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
10526120 203149 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 419 7 3 4 2.0 CC(C)(C)C#C[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL75636 203149 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 419 7 3 4 2.0 CC(C)(C)C#C[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
44316156 203286 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 355 7 4 5 -0.4 O=C(O)C(O)CNC(=O)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL76719 203286 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 355 7 4 5 -0.4 O=C(O)C(O)CNC(=O)C1CCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL3143282 209413 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@H](CCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
22645287 203158 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 353 7 3 4 1.0 O=C(O)CCNC(=O)C1CCCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
CHEMBL75688 203158 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 353 7 3 4 1.0 O=C(O)CCNC(=O)C1CCCCN(C(=O)CCC2CCNCC2)C1 10.1016/0960-894X(96)00438-6
137653180 158010 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 451 5 1 4 5.5 COC[C@@]1(C)[C@H]2CC[C@@]3(CO3)[C@@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@]2(C)CC[C@H]1O 10.1021/acs.jmedchem.7b00951
CHEMBL4091623 158010 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 451 5 1 4 5.5 COC[C@@]1(C)[C@H]2CC[C@@]3(CO3)[C@@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@]2(C)CC[C@H]1O 10.1021/acs.jmedchem.7b00951
145967675 164544 0 None - 1 Human 4.1 pIC50 = 4.1 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 370 5 2 2 4.1 C#CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
CHEMBL4227184 164544 0 None - 1 Human 4.1 pIC50 = 4.1 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 370 5 2 2 4.1 C#CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
10162707 9238 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 478 9 0 8 5.3 O=[N+]([O-])c1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL111109 9238 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 478 9 0 8 5.3 O=[N+]([O-])c1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL3143266 209404 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccc(C)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
90663293 106156 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 998 29 11 11 1.0 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN)C(=O)CCC(N)=O 10.1021/jm960455s
CHEMBL3143252 106156 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 998 29 11 11 1.0 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN)C(=O)CCC(N)=O 10.1021/jm960455s
1048267 32212 87 None - 1 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 360 5 2 2 4.4 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
CHEMBL1411333 32212 87 None - 1 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 360 5 2 2 4.4 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
44306708 100443 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 817 20 6 7 5.5 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL293867 100443 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 817 20 6 7 5.5 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
90663302 106161 0 None - 1 Human 4.1 pIC50 = 4.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 765 20 9 7 1.1 CC(=O)N(C1CCCC1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143262 106161 0 None - 1 Human 4.1 pIC50 = 4.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 765 20 9 7 1.1 CC(=O)N(C1CCCC1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
137632975 155807 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 508 5 1 6 5.1 COC(=O)[C@@]1(C)[C@H]2CC[C@@]3(CO3)[C@@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@]2(C)CC[C@H]1OC(N)=O 10.1021/acs.jmedchem.7b00951
CHEMBL4065905 155807 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 508 5 1 6 5.1 COC(=O)[C@@]1(C)[C@H]2CC[C@@]3(CO3)[C@@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@]2(C)CC[C@H]1OC(N)=O 10.1021/acs.jmedchem.7b00951
CHEMBL3143310 209424 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@H](CCCN)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)NC(=O)/C=C/c1ccccc1 10.1021/jm960455s
137652024 156578 0 None - 1 Human 4.1 pIC50 = 4.1 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 485 5 0 4 6.7 C[C@H]1CC[C@@H]2C(C)(C)[C@H](OS(C)(=O)=O)CC[C@@]2(C)[C@@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
CHEMBL4074902 156578 0 None - 1 Human 4.1 pIC50 = 4.1 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 485 5 0 4 6.7 C[C@H]1CC[C@@H]2C(C)(C)[C@H](OS(C)(=O)=O)CC[C@@]2(C)[C@@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
CHEMBL3143289 209417 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@H](CC1CCCCC1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
90663338 106179 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 833 22 9 9 1.8 C=CC(=O)c1ccsc1N(C(C)=O)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143302 106179 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 833 22 9 9 1.8 C=CC(=O)c1ccsc1N(C(C)=O)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44338791 9236 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 559 8 0 6 5.9 Ic1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL111106 9236 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 559 8 0 6 5.9 Ic1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
9847494 5771 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 469 8 0 6 5.6 Fc1cc(F)cc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL107920 5771 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 469 8 0 6 5.6 Fc1cc(F)cc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
44338791 9236 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 559 8 0 6 5.9 Ic1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL111106 9236 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 559 8 0 6 5.9 Ic1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL3143249 209397 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccc(F)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
10622095 203568 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 421 8 3 5 2.4 O=C(O)C[C@H](NC(=O)[C@@H]1CCCN(C(=O)CCC2CCNCC2)C1)c1cccs1 10.1016/0960-894X(96)00438-6
CHEMBL79087 203568 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.In vitro inhibition of thrombin-induced human gel-filtered platelet aggregation.
ChEMBL 421 8 3 5 2.4 O=C(O)C[C@H](NC(=O)[C@@H]1CCCN(C(=O)CCC2CCNCC2)C1)c1cccs1 10.1016/0960-894X(96)00438-6
44306894 102239 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 806 18 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4cccc(C)c4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL304829 102239 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 806 18 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4cccc(C)c4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
44306660 202126 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 797 20 6 7 5.6 CCN(CC)Cc1cn(Cc2ccc(F)cc2)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC3CCCCC3)ccc12 10.1016/s0960-894x(01)00378-x
CHEMBL68458 202126 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)In vitro inhibition of human platelet aggregation induced by SFLLRN-NH2 (at a concentration of 2 uM)
ChEMBL 797 20 6 7 5.6 CCN(CC)Cc1cn(Cc2ccc(F)cc2)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC3CCCCC3)ccc12 10.1016/s0960-894x(01)00378-x
44306732 102131 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 775 14 5 6 6.4 NCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL304128 102131 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 775 14 5 6 6.4 NCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
10819322 203205 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 839 18 7 7 6.4 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL7610 203205 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 839 18 7 7 6.4 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
128205 9359 2 None - 1 Human 5.1 pIC50 = 5.1 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 375 8 0 4 5.2 c1ccc(CN(CCCN2CCCCC2)c2cc(-c3ccccc3)no2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL111790 9359 2 None - 1 Human 5.1 pIC50 = 5.1 Functional
Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)Antagonistic activity against thrombin receptor, inhibition of secreted radiolabeled [3H]5-HT from washed human platelets stimulated by 3 uM thrombin receptor activating peptide (TRAP)
ChEMBL 375 8 0 4 5.2 c1ccc(CN(CCCN2CCCCC2)c2cc(-c3ccccc3)no2)cc1 10.1016/s0960-894x(01)00745-4
44328197 81972 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 1051 28 10 9 5.0 CCC(=O)NCCC[C@H](NC(=O)[C@H](Cc1ccc(C(=O)c2ccccc2)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)O 10.1016/s0960-894x(98)00730-6
CHEMBL217237 81972 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 1051 28 10 9 5.0 CCC(=O)NCCC[C@H](NC(=O)[C@H](Cc1ccc(C(=O)c2ccccc2)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)O 10.1016/s0960-894x(98)00730-6
90663321 106170 0 None - 1 Human 4.1 pIC50 = 4.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 850 23 6 8 1.5 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@H](CCCCN=C(N(C)C)N(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143283 106170 0 None - 1 Human 4.1 pIC50 = 4.1 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 850 23 6 8 1.5 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@H](CCCCN=C(N(C)C)N(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
12018758 9257 0 None - 1 Human 6.0 pIC50 = 6.0 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 467 8 0 6 6.0 Clc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL111241 9257 0 None - 1 Human 6.0 pIC50 = 6.0 Functional
Inhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombinInhibition of secretion of radiolabeled serotonin from washed human platelets stimulated by 1 nM thrombin
ChEMBL 467 8 0 6 6.0 Clc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
137659611 158905 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 437 4 2 4 4.9 C[C@@]12CC[C@@H](O)[C@@](C)(CO)[C@H]1CC[C@@]1(CO1)[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
CHEMBL4101239 158905 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 437 4 2 4 4.9 C[C@@]12CC[C@@H](O)[C@@](C)(CO)[C@H]1CC[C@@]1(CO1)[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
145971090 164483 0 None - 1 Human 4.0 pIC50 = 4.0 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 323 6 2 3 4.6 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2N=[N+]=[N-])c1 10.1016/j.bmc.2018.04.016
CHEMBL4226195 164483 0 None - 1 Human 4.0 pIC50 = 4.0 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 323 6 2 3 4.6 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2N=[N+]=[N-])c1 10.1016/j.bmc.2018.04.016
90663331 106173 0 None - 1 Human 4.0 pIC50 = 4.0 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 773 20 9 7 1.4 CC(=O)N(c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143294 106173 0 None - 1 Human 4.0 pIC50 = 4.0 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 773 20 9 7 1.4 CC(=O)N(c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143266 209404 0 None - 1 Human 6.0 pIC50 = 6.0 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccc(C)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
137631870 155803 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 487 4 2 4 5.7 C[C@@]12CC[C@@H](O)[C@@](C)(CO)[C@H]1CC[C@@]1(CO1)[C@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1021/acs.jmedchem.7b00951
CHEMBL4065873 155803 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
Antagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assayAntagonist activity at human PAR1 expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of haTRAP-induced calcium mobilization preincubated for 15 mins followed by haTRAP addition by calcium-4 dye based FLIPR assay
ChEMBL 487 4 2 4 5.7 C[C@@]12CC[C@@H](O)[C@@](C)(CO)[C@H]1CC[C@@]1(CO1)[C@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1021/acs.jmedchem.7b00951
155526775 170616 0 None - 1 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 1309 45 6 19 5.6 NCCOCCOCCOCCOCCOCCOCCOCCOCCn1cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc2ccc(F)c(F)c2)NC(=O)Nc2ccc3c(CN4CCCC4)nn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)NCc2ccccc2)nn1 10.1021/acsmedchemlett.8b00538
CHEMBL4459024 170616 0 None - 1 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization preincubated for 15 mins followed by TFLLRN-NH2 addition by Fluo-4-AM dye based fluorescence assay
ChEMBL 1309 45 6 19 5.6 NCCOCCOCCOCCOCCOCCOCCOCCOCCn1cc(CCC(=O)NCC[C@H](NC(=O)[C@H](Cc2ccc(F)c(F)c2)NC(=O)Nc2ccc3c(CN4CCCC4)nn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)NCc2ccccc2)nn1 10.1021/acsmedchemlett.8b00538
51003683 75301 0 None - 1 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 346 6 2 2 4.9 CCCCNc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
CHEMBL2047297 75301 0 None - 1 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 346 6 2 2 4.9 CCCCNc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
CHEMBL4227548 75301 0 None - 1 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assayAntagonist activity at PAR1 in human EAhy926 cells assessed as inhibition of TFLLRN-NH2-induced intracellular calcium mobilization pretreated for 15 mins followed by TFLLRN-NH2 addition measured at 5 secs interval for 250 secs by Fluo-4/AM dye based fluorescence assay
ChEMBL 346 6 2 2 4.9 CCCCNc1cccc(NC(=O)c2ccccc2Br)c1 10.1016/j.bmc.2018.04.016
44328383 158417 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 1222 32 12 11 5.3 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)N[C@@H](Cc1ccc(C(=O)c2ccccc2)cc1)C(=O)N[C@@H](CCCNC(=O)CCCCC1SC[C@H]2NC(=O)N[C@@H]12)C(=O)O 10.1016/s0960-894x(98)00730-6
CHEMBL409602 158417 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
Human Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregationHuman Thrombin receptor 1 (PAR-1) antagonistic ability to inhibit SFLLRN-NH2 (2.7 uM)-induced platelet aggregation
ChEMBL 1222 32 12 11 5.3 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)N[C@@H](Cc1ccc(C(=O)c2ccccc2)cc1)C(=O)N[C@@H](CCCNC(=O)CCCCC1SC[C@H]2NC(=O)N[C@@H]12)C(=O)O 10.1016/s0960-894x(98)00730-6
44306611 201908 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 775 18 6 7 4.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL66958 201908 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)In vitro inhibition of human platelet aggregation induced by alpha-thrombin (at a concentration of 0.15 nM)
ChEMBL 775 18 6 7 4.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
90663342 106183 0 None - 1 Human 5.0 pIC50 = 5 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 828 21 10 8 1.6 CC(=O)N(Oc1c[nH]c2ccccc12)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143307 106183 0 None - 1 Human 5.0 pIC50 = 5 Functional
Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%Concentration required to inhibit agonist (SFFLRR-NH2, at 3 uM) induced platelet aggregation by 50%
ChEMBL 828 21 10 8 1.6 CC(=O)N(Oc1c[nH]c2ccccc12)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44264790 97871 0 None - 0 Human 9.4 pKd = 9.4 Functional
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 862 18 7 8 5.8 NC(CCN[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1)C(=O)O 10.1021/jm000506s
CHEMBL275003 97871 0 None - 0 Human 9.4 pKd = 9.4 Functional
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 862 18 7 8 5.8 NC(CCN[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1)C(=O)O 10.1021/jm000506s
19323337 1586 1 None - 1 Human 6.4 pKd = 6.4 Functional
Antagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assayAntagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assay
ChEMBL 358 4 0 2 3.8 Fc1ccc(cc1)CN1CCN(CC1)C(=O)/C=C/c1ccccc1Cl 10.1016/j.bmcl.2010.01.050
9255 1586 1 None - 1 Human 6.4 pKd = 6.4 Functional
Antagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assayAntagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assay
ChEMBL 358 4 0 2 3.8 Fc1ccc(cc1)CN1CCN(CC1)C(=O)/C=C/c1ccccc1Cl 10.1016/j.bmcl.2010.01.050
CHEMBL559808 1586 1 None - 1 Human 6.4 pKd = 6.4 Functional
Antagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assayAntagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assay
ChEMBL 358 4 0 2 3.8 Fc1ccc(cc1)CN1CCN(CC1)C(=O)/C=C/c1ccccc1Cl 10.1016/j.bmcl.2010.01.050
46865538 6060 0 None - 0 Human 6.4 pKd = 6.4 Functional
Antagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assayAntagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assay
ChEMBL 389 5 0 6 2.7 N#Cc1ccccc1/C=C/c1c(N2CCN(Cc3ccsc3)CC2)c(=O)c1=O 10.1016/j.bmcl.2010.01.050
CHEMBL1080910 6060 0 None - 0 Human 6.4 pKd = 6.4 Functional
Antagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assayAntagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assay
ChEMBL 389 5 0 6 2.7 N#Cc1ccccc1/C=C/c1c(N2CCN(Cc3ccsc3)CC2)c(=O)c1=O 10.1016/j.bmcl.2010.01.050
46880808 6257 0 None - 0 Human 6.4 pKd = 6.4 Functional
Antagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assayAntagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assay
ChEMBL 376 4 1 2 4.5 O=C(/C=C\c1ccccc1Cl)N1CCC(Nc2ccc(F)cc2)C(F)C1 10.1016/j.bmcl.2010.01.050
CHEMBL1081998 6257 0 None - 0 Human 6.4 pKd = 6.4 Functional
Antagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assayAntagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assay
ChEMBL 376 4 1 2 4.5 O=C(/C=C\c1ccccc1Cl)N1CCC(Nc2ccc(F)cc2)C(F)C1 10.1016/j.bmcl.2010.01.050
46880668 6088 0 None - 0 Human 6.4 pKd = 6.4 Functional
Antagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assayAntagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assay
ChEMBL 389 5 0 5 3.0 N#Cc1ccccc1/C=C/c1c(N2CCN(CC3CCCCC3)CC2)c(=O)c1=O 10.1016/j.bmcl.2010.01.050
CHEMBL1081077 6088 0 None - 0 Human 6.4 pKd = 6.4 Functional
Antagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assayAntagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assay
ChEMBL 389 5 0 5 3.0 N#Cc1ccccc1/C=C/c1c(N2CCN(CC3CCCCC3)CC2)c(=O)c1=O 10.1016/j.bmcl.2010.01.050
46865537 7397 0 None - 0 Human 6.2 pKd = 6.2 Functional
Antagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assayAntagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assay
ChEMBL 472 7 0 4 4.7 N#Cc1ccccc1/C=C\C(=O)N1CCC(N(Cc2ccc(F)cc2)Cc2ccccn2)C(F)C1 10.1016/j.bmcl.2010.01.050
CHEMBL1087016 7397 0 None - 0 Human 6.2 pKd = 6.2 Functional
Antagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assayAntagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assay
ChEMBL 472 7 0 4 4.7 N#Cc1ccccc1/C=C\C(=O)N1CCC(N(Cc2ccc(F)cc2)Cc2ccccn2)C(F)C1 10.1016/j.bmcl.2010.01.050
44251419 6224 0 None - 0 Human 6.0 pKd = 6.0 Functional
Antagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assayAntagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assay
ChEMBL 317 5 1 4 4.2 N#Cc1ccccc1/C=C/C(=O)c1ccc(NC2CCCC2)nc1 10.1016/j.bmcl.2010.01.050
CHEMBL1081797 6224 0 None - 0 Human 6.0 pKd = 6.0 Functional
Antagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assayAntagonist activity at PAR1 expressed in CHO cells assessed as inhibition of SFLLR-NH2-induced calcium release by FLIPR assay
ChEMBL 317 5 1 4 4.2 N#Cc1ccccc1/C=C/C(=O)c1ccc(NC2CCCC2)nc1 10.1016/j.bmcl.2010.01.050
10077130 3944 49 None - 1 Human 9.0 pKi = 9.0 Functional
Antagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced calcium effluxAntagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced calcium efflux
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
4047 3944 49 None - 1 Human 9.0 pKi = 9.0 Functional
Antagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced calcium effluxAntagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced calcium efflux
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
4870 3944 49 None - 1 Human 9.0 pKi = 9.0 Functional
Antagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced calcium effluxAntagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced calcium efflux
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
CHEMBL493982 3944 49 None - 1 Human 9.0 pKi = 9.0 Functional
Antagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced calcium effluxAntagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced calcium efflux
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
DB09030 3944 49 None - 1 Human 9.0 pKi = 9.0 Functional
Antagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced calcium effluxAntagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced calcium efflux
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
10077130 3944 49 None - 1 Human 7.9 pKi = 7.9 Functional
Antagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced thymidine incorporationAntagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced thymidine incorporation
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
4047 3944 49 None - 1 Human 7.9 pKi = 7.9 Functional
Antagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced thymidine incorporationAntagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced thymidine incorporation
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
4870 3944 49 None - 1 Human 7.9 pKi = 7.9 Functional
Antagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced thymidine incorporationAntagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced thymidine incorporation
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
CHEMBL493982 3944 49 None - 1 Human 7.9 pKi = 7.9 Functional
Antagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced thymidine incorporationAntagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced thymidine incorporation
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
DB09030 3944 49 None - 1 Human 7.9 pKi = 7.9 Functional
Antagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced thymidine incorporationAntagonist activity at human PAR1 in HCASMC assessed as inhibition of thrombin-induced thymidine incorporation
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
10146183 3731 0 None - 1 Human 5.4 pEC50 = 5.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology None None None None 9315351
3742 3731 0 None - 1 Human 5.4 pEC50 = 5.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology None None None None 9315351
CHEMBL4065100 3731 0 None - 1 Human 5.4 pEC50 = 5.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology None None None None 9315351
19323337 1586 1 None - 1 Human 5.2 pIC50 = 5.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 358 4 0 2 3.8 Fc1ccc(cc1)CN1CCN(CC1)C(=O)/C=C/c1ccccc1Cl None
9255 1586 1 None - 1 Human 5.2 pIC50 = 5.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 358 4 0 2 3.8 Fc1ccc(cc1)CN1CCN(CC1)C(=O)/C=C/c1ccccc1Cl None
CHEMBL559808 1586 1 None - 1 Human 5.2 pIC50 = 5.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 358 4 0 2 3.8 Fc1ccc(cc1)CN1CCN(CC1)C(=O)/C=C/c1ccccc1Cl None
3525 3367 8 None - 1 Human 6.4 pIC50 = 6.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 789 15 5 6 6.8 NCC[C@@H](C(=O)NCc1ccccc1)NC(=O)[C@H](Cc1ccc(c(c1)F)F)NC(=O)Nc1ccc2c(c1)n(Cc1c(Cl)cccc1Cl)cc2CN1CCCC1 10535908
9853822 3367 8 None - 1 Human 6.4 pIC50 = 6.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 789 15 5 6 6.8 NCC[C@@H](C(=O)NCc1ccccc1)NC(=O)[C@H](Cc1ccc(c(c1)F)F)NC(=O)Nc1ccc2c(c1)n(Cc1c(Cl)cccc1Cl)cc2CN1CCCC1 10535908
CHEMBL311626 3367 8 None - 1 Human 6.4 pIC50 = 6.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 789 15 5 6 6.8 NCC[C@@H](C(=O)NCc1ccccc1)NC(=O)[C@H](Cc1ccc(c(c1)F)F)NC(=O)Nc1ccc2c(c1)n(Cc1c(Cl)cccc1Cl)cc2CN1CCCC1 10535908
10971 3502 24 None 158 2 Human 7.2 pIC50 = 7.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 371 5 2 5 4.9 CC(c1ccc(cc1)Cn1ccc2c1ccc1c2c(N)nc(n1)NC1CC1)C 11020444
4259181 3502 24 None 158 2 Human 7.2 pIC50 = 7.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 371 5 2 5 4.9 CC(c1ccc(cc1)Cn1ccc2c1ccc1c2c(N)nc(n1)NC1CC1)C 11020444
CHEMBL63426 3502 24 None 158 2 Human 7.2 pIC50 = 7.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 371 5 2 5 4.9 CC(c1ccc(cc1)Cn1ccc2c1ccc1c2c(N)nc(n1)NC1CC1)C 11020444
10459564 514 34 None - 1 Human 7.7 pIC50 = 7.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC 21300059
4048 514 34 None - 1 Human 7.7 pIC50 = 7.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC 21300059
CHEMBL2103856 514 34 None - 1 Human 7.7 pIC50 = 7.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC 21300059
DB12046 514 34 None - 1 Human 7.7 pIC50 = 7.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC 21300059


Get vendors


Ligands Receptor Assay information Chemical information
Sel. page Common
name		 GPCRdb ID #Vendors Reference
ligand		 Fold selectivity
(Affinity)		 # tested GPCRs
(Affinity)		 Species p-value
(-log)		 Type Activity
Relation		 Activity
Value		 Assay Type Assay Description Source Mol
weight		 Rot
Bonds		 H don H acc LogP Smiles DOI
CHEMBL2370701 208172 0 None - 0 Human 5.5 pEC50 = 5.5 Binding
Activation of PAR-1 in human platelet-rich plasma assessed as induction of platelet aggregation by turbidimetric methodActivation of PAR-1 in human platelet-rich plasma assessed as induction of platelet aggregation by turbidimetric method
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(N)=O 10.1016/j.bmc.2021.116498
CHEMBL5088108 213365 0 None - 0 Human 4.3 pEC50 = 4.3 Binding
Activation of PAR-1 in human platelet-rich plasma assessed as induction of platelet aggregation by turbidimetric methodActivation of PAR-1 in human platelet-rich plasma assessed as induction of platelet aggregation by turbidimetric method
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1cc(F)c(F)c(F)c1F)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(N)=O 10.1016/j.bmc.2021.116498
CHEMBL5081145 212955 0 None - 0 Human 5.1 pEC50 = 5.1 Binding
Activation of PAR-1 in human platelet-rich plasma assessed as induction of platelet aggregation by turbidimetric methodActivation of PAR-1 in human platelet-rich plasma assessed as induction of platelet aggregation by turbidimetric method
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c(F)cc(F)c(F)c1F)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(N)=O 10.1016/j.bmc.2021.116498
CHEMBL5087962 213357 0 None - 0 Human 4.0 pEC50 = 4 Binding
Activation of PAR-1 in human platelet-rich plasma assessed as induction of platelet aggregation by turbidimetric methodActivation of PAR-1 in human platelet-rich plasma assessed as induction of platelet aggregation by turbidimetric method
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(N)=O 10.1016/j.bmc.2021.116498
127053962 150000 0 None - 0 Human 9.1 pIC50 = 9.1 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 513 5 0 6 6.2 Cc1nnc(C[C@@]23CC(F)(F)[C@@H](C)[C@H](/C=C/c4ccc(-c5ccccc5Cl)cn4)C2[C@@H](C)OC3=O)o1 nan
CHEMBL3954641 150000 0 None - 0 Human 9.1 pIC50 = 9.1 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 513 5 0 6 6.2 Cc1nnc(C[C@@]23CC(F)(F)[C@@H](C)[C@H](/C=C/c4ccc(-c5ccccc5Cl)cn4)C2[C@@H](C)OC3=O)o1 nan
127053955 159885 0 None - 0 Human 9.1 pIC50 = 9.1 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 521 5 1 7 5.7 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2cscn2)CC1(F)F nan
CHEMBL4111522 159885 0 None - 0 Human 9.1 pIC50 = 9.1 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 521 5 1 7 5.7 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2cscn2)CC1(F)F nan
127053997 148418 0 None - 0 Human 9.0 pIC50 = 9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 513 5 0 7 5.0 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3Cl)cn2)C2[C@@H](C)OC(=O)[C@]2(Cc2nnnn2C)CC1(F)F nan
CHEMBL3942006 148418 0 None - 0 Human 9.0 pIC50 = 9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 513 5 0 7 5.0 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3Cl)cn2)C2[C@@H](C)OC(=O)[C@]2(Cc2nnnn2C)CC1(F)F nan
10077130 3944 49 None - 1 Human 9.0 pIC50 = 9.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400235c
4047 3944 49 None - 1 Human 9.0 pIC50 = 9.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400235c
4870 3944 49 None - 1 Human 9.0 pIC50 = 9.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400235c
CHEMBL493982 3944 49 None - 1 Human 9.0 pIC50 = 9.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400235c
DB09030 3944 49 None - 1 Human 9.0 pIC50 = 9.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400235c
127053960 147119 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 499 5 0 6 5.9 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3Cl)cn2)C2[C@@H](C)OC(=O)[C@]2(Cc2ncon2)CC1(F)F nan
CHEMBL3931589 147119 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 499 5 0 6 5.9 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3Cl)cn2)C2[C@@H](C)OC(=O)[C@]2(Cc2ncon2)CC1(F)F nan
127053994 151406 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 451 4 1 5 4.7 Cc1cccc(-c2ccc(/C=C/[C@@H]3C4[C@@H](C)OC(=O)[C@]4(CN)CC(F)(F)[C@H]3C)nc2)c1C#N nan
CHEMBL3966338 151406 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 451 4 1 5 4.7 Cc1cccc(-c2ccc(/C=C/[C@@H]3C4[C@@H](C)OC(=O)[C@]4(CN)CC(F)(F)[C@H]3C)nc2)c1C#N nan
127053955 159885 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 521 5 1 7 5.7 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2cscn2)CC1(F)F nan
CHEMBL4111522 159885 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 521 5 1 7 5.7 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2cscn2)CC1(F)F nan
127053956 160163 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 521 5 1 7 5.7 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2nccs2)CC1(F)F nan
CHEMBL4113709 160163 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 521 5 1 7 5.7 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2nccs2)CC1(F)F nan
127053958 160311 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 505 5 1 7 5.2 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2ncco2)CC1(F)F nan
CHEMBL4114937 160311 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 505 5 1 7 5.2 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2ncco2)CC1(F)F nan
72547307 103392 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 428 5 0 3 5.0 CN(C1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1)S(C)(=O)=O 10.1021/ml400235c
CHEMBL3091980 103392 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 428 5 0 3 5.0 CN(C1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1)S(C)(=O)=O 10.1021/ml400235c
127053975 142770 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 520 6 1 7 5.5 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCc2cncs2)CC1(F)F nan
CHEMBL3897109 142770 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 520 6 1 7 5.5 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCc2cncs2)CC1(F)F nan
127053965 159326 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 489 4 0 7 4.8 Cc1cn([C@@]23CC(F)(F)C(C)[C@H](/C=C/c4ccc(-c5ccccc5C#N)cn4)C2[C@@H](C)OC3=O)nn1 nan
CHEMBL4106770 159326 0 None - 0 Human 8.9 pIC50 = 8.9 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 489 4 0 7 4.8 Cc1cn([C@@]23CC(F)(F)C(C)[C@H](/C=C/c4ccc(-c5ccccc5C#N)cn4)C2[C@@H](C)OC3=O)nn1 nan
10077130 3944 49 None - 1 Human 8.8 pIC50 = 8.8 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400235c
4047 3944 49 None - 1 Human 8.8 pIC50 = 8.8 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400235c
4870 3944 49 None - 1 Human 8.8 pIC50 = 8.8 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400235c
CHEMBL493982 3944 49 None - 1 Human 8.8 pIC50 = 8.8 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400235c
DB09030 3944 49 None - 1 Human 8.8 pIC50 = 8.8 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400235c
127053995 147308 0 None - 0 Human 8.8 pIC50 = 8.8 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 407 3 1 3 4.7 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2C(CC1(F)F)C(=O)N[C@@H]2C nan
CHEMBL3933019 147308 0 None - 0 Human 8.8 pIC50 = 8.8 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 407 3 1 3 4.7 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2C(CC1(F)F)C(=O)N[C@@H]2C nan
127053938 147892 0 None - 0 Human 8.8 pIC50 = 8.8 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 408 3 0 4 5.1 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2C(CC1(F)F)C(=O)O[C@@H]2C nan
CHEMBL3937747 147892 0 None - 0 Human 8.8 pIC50 = 8.8 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 408 3 0 4 5.1 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2C(CC1(F)F)C(=O)O[C@@H]2C nan
127053976 151637 0 None - 0 Human 8.8 pIC50 = 8.8 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 520 6 1 7 5.5 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCc2cscn2)CC1(F)F nan
CHEMBL3968240 151637 0 None - 0 Human 8.8 pIC50 = 8.8 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 520 6 1 7 5.5 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCc2cscn2)CC1(F)F nan
127053985 160148 0 None - 0 Human 8.8 pIC50 = 8.8 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 545 5 1 5 5.8 C[C@H]1OC(=O)[C@]2(NC(=O)c3ccc(F)cc3)CC(F)(F)[C@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@@H]12 nan
CHEMBL4113548 160148 0 None - 0 Human 8.8 pIC50 = 8.8 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 545 5 1 5 5.8 C[C@H]1OC(=O)[C@]2(NC(=O)c3ccc(F)cc3)CC(F)(F)[C@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@@H]12 nan
127053957 159774 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 505 5 1 7 5.2 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2cocn2)CC1(F)F nan
CHEMBL4110608 159774 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 505 5 1 7 5.2 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2cocn2)CC1(F)F nan
CHEMBL4764659 212285 0 None - 0 Human 8.0 pIC50 = 8 Binding
Affinity On-target Cellular interaction (Functional cellular assay in HEK cells expressing F2R) EUB0000291b F2RAffinity On-target Cellular interaction (Functional cellular assay in HEK cells expressing F2R) EUB0000291b F2R
ChEMBL None None None O=C(N1CCS(=O)(=O)CC1)N1C[C@@](S)(c2ccc(OC(F)(F)F)cc2)C[C@@](S)(c2nc(C3CC3)no2)C1 nan
127050657 140289 0 None - 0 Human 8.0 pIC50 = 8 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 486 7 2 5 2.9 CCN(C(=O)CO)C1CN(/C(=N\C#N)NCCc2cccc(Cl)c2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
CHEMBL3819038 140289 0 None - 0 Human 8.0 pIC50 = 8 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 486 7 2 5 2.9 CCN(C(=O)CO)C1CN(/C(=N\C#N)NCCc2cccc(Cl)c2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
44432773 86600 0 None - 0 Human 8.0 pIC50 = 8 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 419 3 0 3 5.7 O=C1OC[C@H]2[C@@H]1Cc1ccc(F)cc1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL232534 86600 0 None - 0 Human 8.0 pIC50 = 8 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 419 3 0 3 5.7 O=C1OC[C@H]2[C@@H]1Cc1ccc(F)cc1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
9889179 87544 0 None - 0 Human 8.0 pIC50 = 8 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 435 3 0 3 5.9 O=C1OC[C@H]2[C@@H]1Cc1ccccc1[C@@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL234190 87544 0 None - 0 Human 8.0 pIC50 = 8 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 435 3 0 3 5.9 O=C1OC[C@H]2[C@@H]1Cc1ccccc1[C@@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2007.04.061
44432790 96836 0 None - 0 Human 8.0 pIC50 = 8 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 403 3 0 3 5.2 O=C1OC[C@H]2[C@@H]1Cc1ccc(F)cc1[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL269006 96836 0 None - 0 Human 8.0 pIC50 = 8 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 403 3 0 3 5.2 O=C1OC[C@H]2[C@@H]1Cc1ccc(F)cc1[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
9931987 72220 0 None - 0 Human 8.0 pIC50 = 8 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 421 3 0 3 6.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(Cl)c4)cn3)[C@H]12 10.1021/jm0502236
CHEMBL199201 72220 0 None - 0 Human 8.0 pIC50 = 8 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 421 3 0 3 6.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(Cl)c4)cn3)[C@H]12 10.1021/jm0502236
71736052 146299 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 493 5 1 5 5.9 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCC(C)(C)C)CC1(F)F nan
CHEMBL3924976 146299 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 493 5 1 5 5.9 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCC(C)(C)C)CC1(F)F nan
121335751 148178 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 479 5 1 6 4.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC2COC2)CC1(F)F nan
CHEMBL3940064 148178 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 479 5 1 6 4.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC2COC2)CC1(F)F nan
44428104 143890 0 None - 1 Human 8.0 pIC50 = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 478 4 0 5 5.2 CCOC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)C1 10.1021/jm070704k
CHEMBL390630 143890 0 None - 1 Human 8.0 pIC50 = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 478 4 0 5 5.2 CCOC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)C1 10.1021/jm070704k
127053947 149756 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 445 4 1 4 4.8 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)C2[C@@H](C)OC(=O)[C@]2(C(=O)O)CC1(F)F nan
CHEMBL3952737 149756 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 445 4 1 4 4.8 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)C2[C@@H](C)OC(=O)[C@]2(C(=O)O)CC1(F)F nan
127049415 140322 0 None - 0 Human 7.0 pIC50 = 7 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 473 5 2 6 2.7 N#C/N=C(/Nc1cccc(OC(F)F)c1)N1CC(N2CNCC2=O)C(c2ccc(Cl)cc2)=N1 10.1021/acs.jmedchem.5b01890
CHEMBL3819515 140322 0 None - 0 Human 7.0 pIC50 = 7 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 473 5 2 6 2.7 N#C/N=C(/Nc1cccc(OC(F)F)c1)N1CC(N2CNCC2=O)C(c2ccc(Cl)cc2)=N1 10.1021/acs.jmedchem.5b01890
72547556 103405 0 None - 0 Human 7.0 pIC50 = 7 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 394 4 1 3 5.6 CC1(OC(N)=O)C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091993 103405 0 None - 0 Human 7.0 pIC50 = 7 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 394 4 1 3 5.6 CC1(OC(N)=O)C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
44408851 75057 0 None - 0 Human 7.0 pIC50 = 7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 361 2 0 3 5.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL204009 75057 0 None - 0 Human 7.0 pIC50 = 7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 361 2 0 3 5.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
44409253 75679 0 None - 0 Human 7.0 pIC50 = 7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 418 3 1 4 5.2 CC(=O)Nc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2005.12.042
CHEMBL205683 75679 0 None - 0 Human 7.0 pIC50 = 7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 418 3 1 4 5.2 CC(=O)Nc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2005.12.042
11576348 71678 0 None - 0 Human 7.0 pIC50 = 7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 466 4 1 5 4.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(S(N)(=O)=O)c4)cn3)[C@H]12 10.1021/jm0502236
CHEMBL197523 71678 0 None - 0 Human 7.0 pIC50 = 7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 466 4 1 5 4.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(S(N)(=O)=O)c4)cn3)[C@H]12 10.1021/jm0502236
44305948 100133 0 None - 0 Human 7.0 pIC50 = 7 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 399 4 1 5 5.3 CC(C)c1ccc(Cn2ccc3c4c(N)nc(N5CCCCC5)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
CHEMBL291807 100133 0 None - 0 Human 7.0 pIC50 = 7 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 399 4 1 5 5.3 CC(C)c1ccc(Cn2ccc3c4c(N)nc(N5CCCCC5)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
44305954 162023 0 None - 0 Human 7.0 pIC50 = 7 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 359 4 1 5 4.4 CC(C)c1ccc(Cn2ccc3c4c(N)nc(N(C)C)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
CHEMBL416862 162023 0 None - 0 Human 7.0 pIC50 = 7 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 359 4 1 5 4.4 CC(C)c1ccc(Cn2ccc3c4c(N)nc(N(C)C)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
CHEMBL3143263 209402 0 None - 0 Human 6.0 pIC50 = 6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)c1ccccc1N)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
9805672 205368 0 None - 0 Human 6.0 pIC50 = 6 Binding
Binding affinity against platelet thrombin receptorBinding affinity against platelet thrombin receptor
ChEMBL 491 5 3 3 5.8 C[C@H]1CC[C@@H]([C@@H](O)c2ccc(Cl)c(Cl)c2)N1C(=O)Nc1ccc(CNC(=O)C(C)(C)C)cc1 10.1016/s0960-894x(01)00538-8
CHEMBL91987 205368 0 None - 0 Human 6.0 pIC50 = 6 Binding
Binding affinity against platelet thrombin receptorBinding affinity against platelet thrombin receptor
ChEMBL 491 5 3 3 5.8 C[C@H]1CC[C@@H]([C@@H](O)c2ccc(Cl)c(Cl)c2)N1C(=O)Nc1ccc(CNC(=O)C(C)(C)C)cc1 10.1016/s0960-894x(01)00538-8
44409265 74665 0 None - 0 Human 6.0 pIC50 = 6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 434 5 1 5 4.1 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OCC(N)=O)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL203376 74665 0 None - 0 Human 6.0 pIC50 = 6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 434 5 1 5 4.1 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OCC(N)=O)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
44306404 201219 0 None - 0 Human 6.0 pIC50 = 6 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 813 20 6 7 5.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccccc4C)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL62775 201219 0 None - 0 Human 6.0 pIC50 = 6 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 813 20 6 7 5.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccccc4C)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
11502697 133900 0 None - 0 Human 6.0 pIC50 = 6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 421 3 0 3 6.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccc(Cl)cc4)cn3)[C@H]12 10.1021/jm0502236
CHEMBL371751 133900 0 None - 0 Human 6.0 pIC50 = 6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 421 3 0 3 6.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccc(Cl)cc4)cn3)[C@H]12 10.1021/jm0502236
752812 2537 43 None - 0 Human 5.0 pIC50 = 5 Binding
Antagonist activity at PAR1 in PAR-1-AP-stimulated human platelets compound pretreated for 5 mins by fluorescent PAC1 integrin alpha2bb3 activation assayAntagonist activity at PAR1 in PAR-1-AP-stimulated human platelets compound pretreated for 5 mins by fluorescent PAC1 integrin alpha2bb3 activation assay
ChEMBL 282 3 1 4 3.2 OCc1c(c2ccccc2)c2c(n1C)ccc(c2)[N+](=O)[O-] 10.1016/j.bmcl.2014.08.021
9459 2537 43 None - 0 Human 5.0 pIC50 = 5 Binding
Antagonist activity at PAR1 in PAR-1-AP-stimulated human platelets compound pretreated for 5 mins by fluorescent PAC1 integrin alpha2bb3 activation assayAntagonist activity at PAR1 in PAR-1-AP-stimulated human platelets compound pretreated for 5 mins by fluorescent PAC1 integrin alpha2bb3 activation assay
ChEMBL 282 3 1 4 3.2 OCc1c(c2ccccc2)c2c(n1C)ccc(c2)[N+](=O)[O-] 10.1016/j.bmcl.2014.08.021
CHEMBL1609104 2537 43 None - 0 Human 5.0 pIC50 = 5 Binding
Antagonist activity at PAR1 in PAR-1-AP-stimulated human platelets compound pretreated for 5 mins by fluorescent PAC1 integrin alpha2bb3 activation assayAntagonist activity at PAR1 in PAR-1-AP-stimulated human platelets compound pretreated for 5 mins by fluorescent PAC1 integrin alpha2bb3 activation assay
ChEMBL 282 3 1 4 3.2 OCc1c(c2ccccc2)c2c(n1C)ccc(c2)[N+](=O)[O-] 10.1016/j.bmcl.2014.08.021
44187282 124623 0 None - 0 Human 5.0 pIC50 = 5 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 482 11 1 8 4.0 CCC(CC)Oc1ccc2n(n1)c(N)n[n+]2CC(=O)c1cc(OC)cc(OCC2CCCCC2)c1 nan
CHEMBL3644439 124623 0 None - 0 Human 5.0 pIC50 = 5 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 482 11 1 8 4.0 CCC(CC)Oc1ccc2n(n1)c(N)n[n+]2CC(=O)c1cc(OC)cc(OCC2CCCCC2)c1 nan
44290104 177986 0 None - 0 Human 5.0 pIC50 = 5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 735 19 7 8 2.8 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cs1 10.1016/s0960-894x(98)00292-3
CHEMBL46702 177986 0 None - 0 Human 5.0 pIC50 = 5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 735 19 7 8 2.8 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cs1 10.1016/s0960-894x(98)00292-3
44280898 99302 0 None - 0 Human 5.0 pIC50 = 5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 566 15 8 5 1.0 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL285075 99302 0 None - 0 Human 5.0 pIC50 = 5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 566 15 8 5 1.0 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280876 99453 0 None - 0 Human 5.0 pIC50 = 5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 507 13 8 8 -2.0 C[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL286141 99453 0 None - 0 Human 5.0 pIC50 = 5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 507 13 8 8 -2.0 C[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280731 99818 0 None - 0 Human 5.0 pIC50 = 5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 597 16 9 8 -0.2 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](CCc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL289020 99818 0 None - 0 Human 5.0 pIC50 = 5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 597 16 9 8 -0.2 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](CCc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44281047 167264 0 None - 0 Human 4.0 pIC50 = 4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 752 18 10 8 2.0 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2c[nH]c3ccccc23)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL430734 167264 0 None - 0 Human 4.0 pIC50 = 4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 752 18 10 8 2.0 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2c[nH]c3ccccc23)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
23631377 92764 0 None - 0 Human 7.0 pIC50 = 7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 512 6 0 5 4.8 CCCS(=O)(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)C1 10.1021/jm070704k
CHEMBL244503 92764 0 None - 0 Human 7.0 pIC50 = 7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 512 6 0 5 4.8 CCCS(=O)(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)C1 10.1021/jm070704k
10162707 9238 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 478 9 0 8 5.3 O=[N+]([O-])c1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL111109 9238 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 478 9 0 8 5.3 O=[N+]([O-])c1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
90663347 106185 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 781 21 8 9 0.9 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)NC(=O)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)O 10.1021/jm960455s
CHEMBL3143312 106185 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 781 21 8 9 0.9 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)NC(=O)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)O 10.1021/jm960455s
58046056 132761 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 469 10 2 9 3.4 CCC(CC)Oc1cc(C)c2nn(CC(=O)c3cc(OCCO)cc(C(C)(C)C)c3)c(=N)n2n1 nan
CHEMBL3704461 132761 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 469 10 2 9 3.4 CCC(CC)Oc1cc(C)c2nn(CC(=O)c3cc(OCCO)cc(C(C)(C)C)c3)c(=N)n2n1 nan
66760759 126749 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 394 7 1 3 3.9 CCc1ccc(C2CC(C(=O)Nc3ccccc3)CN(C(=O)CCOC)C2)cc1 nan
CHEMBL3658402 126749 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 394 7 1 3 3.9 CCc1ccc(C2CC(C(=O)Nc3ccccc3)CN(C(=O)CCOC)C2)cc1 nan
66761545 126756 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 399 4 2 2 4.2 CCc1ccc(C2CC(NC(=O)NC(C)(C)C)CN(C(=O)C3CCCC3)C2)cc1 nan
CHEMBL3658409 126756 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 399 4 2 2 4.2 CCc1ccc(C2CC(NC(=O)NC(C)(C)C)CN(C(=O)C3CCCC3)C2)cc1 nan
9804049 133040 2 None - 1 Human 8.0 pIC50 = 8.0 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1016/j.bmcl.2006.06.042
CHEMBL371069 133040 2 None - 1 Human 8.0 pIC50 = 8.0 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1016/j.bmcl.2006.06.042
44418858 82876 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 457 3 0 3 6.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CC(F)(F)CC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4Cl)cn3)[C@H]12 10.1021/jm061043e
CHEMBL218935 82876 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 457 3 0 3 6.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CC(F)(F)CC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4Cl)cn3)[C@H]12 10.1021/jm061043e
9804049 133040 2 None - 1 Human 8.0 pIC50 = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
CHEMBL371069 133040 2 None - 1 Human 8.0 pIC50 = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
23631187 158925 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 528 4 0 5 6.1 CCOC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(C(F)(F)F)c3)cn2)C1 10.1021/jm070704k
CHEMBL410157 158925 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 528 4 0 5 6.1 CCOC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(C(F)(F)F)c3)cn2)C1 10.1021/jm070704k
44432714 86267 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 393 3 0 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccsc4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL231727 86267 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 393 3 0 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccsc4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
9804049 133040 2 None - 1 Human 8.0 pIC50 = 8.0 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL371069 133040 2 None - 1 Human 8.0 pIC50 = 8.0 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
11553497 132930 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 417 4 0 4 5.8 COc1ccccc1-c1ccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)nc1 10.1021/jm0502236
CHEMBL370656 132930 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 417 4 0 4 5.8 COc1ccccc1-c1ccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)nc1 10.1021/jm0502236
9804049 133040 2 None - 1 Human 8.0 pIC50 = 8.0 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm0502236
CHEMBL371069 133040 2 None - 1 Human 8.0 pIC50 = 8.0 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm0502236
66701293 126762 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 469 5 1 4 4.4 O=C(NC1CC(c2ccc(OC(F)(F)F)cc2)CN(C(=O)c2ccncc2)C1)c1ccccc1 nan
CHEMBL3658414 126762 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 469 5 1 4 4.4 O=C(NC1CC(c2ccc(OC(F)(F)F)cc2)CN(C(=O)c2ccncc2)C1)c1ccccc1 nan
46931523 127011 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 474 5 1 4 4.2 CCc1ccc(C2CC(NC(=O)c3cccc(OC)c3)CN(C(=O)N3CCC(C#N)CC3)C2)cc1 nan
CHEMBL3662512 127011 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 474 5 1 4 4.2 CCc1ccc(C2CC(NC(=O)c3cccc(OC)c3)CN(C(=O)N3CCC(C#N)CC3)C2)cc1 nan
90663334 106176 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 807 20 9 7 2.0 CC(=O)N(c1cccc(Cl)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143297 106176 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 807 20 9 7 2.0 CC(=O)N(c1cccc(Cl)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143264 209403 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(N)=O 10.1021/jm960455s
44183021 132756 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 465 10 1 8 4.5 CCC(CC)Oc1ccc2nn(CC(=O)c3cc(OCC4CC4)cc(C(C)(C)C)c3)c(=N)n2n1 nan
CHEMBL3704456 132756 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 465 10 1 8 4.5 CCC(CC)Oc1ccc2nn(CC(=O)c3cc(OCC4CC4)cc(C(C)(C)C)c3)c(=N)n2n1 nan
10184176 205275 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Binding affinity against platelet thrombin receptorBinding affinity against platelet thrombin receptor
ChEMBL 477 5 3 3 5.4 CC(C)(C)C(=O)NCc1ccc(NC(=O)N2CCC[C@H]2[C@@H](O)c2ccc(Cl)c(Cl)c2)cc1 10.1016/s0960-894x(01)00538-8
CHEMBL91441 205275 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Binding affinity against platelet thrombin receptorBinding affinity against platelet thrombin receptor
ChEMBL 477 5 3 3 5.4 CC(C)(C)C(=O)NCc1ccc(NC(=O)N2CCC[C@H]2[C@@H](O)c2ccc(Cl)c(Cl)c2)cc1 10.1016/s0960-894x(01)00538-8
72547305 103395 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 335 3 0 2 5.3 O=C1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091983 103395 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 335 3 0 2 5.3 O=C1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
44306349 102129 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 804 18 7 8 5.1 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc([N+](=O)[O-])cc1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3ccc(F)cc3)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL304120 102129 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 804 18 7 8 5.1 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc([N+](=O)[O-])cc1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3ccc(F)cc3)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
11652756 132301 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 325 2 0 3 4.4 Cc1ccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)nc1 10.1021/jm0502236
CHEMBL370151 132301 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 325 2 0 3 4.4 Cc1ccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)nc1 10.1021/jm0502236
17187534 59686 2 None - 0 Human 6.0 pIC50 = 6.0 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 316 5 2 2 4.3 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Cl)c1 10.1021/ml2002696
CHEMBL1734760 59686 2 None - 0 Human 6.0 pIC50 = 6.0 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 316 5 2 2 4.3 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Cl)c1 10.1021/ml2002696
23631375 142082 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 449 3 1 4 4.1 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CN(C(N)=O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm070704k
CHEMBL389148 142082 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 449 3 1 4 4.1 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CN(C(N)=O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm070704k
CHEMBL3143317 209429 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
807100 75303 13 None - 0 Human 6.0 pIC50 = 6.0 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 310 5 2 2 4.2 Cc1ccccc1C(=O)Nc1cccc(NC(=O)CC(C)C)c1 10.1021/ml2002696
CHEMBL2047300 75303 13 None - 0 Human 6.0 pIC50 = 6.0 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 310 5 2 2 4.2 Cc1ccccc1C(=O)Nc1cccc(NC(=O)CC(C)C)c1 10.1021/ml2002696
44306659 102299 0 None - 0 Human 5.0 pIC50 = 5.0 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 820 16 4 6 8.2 CSCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL305188 102299 0 None - 0 Human 5.0 pIC50 = 5.0 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 820 16 4 6 8.2 CSCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
58136855 132780 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 526 10 2 10 2.4 CCNC(=O)c1nn2/c(=N/C)n(CC(=O)c3cc(OCCCO)c(OC)c(C(C)(C)C)c3)nc2c(C)c1C nan
CHEMBL3704480 132780 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 526 10 2 10 2.4 CCNC(=O)c1nn2/c(=N/C)n(CC(=O)c3cc(OCCCO)c(OC)c(C(C)(C)C)c3)nc2c(C)c1C nan
23631810 92521 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 526 4 0 4 6.1 CC(C)C(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(C(F)(F)F)c3)cn2)C1 10.1021/jm070704k
CHEMBL244107 92521 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 526 4 0 4 6.1 CC(C)C(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(C(F)(F)F)c3)cn2)C1 10.1021/jm070704k
44187280 124622 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 412 9 1 7 3.2 CCC(CC)Oc1ccc2n(n1)c(N)n[n+]2CC(=O)c1cc(OC)cc(C(C)C)c1 nan
CHEMBL3644438 124622 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 412 9 1 7 3.2 CCC(CC)Oc1ccc2n(n1)c(N)n[n+]2CC(=O)c1cc(OC)cc(C(C)C)c1 nan
44432707 146130 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 379 3 0 3 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(C4CCCC4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL392370 146130 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 379 3 0 3 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(C4CCCC4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
12018758 9257 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 467 8 0 6 6.0 Clc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL111241 9257 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 467 8 0 6 6.0 Clc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL3143269 209406 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None COc1ccc(C[C@H](NC(=O)[C@H](Cc2ccc(F)cc2)N(C(C)=O)C(=O)/C=C/c2ccccc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)cc1 10.1021/jm960455s
58046049 132771 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 512 11 2 10 3.4 CCN(CC)c1nn2c(=N)n(CC(=O)c3cc(OCCCO)c(OC)c(C(C)(C)C)c3)nc2c(C)c1C nan
CHEMBL3704471 132771 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 512 11 2 10 3.4 CCN(CC)c1nn2c(=N)n(CC(=O)c3cc(OCCCO)c(OC)c(C(C)(C)C)c3)nc2c(C)c1C nan
CHEMBL3143284 209414 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@H](CCCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44418855 136037 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 457 3 0 3 6.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CC(F)(F)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(Cl)c4)cn3)[C@H]12 10.1021/jm061043e
CHEMBL373836 136037 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 457 3 0 3 6.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CC(F)(F)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(Cl)c4)cn3)[C@H]12 10.1021/jm061043e
44432711 87131 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 377 3 0 4 5.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccco4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL233546 87131 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 377 3 0 4 5.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccco4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
44432843 87719 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 371 3 0 4 4.4 COc1ccc2nc(/C=C/[C@@H]3c4ccccc4C[C@H]4C(=O)OC[C@@H]34)ccc2c1 10.1016/j.bmcl.2007.04.061
CHEMBL234690 87719 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 371 3 0 4 4.4 COc1ccc2nc(/C=C/[C@@H]3c4ccccc4C[C@H]4C(=O)OC[C@@H]34)ccc2c1 10.1016/j.bmcl.2007.04.061
44309477 102743 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 803 16 5 6 6.8 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCCc1ccccc1 10.1016/s0960-894x(03)00325-1
CHEMBL308435 102743 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 803 16 5 6 6.8 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCCc1ccccc1 10.1016/s0960-894x(03)00325-1
10077130 3944 49 None - 1 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400235c
4047 3944 49 None - 1 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400235c
4870 3944 49 None - 1 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400235c
CHEMBL493982 3944 49 None - 1 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400235c
DB09030 3944 49 None - 1 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400235c
10300275 205146 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Binding affinity against platelet thrombin receptorBinding affinity against platelet thrombin receptor
ChEMBL 493 8 3 3 6.0 CC[C@@H](C)N(C[C@@H](O)c1ccc(Cl)c(Cl)c1)C(=O)Nc1ccc(CNC(=O)C(C)(C)C)cc1 10.1016/s0960-894x(01)00538-8
CHEMBL90698 205146 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Binding affinity against platelet thrombin receptorBinding affinity against platelet thrombin receptor
ChEMBL 493 8 3 3 6.0 CC[C@@H](C)N(C[C@@H](O)c1ccc(Cl)c(Cl)c1)C(=O)Nc1ccc(CNC(=O)C(C)(C)C)cc1 10.1016/s0960-894x(01)00538-8
44432774 145171 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 435 3 0 3 6.2 O=C1OC[C@H]2[C@@H]1Cc1ccc(Cl)cc1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL391625 145171 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 435 3 0 3 6.2 O=C1OC[C@H]2[C@@H]1Cc1ccc(Cl)cc1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
76313663 103388 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 424 4 0 3 6.0 CN(C)C(=S)OC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091976 103388 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 424 4 0 3 6.0 CN(C)C(=S)OC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
10120960 205141 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Binding affinity against platelet thrombin receptorBinding affinity against platelet thrombin receptor
ChEMBL 578 9 4 5 4.5 CC(C)N(C[C@@H](O)c1ccc(Cl)c(Cl)c1)C(=O)Nc1ccc(CNC(=O)c2ccc(S(N)(=O)=O)cc2)cc1 10.1016/s0960-894x(01)00538-8
CHEMBL90682 205141 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Binding affinity against platelet thrombin receptorBinding affinity against platelet thrombin receptor
ChEMBL 578 9 4 5 4.5 CC(C)N(C[C@@H](O)c1ccc(Cl)c(Cl)c1)C(=O)Nc1ccc(CNC(=O)c2ccc(S(N)(=O)=O)cc2)cc1 10.1016/s0960-894x(01)00538-8
44338946 9216 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 493 10 0 8 5.4 COc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1OC 10.1016/s0960-894x(01)00745-4
CHEMBL110998 9216 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 493 10 0 8 5.4 COc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1OC 10.1016/s0960-894x(01)00745-4
44280936 116020 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 731 18 9 8 1.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccc(F)cc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33617 116020 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 731 18 9 8 1.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccc(F)cc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44432831 144385 0 None - 0 Human 4.9 pIC50 = 4.9 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 291 2 0 3 3.2 O=C1OC[C@H]2[C@H](/C=C/c3ccccn3)c3ccccc3C[C@@H]12 10.1016/j.bmcl.2007.04.061
CHEMBL391025 144385 0 None - 0 Human 4.9 pIC50 = 4.9 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 291 2 0 3 3.2 O=C1OC[C@H]2[C@H](/C=C/c3ccccn3)c3ccccc3C[C@@H]12 10.1016/j.bmcl.2007.04.061
44306065 201749 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 345 2 2 5 4.1 CC(C)(C)c1ccc(Cn2ccc3c4c(N)nc(N)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
CHEMBL65778 201749 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 345 2 2 5 4.1 CC(C)(C)c1ccc(Cn2ccc3c4c(N)nc(N)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
44409082 137964 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 405 4 0 4 5.7 CCOc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2005.12.042
CHEMBL377486 137964 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 405 4 0 4 5.7 CCOc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2005.12.042
44409083 76187 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 467 5 0 4 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OCc5ccccc5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL206110 76187 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 467 5 0 4 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OCc5ccccc5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
11559190 71759 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 340 3 1 4 4.1 CNc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
CHEMBL197782 71759 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 340 3 1 4 4.1 CNc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
44305882 201329 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 387 5 0 5 4.9 CC(C)c1ccc(Cn2ccc3c4c(N(C)C)nc(N(C)C)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
CHEMBL63305 201329 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 387 5 0 5 4.9 CC(C)c1ccc(Cn2ccc3c4c(N(C)C)nc(N(C)C)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
58045963 132770 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 499 11 2 10 3.4 CCOc1nn2c(=N)n(CC(=O)c3cc(OCCCCO)c(OC)c(C(C)(C)C)c3)nc2c(C)c1C nan
CHEMBL3704470 132770 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 499 11 2 10 3.4 CCOc1nn2c(=N)n(CC(=O)c3cc(OCCCCO)c(OC)c(C(C)(C)C)c3)nc2c(C)c1C nan
90663333 106175 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 843 23 9 8 2.4 CCCC(=O)c1ccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)cc1 10.1021/jm960455s
CHEMBL3143296 106175 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 843 23 9 8 2.4 CCCC(=O)c1ccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)cc1 10.1021/jm960455s
50910547 75444 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 350 5 2 2 4.7 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2C(F)(F)F)c1 10.1021/ml2002696
CHEMBL2048420 75444 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 350 5 2 2 4.7 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2C(F)(F)F)c1 10.1021/ml2002696
44432779 86262 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 419 3 0 3 5.7 O=C1OC[C@H]2[C@@H]1Cc1cc(F)ccc1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL231713 86262 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 419 3 0 3 5.7 O=C1OC[C@H]2[C@@H]1Cc1cc(F)ccc1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
23631185 92680 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 423 3 0 4 5.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3COCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4Cl)cn3)[C@H]12 10.1021/jm070704k
CHEMBL244294 92680 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 423 3 0 4 5.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3COCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4Cl)cn3)[C@H]12 10.1021/jm070704k
59110452 72903 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 443 4 0 3 6.9 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(Cl)c2Cl)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012497 72903 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 443 4 0 3 6.9 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(Cl)c2Cl)cn1 10.1016/j.bmcl.2012.01.138
11611061 71726 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 401 3 0 3 6.1 Cc1cccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc2)c1 10.1021/jm0502236
CHEMBL197686 71726 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 401 3 0 3 6.1 Cc1cccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc2)c1 10.1021/jm0502236
44310323 202572 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 791 16 6 7 5.9 NCCCNC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccc(Cl)cc1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1 10.1016/s0960-894x(03)00325-1
CHEMBL71246 202572 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 791 16 6 7 5.9 NCCCNC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccc(Cl)cc1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1 10.1016/s0960-894x(03)00325-1
127050672 140281 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 491 5 2 5 3.8 CCN(C(=O)CN)C1CN(/C(=N\C#N)Nc2ccc(Cl)c(Cl)c2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
CHEMBL3818932 140281 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 491 5 2 5 3.8 CCN(C(=O)CN)C1CN(/C(=N\C#N)Nc2ccc(Cl)c(Cl)c2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
90663321 106170 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 850 23 6 8 1.5 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@H](CCCCN=C(N(C)C)N(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143283 106170 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 850 23 6 8 1.5 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@H](CCCCN=C(N(C)C)N(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
90663342 106183 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 828 21 10 8 1.6 CC(=O)N(Oc1c[nH]c2ccccc12)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143307 106183 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 828 21 10 8 1.6 CC(=O)N(Oc1c[nH]c2ccccc12)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44432704 86604 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 399 3 0 3 6.0 Cc1nc(/C=C/[C@H]2[C@@H]3CCCCC3=C[C@H]3C(=O)O[C@H](C)[C@@H]23)ccc1-c1ccccc1 10.1016/j.bmcl.2007.06.002
CHEMBL232539 86604 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 399 3 0 3 6.0 Cc1nc(/C=C/[C@H]2[C@@H]3CCCCC3=C[C@H]3C(=O)O[C@H](C)[C@@H]23)ccc1-c1ccccc1 10.1016/j.bmcl.2007.06.002
44306708 100443 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 817 20 6 7 5.5 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL293867 100443 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 817 20 6 7 5.5 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
44306698 102238 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 826 15 5 6 7.4 O=C(Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)N[C@@H](Cc1ccc(F)c(F)c1)C(=O)NC(Cc1c[nH]cn1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL304827 102238 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 826 15 5 6 7.4 O=C(Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)N[C@@H](Cc1ccc(F)c(F)c1)C(=O)NC(Cc1c[nH]cn1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
10819322 203205 0 None - 1 Human 5.9 pIC50 = 5.9 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 839 18 7 7 6.4 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL7610 203205 0 None - 1 Human 5.9 pIC50 = 5.9 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 839 18 7 7 6.4 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
44280804 99216 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 578 15 7 6 1.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cccnc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL284498 99216 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 578 15 7 6 1.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cccnc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44281069 117575 0 None - 0 Human 4.9 pIC50 = 4.9 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 653 16 7 5 3.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc(-c2ccccc2)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL34055 117575 0 None - 0 Human 4.9 pIC50 = 4.9 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 653 16 7 5 3.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc(-c2ccccc2)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44186917 124620 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 466 10 1 7 4.1 CCC(CC)Oc1ccc2n(n1)c(N)n[n+]2CC(=O)c1cc(OCC2CC2)cc(C(C)(C)C)c1 nan
CHEMBL3644436 124620 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 466 10 1 7 4.1 CCC(CC)Oc1ccc2n(n1)c(N)n[n+]2CC(=O)c1cc(OCC2CC2)cc(C(C)(C)C)c1 nan
44432716 86269 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 377 3 1 4 4.5 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ncc[nH]4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL231729 86269 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 377 3 1 4 4.5 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ncc[nH]4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
44328579 206221 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 537 5 2 5 7.5 CC(C)(C)c1cc(C(=O)Cn2c(=N)n(Cc3ccc(Cl)c(Cl)c3)c3ccccc32)cc(C(C)(C)C)c1O 10.1016/s0960-894x(01)00555-8
CHEMBL97110 206221 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 537 5 2 5 7.5 CC(C)(C)c1cc(C(=O)Cn2c(=N)n(Cc3ccc(Cl)c(Cl)c3)c3ccccc32)cc(C(C)(C)C)c1O 10.1016/s0960-894x(01)00555-8
58136992 124619 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 484 11 1 8 4.1 CCOc1cc(C(=O)C[n+]2nc(N)n3nc(OC(CC)CC)ccc32)cc(C(C)(C)C)c1OCC nan
CHEMBL3644435 124619 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 484 11 1 8 4.1 CCOc1cc(C(=O)C[n+]2nc(N)n3nc(OC(CC)CC)ccc32)cc(C(C)(C)C)c1OCC nan
44432770 86515 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 469 3 0 3 6.6 O=C1OC[C@H]2[C@@H]1Cc1ccc(Cl)cc1[C@@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL232332 86515 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 469 3 0 3 6.6 O=C1OC[C@H]2[C@@H]1Cc1ccc(Cl)cc1[C@@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2007.04.061
44418847 83015 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 417 3 1 4 5.0 Cc1ccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4C[C@H](O)CC[C@H]43)nc2)cc1 10.1021/jm061043e
CHEMBL219701 83015 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 417 3 1 4 5.0 Cc1ccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4C[C@H](O)CC[C@H]43)nc2)cc1 10.1021/jm061043e
11567556 168059 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 401 3 0 3 6.1 Cc1ccccc1-c1ccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)nc1 10.1021/jm0502236
CHEMBL436130 168059 0 None - 0 Human 7.9 pIC50 = 7.9 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 401 3 0 3 6.1 Cc1ccccc1-c1ccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)nc1 10.1021/jm0502236
44432798 144928 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 419 3 0 3 5.7 O=C1OC[C@H]2[C@@H]1Cc1ccc(Cl)cc1[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL391436 144928 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 419 3 0 3 5.7 O=C1OC[C@H]2[C@@H]1Cc1ccc(Cl)cc1[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
44432817 154179 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 401 3 0 3 5.5 O=C1OC[C@H]2[C@@H]1Cc1ccccc1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL399820 154179 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 401 3 0 3 5.5 O=C1OC[C@H]2[C@@H]1Cc1ccccc1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
66701509 127008 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 473 3 1 2 5.3 C[C@@H]1CC[C@@H](C)N1C(=O)N1CC(NC(=O)c2ccccc2)CC(c2ccc(C(F)(F)F)cc2)C1 nan
CHEMBL3662509 127008 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 473 3 1 2 5.3 C[C@@H]1CC[C@@H](C)N1C(=O)N1CC(NC(=O)c2ccccc2)CC(c2ccc(C(F)(F)F)cc2)C1 nan
72547554 103401 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 414 5 1 3 4.6 CS(=O)(=O)NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091989 103401 0 None - 0 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 414 5 1 3 4.6 CS(=O)(=O)NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
58136847 132762 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 471 11 2 10 2.3 COCCCOc1cc(C(=O)Cn2nc3c(C)cc(OCCO)nn3c2=N)cc(C(C)(C)C)c1 nan
CHEMBL3704462 132762 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 471 11 2 10 2.3 COCCCOc1cc(C(=O)Cn2nc3c(C)cc(OCCO)nn3c2=N)cc(C(C)(C)C)c1 nan
58136785 132779 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 483 9 2 10 2.3 Cc1cc(OCC2(C)COC2)nn2c(=N)n(CC(=O)c3cc(OCCO)cc(C(C)(C)C)c3)nc12 nan
CHEMBL3704479 132779 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 483 9 2 10 2.3 Cc1cc(OCC2(C)COC2)nn2c(=N)n(CC(=O)c3cc(OCCO)cc(C(C)(C)C)c3)nc12 nan
58137006 124627 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 551 10 1 9 4.1 CCC(CC)Oc1nn2c(N)n[n+](CC(=O)c3cc(N4CCOCC4)c(OC)c(C(C)(C)C)c3)c2cc1C1CC1 nan
CHEMBL3644443 124627 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 551 10 1 9 4.1 CCC(CC)Oc1nn2c(N)n[n+](CC(=O)c3cc(N4CCOCC4)c(OC)c(C(C)(C)C)c3)c2cc1C1CC1 nan
9875337 98790 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 747 18 9 8 2.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccccc2Cl)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL281753 98790 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 747 18 9 8 2.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccccc2Cl)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280650 114621 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 747 18 9 8 2.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccc(Cl)cc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33435 114621 0 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 747 18 9 8 2.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccc(Cl)cc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
3378161 75543 7 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 360 4 2 2 4.3 CC(C)C(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1021/ml2002696
CHEMBL2049121 75543 7 None - 0 Human 5.9 pIC50 = 5.9 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 360 4 2 2 4.3 CC(C)C(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1021/ml2002696
11603083 70035 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 367 5 0 3 5.4 CCCCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
CHEMBL194526 70035 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 367 5 0 3 5.4 CCCCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
44432717 145710 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 391 3 0 5 4.5 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cncn4C)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL392046 145710 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 391 3 0 5 4.5 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cncn4C)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
44418844 82940 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 417 3 1 4 5.0 Cc1cccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4C[C@H](O)CC[C@H]43)nc2)c1 10.1021/jm061043e
CHEMBL219282 82940 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 417 3 1 4 5.0 Cc1cccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4C[C@H](O)CC[C@H]43)nc2)c1 10.1021/jm061043e
58045908 132772 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 513 12 2 10 3.5 CCOc1nn2c(=N)n(CC(=O)c3cc(OCCCO)c(OC)c(C(C)(C)C)c3)nc2c(CC)c1CC nan
CHEMBL3704472 132772 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 513 12 2 10 3.5 CCOc1nn2c(=N)n(CC(=O)c3cc(OCCCO)c(OC)c(C(C)(C)C)c3)nc2c(CC)c1CC nan
44408873 76357 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 391 3 0 4 5.3 COc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2006.06.042
CHEMBL206502 76357 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 391 3 0 4 5.3 COc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2006.06.042
44408873 76357 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 391 3 0 4 5.3 COc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2005.12.042
CHEMBL206502 76357 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 391 3 0 4 5.3 COc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2005.12.042
44418850 82988 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 441 3 0 3 6.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CC(F)(F)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm061043e
CHEMBL219522 82988 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 441 3 0 3 6.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CC(F)(F)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm061043e
23631812 92701 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 484 4 0 5 4.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CN(S(C)(=O)=O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm070704k
CHEMBL244315 92701 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 484 4 0 5 4.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CN(S(C)(=O)=O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm070704k
9886874 72897 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 393 4 0 3 5.8 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012491 72897 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 393 4 0 3 5.8 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2012.01.138
66761741 127009 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 509 3 1 4 3.1 O=C(NC1CC(c2ccc(C(F)(F)F)cc2)CN(C(=O)N2CCS(=O)(=O)CC2)C1)c1ccccc1 nan
CHEMBL3662510 127009 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 509 3 1 4 3.1 O=C(NC1CC(c2ccc(C(F)(F)F)cc2)CN(C(=O)N2CCS(=O)(=O)CC2)C1)c1ccccc1 nan
44432783 86533 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 437 3 0 3 5.8 O=C1OC[C@H]2[C@@H]1Cc1c(ccc(F)c1F)[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL232348 86533 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 437 3 0 3 5.8 O=C1OC[C@H]2[C@@H]1Cc1c(ccc(F)c1F)[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
23631374 92524 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 474 4 0 4 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CN(C(=O)C4CC4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm070704k
CHEMBL244109 92524 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 474 4 0 4 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CN(C(=O)C4CC4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm070704k
127053988 143946 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 486 4 0 6 4.3 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(S(C)(=O)=O)CC1(F)F nan
CHEMBL3906737 143946 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 486 4 0 6 4.3 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(S(C)(=O)=O)CC1(F)F nan
66761350 126763 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 405 4 2 3 3.3 Cc1ccc(C2CC(NC(=O)c3ccccc3)CN(C(=O)C3(N)CCC3)C2)cc1C nan
CHEMBL3658415 126763 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 405 4 2 3 3.3 Cc1ccc(C2CC(NC(=O)c3ccccc3)CN(C(=O)C3(N)CCC3)C2)cc1C nan
44416562 79593 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 373 2 0 3 5.6 CC1(C)OC(=O)[C@@H]2C=C3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@@H]21 10.1016/j.bmcl.2006.06.042
CHEMBL212788 79593 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 373 2 0 3 5.6 CC1(C)OC(=O)[C@@H]2C=C3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@@H]21 10.1016/j.bmcl.2006.06.042
44416690 80687 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 359 2 0 3 5.2 C[C@H]1OC(=O)[C@@H]2C=C3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@H]12 10.1016/j.bmcl.2006.06.042
CHEMBL215579 80687 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 359 2 0 3 5.2 C[C@H]1OC(=O)[C@@H]2C=C3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@H]12 10.1016/j.bmcl.2006.06.042
9847494 5771 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 469 8 0 6 5.6 Fc1cc(F)cc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL107920 5771 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 469 8 0 6 5.6 Fc1cc(F)cc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
44408616 74081 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 375 2 0 3 5.6 Cc1ccc2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc2c1 10.1016/j.bmcl.2005.12.042
CHEMBL202678 74081 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 375 2 0 3 5.6 Cc1ccc2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc2c1 10.1016/j.bmcl.2005.12.042
44416690 80687 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 359 2 0 3 5.2 C[C@H]1OC(=O)[C@@H]2C=C3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL215579 80687 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 359 2 0 3 5.2 C[C@H]1OC(=O)[C@@H]2C=C3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@H]12 10.1016/j.bmcl.2007.06.002
11537143 71435 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 325 2 0 3 4.4 Cc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
CHEMBL196727 71435 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 325 2 0 3 4.4 Cc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
11544606 71697 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 337 3 0 3 4.7 C=Cc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
CHEMBL197618 71697 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 337 3 0 3 4.7 C=Cc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
44416541 82055 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 373 3 0 3 5.6 CC[C@H]1OC(=O)[C@@H]2C=C3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@H]12 10.1016/j.bmcl.2006.06.042
CHEMBL217611 82055 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 373 3 0 3 5.6 CC[C@H]1OC(=O)[C@@H]2C=C3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@H]12 10.1016/j.bmcl.2006.06.042
11515660 71082 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 341 3 1 4 3.6 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3cccc(CO)n3)[C@H]12 10.1021/jm0502236
CHEMBL196002 71082 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 341 3 1 4 3.6 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3cccc(CO)n3)[C@H]12 10.1021/jm0502236
10925413 140169 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 325 2 0 3 4.4 Cc1cccc(/C=C/[C@@H]2[C@H]3CCCC[C@@H]3C[C@@H]3C(=O)O[C@@H](C)[C@@H]32)n1 10.1021/jm0502236
CHEMBL381628 140169 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 325 2 0 3 4.4 Cc1cccc(/C=C/[C@@H]2[C@H]3CCCC[C@@H]3C[C@@H]3C(=O)O[C@@H](C)[C@@H]32)n1 10.1021/jm0502236
44328728 205902 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 379 3 2 5 4.8 CC(C)(C)c1cc(C(=O)Cn2c(N)nc3ccccc32)cc(C(C)(C)C)c1O 10.1016/s0960-894x(01)00555-8
CHEMBL95216 205902 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 379 3 2 5 4.8 CC(C)(C)c1cc(C(=O)Cn2c(N)nc3ccccc32)cc(C(C)(C)C)c1O 10.1016/s0960-894x(01)00555-8
44280935 99627 0 None - 0 Human 4.8 pIC50 = 4.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 747 18 9 8 2.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccc(Cl)c2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL287368 99627 0 None - 0 Human 4.8 pIC50 = 4.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 747 18 9 8 2.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccc(Cl)c2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44189604 124618 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 454 10 1 7 3.9 CCOCc1cc(C(=O)C[n+]2nc(N)n3nc(OC(CC)CC)ccc32)cc(C(C)(C)C)c1 nan
CHEMBL3644434 124618 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 454 10 1 7 3.9 CCOCc1cc(C(=O)C[n+]2nc(N)n3nc(OC(CC)CC)ccc32)cc(C(C)(C)C)c1 nan
23631639 92760 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 478 4 0 5 5.3 CCOC(=O)N1CCC[C@H]2[C@H](/C=C/c3ccc(-c4ccccc4F)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]21 10.1021/jm070704k
CHEMBL244485 92760 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 478 4 0 5 5.3 CCOC(=O)N1CCC[C@H]2[C@H](/C=C/c3ccc(-c4ccccc4F)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]21 10.1021/jm070704k
90663358 106187 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 903 22 9 8 3.1 CC(=O)N(C(=O)/C=C/c1ccc(-c2ccccc2)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143324 106187 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 903 22 9 8 3.1 CC(=O)N(C(=O)/C=C/c1ccc(-c2ccccc2)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
58045767 132776 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 455 9 2 9 2.8 CCOc1nn2c(=N)n(CC(=O)c3cc(OCCO)cc(C(C)(C)C)c3)nc2c(CC)c1C nan
CHEMBL3704476 132776 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 455 9 2 9 2.8 CCOc1nn2c(=N)n(CC(=O)c3cc(OCCO)cc(C(C)(C)C)c3)nc2c(CC)c1C nan
44408874 139718 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 395 2 0 3 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(Cl)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL380544 139718 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 395 2 0 3 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(Cl)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
44432712 87132 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 393 3 0 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccs4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL233548 87132 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 393 3 0 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccs4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
44418849 136446 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 6.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(Cl)c4Cl)cn3)[C@H]12 10.1021/jm061043e
CHEMBL374503 136446 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 6.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(Cl)c4Cl)cn3)[C@H]12 10.1021/jm061043e
23631813 148882 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 508 6 0 6 4.8 COCCOC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)C1 10.1021/jm070704k
CHEMBL394576 148882 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 508 6 0 6 4.8 COCCOC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)C1 10.1021/jm070704k
90663314 106165 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 984 28 11 11 0.6 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN)C(=O)CC(N)=O 10.1021/jm960455s
CHEMBL3143274 106165 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 984 28 11 11 0.6 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN)C(=O)CC(N)=O 10.1021/jm960455s
44309750 103098 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 779 15 5 7 6.3 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccco1 10.1016/s0960-894x(03)00325-1
CHEMBL308588 103098 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 779 15 5 7 6.3 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccco1 10.1016/s0960-894x(03)00325-1
90663330 106172 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 791 20 9 7 1.5 CC(=O)N(c1cccc(F)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143293 106172 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 791 20 9 7 1.5 CC(=O)N(c1cccc(F)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
137661486 158929 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Antagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in TRAP-stimulated platelet aggregation preincubated for 20 mins followed by TRAP stimulation measured after 5 mins by aggregometric analysisAntagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in TRAP-stimulated platelet aggregation preincubated for 20 mins followed by TRAP stimulation measured after 5 mins by aggregometric analysis
ChEMBL 407 3 1 2 6.8 C[C@H]1CC[C@@H]2C(C)(C)[C@H](O)CC[C@@]2(C)[C@@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
CHEMBL4101591 158929 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Antagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in TRAP-stimulated platelet aggregation preincubated for 20 mins followed by TRAP stimulation measured after 5 mins by aggregometric analysisAntagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in TRAP-stimulated platelet aggregation preincubated for 20 mins followed by TRAP stimulation measured after 5 mins by aggregometric analysis
ChEMBL 407 3 1 2 6.8 C[C@H]1CC[C@@H]2C(C)(C)[C@H](O)CC[C@@]2(C)[C@@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
9810474 100687 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 719 19 7 8 2.4 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)co1 10.1016/s0960-894x(98)00292-3
CHEMBL295437 100687 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 719 19 7 8 2.4 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)co1 10.1016/s0960-894x(98)00292-3
9961058 99489 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 645 15 7 7 1.8 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc(=O)c2ccccc2o1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL286382 99489 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 645 15 7 7 1.8 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc(=O)c2ccccc2o1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44826171 116366 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 758 19 9 10 1.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccccc2[N+](=O)[O-])n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33818 116366 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 758 19 9 10 1.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccccc2[N+](=O)[O-])n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280684 98681 0 None - 0 Human 4.8 pIC50 = 4.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 594 15 7 6 0.2 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)C1C=CC=NC1=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL281079 98681 0 None - 0 Human 4.8 pIC50 = 4.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 594 15 7 6 0.2 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)C1C=CC=NC1=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
9962227 99182 0 None - 0 Human 4.8 pIC50 = 4.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 763 18 9 8 2.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccc3ccccc23)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL284285 99182 0 None - 0 Human 4.8 pIC50 = 4.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 763 18 9 8 2.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccc3ccccc23)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280954 116048 0 None - 0 Human 4.8 pIC50 = 4.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 633 15 7 7 1.7 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)C1=COc2ccccc2O1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33630 116048 0 None - 0 Human 4.8 pIC50 = 4.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 633 15 7 7 1.7 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)C1=COc2ccccc2O1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
90663343 106184 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 865 21 9 8 2.1 CC(=O)N(C(=O)Cc1cccc2ccccc12)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143308 106184 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 865 21 9 8 2.1 CC(=O)N(C(=O)Cc1cccc2ccccc12)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
68075447 126758 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 375 3 1 4 2.2 CCc1ccc(C2CC(NC(=O)OC)CN(C(=O)N3CCOCC3)C2)cc1 nan
CHEMBL3658410 126758 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 375 3 1 4 2.2 CCc1ccc(C2CC(NC(=O)OC)CN(C(=O)N3CCOCC3)C2)cc1 nan
877874 23121 16 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 346 4 2 2 4.1 CCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1021/ml2002696
CHEMBL1332325 23121 16 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 346 4 2 2 4.1 CCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1021/ml2002696
CHEMBL3143254 209398 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN)C(N)=O 10.1021/jm960455s
44137613 153987 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 584 11 2 8 4.2 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCN(CC(=O)O)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3978297 153987 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 584 11 2 8 4.2 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCN(CC(=O)O)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3990813 153987 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 584 11 2 8 4.2 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCN(CC(=O)O)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
9890926 82875 0 None - 1 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
CHEMBL218933 82875 0 None - 1 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
23631103 143625 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 457 3 0 4 5.6 C[C@H]1OC(=O)[C@@H]2C[C@@H]3COCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
CHEMBL390399 143625 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 457 3 0 4 5.6 C[C@H]1OC(=O)[C@@H]2C[C@@H]3COCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
127053948 146306 0 None - 1 Human 7.8 pIC50 = 7.8 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 488 6 2 5 3.8 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)C2[C@@H](C)OC(=O)[C@]2(C(=O)NCCO)CC1(F)F nan
CHEMBL3925032 146306 0 None - 1 Human 7.8 pIC50 = 7.8 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 488 6 2 5 3.8 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)C2[C@@H](C)OC(=O)[C@]2(C(=O)NCCO)CC1(F)F nan
66701371 127006 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 461 3 1 3 3.7 O=C(NC1CC(c2ccc(C(F)(F)F)cc2)CN(C(=O)N2CCOCC2)C1)c1ccccc1 nan
CHEMBL3662507 127006 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 461 3 1 3 3.7 O=C(NC1CC(c2ccc(C(F)(F)F)cc2)CN(C(=O)N2CCOCC2)C1)c1ccccc1 nan
66761956 126754 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 420 4 2 2 4.4 CCc1ccc(C2CC(NC(=O)Nc3ccccc3)CN(C(=O)N3CCCC3)C2)cc1 nan
CHEMBL3658407 126754 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 420 4 2 2 4.4 CCc1ccc(C2CC(NC(=O)Nc3ccccc3)CN(C(=O)N3CCCC3)C2)cc1 nan
CHEMBL3143310 209424 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@H](CCCN)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)NC(=O)/C=C/c1ccccc1 10.1021/jm960455s
117072551 140253 30 None - 0 Human 5.8 pIC50 = 5.8 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 524 7 2 6 3.8 CCN(C(=O)CO)[C@H]1CN(/C(=N\C#N)Nc2cccc(OC(F)F)c2)N=C1c1ccc(Cl)c(Cl)c1 10.1021/acs.jmedchem.5b01890
CHEMBL3818617 140253 30 None - 0 Human 5.8 pIC50 = 5.8 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 524 7 2 6 3.8 CCN(C(=O)CO)[C@H]1CN(/C(=N\C#N)Nc2cccc(OC(F)F)c2)N=C1c1ccc(Cl)c(Cl)c1 10.1021/acs.jmedchem.5b01890
58137003 124626 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 511 8 1 9 3.1 CCOc1nn2c(NC)n[n+](CC(=O)c3cc(N4CCOCC4)c(OC)c(C(C)(C)C)c3)c2c(C)c1C nan
CHEMBL3644442 124626 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 511 8 1 9 3.1 CCOc1nn2c(NC)n[n+](CC(=O)c3cc(N4CCOCC4)c(OC)c(C(C)(C)C)c3)c2c(C)c1C nan
9895920 99558 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 656 15 7 6 1.9 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cncc(Br)c1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL286837 99558 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 656 15 7 6 1.9 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cncc(Br)c1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
58045926 132774 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 512 9 2 10 2.0 CCNC(=O)c1nn2/c(=N/C)n(CC(=O)c3cc(OCCO)c(OC)c(C(C)(C)C)c3)nc2c(C)c1C nan
CHEMBL3704474 132774 0 None - 0 Human 6.8 pIC50 = 6.8 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 512 9 2 10 2.0 CCNC(=O)c1nn2/c(=N/C)n(CC(=O)c3cc(OCCO)c(OC)c(C(C)(C)C)c3)nc2c(C)c1C nan
44305942 201313 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 353 2 2 5 4.3 Cc1ccc2cc(Cn3ccc4c5c(N)nc(N)nc5ccc43)ccc2c1 10.1016/s0960-894x(99)00339-x
CHEMBL63192 201313 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 353 2 2 5 4.3 Cc1ccc2cc(Cn3ccc4c5c(N)nc(N)nc5ccc43)ccc2c1 10.1016/s0960-894x(99)00339-x
16046150 165300 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 459 5 2 3 6.2 C[C@@H](O)[C@@H]1[C@H](CO)C[C@@H]2CCCC[C@H]2[C@@H]1/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2006.06.042
CHEMBL424893 165300 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 459 5 2 3 6.2 C[C@@H](O)[C@@H]1[C@H](CO)C[C@@H]2CCCC[C@H]2[C@@H]1/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2006.06.042
70687427 72911 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 421 5 1 5 4.7 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(OC)c2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012506 72911 0 None - 0 Human 7.8 pIC50 = 7.8 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 421 5 1 5 4.7 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(OC)c2)cn1 10.1016/j.bmcl.2012.01.138
68074840 126760 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 437 4 1 4 4.1 CCc1ccc(C2CC(OC(=O)Nc3ccccc3)CN(C(=O)N3CCOCC3)C2)cc1 nan
CHEMBL3658412 126760 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 437 4 1 4 4.1 CCc1ccc(C2CC(OC(=O)Nc3ccccc3)CN(C(=O)N3CCOCC3)C2)cc1 nan
23631376 152385 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 477 4 1 4 4.8 CCNC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)C1 10.1021/jm070704k
CHEMBL397480 152385 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 477 4 1 4 4.8 CCNC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)C1 10.1021/jm070704k
16214871 18134 3 None - 1 Human 6.8 pIC50 = 6.8 Binding
Inhibition of PAR1-mediated aggregation of TRAP-stimulated human plateletInhibition of PAR1-mediated aggregation of TRAP-stimulated human platelet
ChEMBL 475 5 1 6 4.9 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccn2)cn1 10.1016/j.bmcl.2010.09.009
CHEMBL1270738 18134 3 None - 1 Human 6.8 pIC50 = 6.8 Binding
Inhibition of PAR1-mediated aggregation of TRAP-stimulated human plateletInhibition of PAR1-mediated aggregation of TRAP-stimulated human platelet
ChEMBL 475 5 1 6 4.9 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccn2)cn1 10.1016/j.bmcl.2010.09.009
44306696 101659 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 817 16 5 6 6.7 NC(=O)CCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL302433 101659 0 None - 0 Human 5.8 pIC50 = 5.8 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 817 16 5 6 6.7 NC(=O)CCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
17222608 75299 15 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 316 5 2 2 3.7 CCCNC(=O)c1cccc(NC(=O)c2ccccc2Cl)c1 10.1021/ml2002696
CHEMBL2047284 75299 15 None - 0 Human 5.8 pIC50 = 5.8 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 316 5 2 2 3.7 CCCNC(=O)c1cccc(NC(=O)c2ccccc2Cl)c1 10.1021/ml2002696
44281174 110981 0 None - 0 Human 4.8 pIC50 = 4.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 498 11 6 7 0.2 C[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL32762 110981 0 None - 0 Human 4.8 pIC50 = 4.8 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 498 11 6 7 0.2 C[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
58045878 132768 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 485 11 2 10 2.9 CCOc1cc(CC)c2nn(CC(=O)c3cc(OCCCO)c(OC)c(C(C)(C)C)c3)c(=N)n2n1 nan
CHEMBL3704469 132768 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 485 11 2 10 2.9 CCOc1cc(CC)c2nn(CC(=O)c3cc(OCCCO)c(OC)c(C(C)(C)C)c3)c(=N)n2n1 nan
10771636 106177 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 798 20 11 7 1.2 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1c[nH]c2ccccc12)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143298 106177 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 798 20 11 7 1.2 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1c[nH]c2ccccc12)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143281 209412 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccc(F)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3144093 209436 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)CSc1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
23631184 92519 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 423 3 0 4 5.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3COCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(Cl)c4)cn3)[C@H]12 10.1021/jm070704k
CHEMBL244103 92519 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 423 3 0 4 5.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3COCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(Cl)c4)cn3)[C@H]12 10.1021/jm070704k
11690507 71760 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 429 4 0 3 6.9 CC(C)c1cccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc2)c1 10.1021/jm0502236
CHEMBL197783 71760 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 429 4 0 3 6.9 CC(C)c1cccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc2)c1 10.1021/jm0502236
11647382 134194 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 417 5 0 4 5.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(OCc4ccccc4)cn3)[C@H]12 10.1021/jm0502236
CHEMBL371850 134194 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 417 5 0 4 5.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(OCc4ccccc4)cn3)[C@H]12 10.1021/jm0502236
46931634 126752 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 549 6 1 3 6.6 CCc1ccc(C2CC(NC(=O)c3ccc(-c4cccc(C(F)(F)F)c4)cn3)CN(C(=O)C3CCCC3)C2)cc1 nan
CHEMBL3658405 126752 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 549 6 1 3 6.6 CCc1ccc(C2CC(NC(=O)c3ccc(-c4cccc(C(F)(F)F)c4)cn3)CN(C(=O)C3CCCC3)C2)cc1 nan
9808447 102442 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 583 15 9 8 -0.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL30612 102442 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 583 15 9 8 -0.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
127053943 142869 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 424 3 1 5 4.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(O)CC1(F)F nan
CHEMBL3897962 142869 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 424 3 1 5 4.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(O)CC1(F)F nan
127053963 146963 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 513 5 0 7 5.0 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3Cl)cn2)C2[C@@H](C)OC(=O)[C@]2(Cc2nnn(C)n2)CC1(F)F nan
CHEMBL3930471 146963 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 513 5 0 7 5.0 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3Cl)cn2)C2[C@@H](C)OC(=O)[C@]2(Cc2nnn(C)n2)CC1(F)F nan
72547307 103392 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 428 5 0 3 5.0 CN(C1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1)S(C)(=O)=O 10.1021/ml400235c
CHEMBL3091980 103392 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 428 5 0 3 5.0 CN(C1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1)S(C)(=O)=O 10.1021/ml400235c
127053957 159774 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 505 5 1 7 5.2 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2cocn2)CC1(F)F nan
CHEMBL4110608 159774 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 505 5 1 7 5.2 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2cocn2)CC1(F)F nan
127053971 159841 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 520 6 1 7 5.5 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NCc2nccs2)CC1(F)F nan
CHEMBL4111197 159841 0 None - 0 Human 8.7 pIC50 = 8.7 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 520 6 1 7 5.5 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NCc2nccs2)CC1(F)F nan
127053993 146596 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 437 4 1 5 4.4 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(CN)CC1(F)F nan
CHEMBL3927578 146596 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 437 4 1 5 4.4 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(CN)CC1(F)F nan
121335547 147291 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 527 5 1 5 5.7 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)c2ccccc2)CC1(F)F nan
CHEMBL3932907 147291 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 527 5 1 5 5.7 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)c2ccccc2)CC1(F)F nan
127053974 159699 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 504 6 1 7 5.0 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NCc2cocn2)CC1(F)F nan
CHEMBL4109959 159699 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 504 6 1 7 5.0 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NCc2cocn2)CC1(F)F nan
117826535 153598 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 438 4 0 5 4.9 CO[C@@]12CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@@H]1[C@@H](C)OC2=O nan
CHEMBL3985342 153598 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 438 4 0 5 4.9 CO[C@@]12CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@@H]1[C@@H](C)OC2=O nan
127053956 160163 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 521 5 1 7 5.7 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2nccs2)CC1(F)F nan
CHEMBL4113709 160163 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 521 5 1 7 5.7 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2nccs2)CC1(F)F nan
72547556 103405 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 394 4 1 3 5.6 CC1(OC(N)=O)C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091993 103405 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 394 4 1 3 5.6 CC1(OC(N)=O)C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
127053981 144048 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 477 6 1 5 5.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCC2CC2)CC1(F)F nan
CHEMBL3907652 144048 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 477 6 1 5 5.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCC2CC2)CC1(F)F nan
127053950 146960 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 438 4 1 5 4.5 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(CO)CC1(F)F nan
CHEMBL3930467 146960 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 438 4 1 5 4.5 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(CO)CC1(F)F nan
121335737 150830 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 552 5 1 6 5.5 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)c2cccc(C#N)c2)CC1(F)F nan
CHEMBL3961310 150830 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 552 5 1 6 5.5 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)c2cccc(C#N)c2)CC1(F)F nan
127053940 153088 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 417 3 0 3 5.9 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3Cl)cn2)C2C(CC1(F)F)C(=O)O[C@@H]2C nan
CHEMBL3980810 153088 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 417 3 0 3 5.9 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3Cl)cn2)C2C(CC1(F)F)C(=O)O[C@@H]2C nan
121335758 145162 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 534 5 1 7 5.1 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)c2nccs2)CC1(F)F nan
CHEMBL3916203 145162 0 None - 0 Human 8.6 pIC50 = 8.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 534 5 1 7 5.1 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)c2nccs2)CC1(F)F nan
72547556 103405 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 394 4 1 3 5.6 CC1(OC(N)=O)C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091993 103405 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 394 4 1 3 5.6 CC1(OC(N)=O)C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
121335739 144159 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 552 5 1 6 5.5 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)c2ccc(C#N)cc2)CC1(F)F nan
CHEMBL3908486 144159 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 552 5 1 6 5.5 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)c2ccc(C#N)cc2)CC1(F)F nan
CHEMBL3143249 209397 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccc(F)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
70685279 72900 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 389 4 0 3 5.9 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccccc2C)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012494 72900 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 389 4 0 3 5.9 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccccc2C)cn1 10.1016/j.bmcl.2012.01.138
70683199 72909 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 416 4 1 5 4.6 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(C#N)c2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012503 72909 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 416 4 1 5 4.6 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(C#N)c2)cn1 10.1016/j.bmcl.2012.01.138
10246587 71762 0 None - 1 Human 7.7 pIC50 = 7.7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 339 3 0 3 4.7 CCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
CHEMBL197791 71762 0 None - 1 Human 7.7 pIC50 = 7.7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 339 3 0 3 4.7 CCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
44432791 154100 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 403 3 0 3 5.2 O=C1OC[C@H]2[C@@H]1Cc1c(F)cccc1[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL399407 154100 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 403 3 0 3 5.2 O=C1OC[C@H]2[C@@H]1Cc1c(F)cccc1[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
44416542 141180 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 345 2 0 3 4.8 O=C1OC[C@H]2[C@@H](/C=C/c3ccc4ccccc4n3)[C@@H]3CCCCC3=C[C@@H]12 10.1016/j.bmcl.2006.06.042
CHEMBL385694 141180 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 345 2 0 3 4.8 O=C1OC[C@H]2[C@@H](/C=C/c3ccc4ccccc4n3)[C@@H]3CCCCC3=C[C@@H]12 10.1016/j.bmcl.2006.06.042
23630914 143349 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 505 3 0 5 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CS(=O)(=O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
CHEMBL390182 143349 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 505 3 0 5 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CS(=O)(=O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
44309450 202361 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 796 16 5 7 5.6 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1cccc2c1c(CN1CCCC1)cn2Cc1c(Cl)cccc1Cl)C(=O)NCCN1CCCC1 10.1016/s0960-894x(03)00325-1
CHEMBL70013 202361 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 796 16 5 7 5.6 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1cccc2c1c(CN1CCCC1)cn2Cc1c(Cl)cccc1Cl)C(=O)NCCN1CCCC1 10.1016/s0960-894x(03)00325-1
44416588 80787 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 363 2 1 3 5.0 C[C@H]1O[C@@H](O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@H]12 10.1016/j.bmcl.2006.06.042
CHEMBL215837 80787 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 363 2 1 3 5.0 C[C@H]1O[C@@H](O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@H]12 10.1016/j.bmcl.2006.06.042
76309942 103400 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 408 5 1 3 5.8 CCOC(=O)NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091988 103400 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 408 5 1 3 5.8 CCOC(=O)NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
44280767 114086 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 577 15 9 8 -1.3 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33377 114086 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 577 15 9 8 -1.3 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280877 116371 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 589 15 9 8 0.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](CC1CCCCC1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33820 116371 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 589 15 9 8 0.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](CC1CCCCC1)C(N)=O 10.1016/s0960-894x(99)00197-3
9851501 116721 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 593 15 8 7 0.7 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc(N)nc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33946 116721 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 593 15 8 7 0.7 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc(N)nc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44281081 119198 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 592 15 8 6 1.3 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cccc(N)c1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL34738 119198 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 592 15 8 6 1.3 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cccc(N)c1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44584152 14728 0 None - 0 Human 4.7 pIC50 = 4.7 Binding
Displacement of [125I]thrombin from thrombin receptor in human platelet membraneDisplacement of [125I]thrombin from thrombin receptor in human platelet membrane
ChEMBL 602 7 5 9 3.3 O=S(=O)(O)OC(=C\c1cc(O)c(O)c(Br)c1)/C(=C\c1ccc(O)c(Br)c1)OS(=O)(=O)O 10.1021/np50120a023
CHEMBL1207950 14728 0 None - 0 Human 4.7 pIC50 = 4.7 Binding
Displacement of [125I]thrombin from thrombin receptor in human platelet membraneDisplacement of [125I]thrombin from thrombin receptor in human platelet membrane
ChEMBL 602 7 5 9 3.3 O=S(=O)(O)OC(=C\c1cc(O)c(O)c(Br)c1)/C(=C\c1ccc(O)c(Br)c1)OS(=O)(=O)O 10.1021/np50120a023
CHEMBL462733 14728 0 None - 0 Human 4.7 pIC50 = 4.7 Binding
Displacement of [125I]thrombin from thrombin receptor in human platelet membraneDisplacement of [125I]thrombin from thrombin receptor in human platelet membrane
ChEMBL 602 7 5 9 3.3 O=S(=O)(O)OC(=C\c1cc(O)c(O)c(Br)c1)/C(=C\c1ccc(O)c(Br)c1)OS(=O)(=O)O 10.1021/np50120a023
11611425 71900 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 417 4 0 4 5.8 COc1ccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc2)cc1 10.1021/jm0502236
CHEMBL198175 71900 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 417 4 0 4 5.8 COc1ccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc2)cc1 10.1021/jm0502236
58045970 132773 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 511 12 2 10 3.4 COc1c(OCCCCO)cc(C(=O)Cn2nc3c(C)cc(OCC4CC4)nn3c2=N)cc1C(C)(C)C nan
CHEMBL3704473 132773 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 511 12 2 10 3.4 COc1c(OCCCCO)cc(C(=O)Cn2nc3c(C)cc(OCC4CC4)nn3c2=N)cc1C(C)(C)C nan
44432720 146777 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 404 3 0 4 4.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccc[n+]([O-])c4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL392905 146777 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 404 3 0 4 4.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccc[n+]([O-])c4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
44137613 153987 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 584 11 2 8 4.2 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCN(CC(=O)O)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3978297 153987 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 584 11 2 8 4.2 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCN(CC(=O)O)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3990813 153987 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 584 11 2 8 4.2 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCN(CC(=O)O)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3143309 209423 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)COc1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
23631186 92681 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 457 3 0 4 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3COCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(Cl)c4Cl)cn3)[C@H]12 10.1021/jm070704k
CHEMBL244295 92681 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 457 3 0 4 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3COCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(Cl)c4Cl)cn3)[C@H]12 10.1021/jm070704k
70687424 72902 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 400 4 0 4 5.5 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(C#N)c2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012496 72902 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 400 4 0 4 5.5 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(C#N)c2)cn1 10.1016/j.bmcl.2012.01.138
46931416 127013 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 467 3 2 3 3.7 O=C(NC1CC(c2ccc(C(F)(F)F)cc2)CN(C(=O)N2CCC(O)CC2)C1)C1CCCC1 nan
CHEMBL3662514 127013 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 467 3 2 3 3.7 O=C(NC1CC(c2ccc(C(F)(F)F)cc2)CN(C(=O)N2CCC(O)CC2)C1)C1CCCC1 nan
9869359 86368 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 471 3 0 3 6.2 O=C1OC[C@H]2[C@@H]1Cc1c(F)cc(F)cc1[C@@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL232172 86368 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 471 3 0 3 6.2 O=C1OC[C@H]2[C@@H]1Cc1c(F)cc(F)cc1[C@@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2007.04.061
90663293 106156 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 998 29 11 11 1.0 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN)C(=O)CCC(N)=O 10.1021/jm960455s
CHEMBL3143252 106156 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 998 29 11 11 1.0 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN)C(=O)CCC(N)=O 10.1021/jm960455s
72547551 103393 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 392 3 1 3 5.2 O=C1NCC2(C[C@@H]3CCCC[C@@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)O1 10.1021/ml400235c
CHEMBL3091981 103393 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 392 3 1 3 5.2 O=C1NCC2(C[C@@H]3CCCC[C@@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)O1 10.1021/ml400235c
72547308 103403 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 392 4 0 2 5.6 CC(=O)N(C)C1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091991 103403 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 392 4 0 2 5.6 CC(=O)N(C)C1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
11544845 133045 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 351 3 0 3 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3cccc(C4CC4)n3)[C@H]12 10.1021/jm0502236
CHEMBL371109 133045 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 351 3 0 3 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3cccc(C4CC4)n3)[C@H]12 10.1021/jm0502236
44187825 124625 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 453 6 1 8 2.2 CCc1ccc2n(n1)c(N)n[n+]2CC(=O)c1cc(N2CCOCC2)c(OC)c(C(C)(C)C)c1 nan
CHEMBL3644441 124625 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 453 6 1 8 2.2 CCc1ccc2n(n1)c(N)n[n+]2CC(=O)c1cc(N2CCOCC2)c(OC)c(C(C)(C)C)c1 nan
10227544 204800 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Binding affinity against platelet thrombin receptorBinding affinity against platelet thrombin receptor
ChEMBL 477 7 3 3 5.4 CC(C)(C)C(=O)NCc1ccc(NC(=O)N(C[C@@H](O)c2ccc(Cl)c(Cl)c2)C2CC2)cc1 10.1016/s0960-894x(01)00538-8
CHEMBL88513 204800 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Binding affinity against platelet thrombin receptorBinding affinity against platelet thrombin receptor
ChEMBL 477 7 3 3 5.4 CC(C)(C)C(=O)NCc1ccc(NC(=O)N(C[C@@H](O)c2ccc(Cl)c(Cl)c2)C2CC2)cc1 10.1016/s0960-894x(01)00538-8
76309941 103384 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 379 3 0 3 5.5 Fc1cccc(-c2ccc(/C=C/[C@H]3[C@H]4CCCC[C@H]4CC34OCCO4)nc2)c1 10.1021/ml400235c
CHEMBL3091972 103384 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 379 3 0 3 5.5 Fc1cccc(-c2ccc(/C=C/[C@H]3[C@H]4CCCC[C@H]4CC34OCCO4)nc2)c1 10.1021/ml400235c
11688420 134743 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 325 2 0 3 4.4 Cc1ccnc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)c1 10.1021/jm0502236
CHEMBL372591 134743 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 325 2 0 3 4.4 Cc1ccnc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)c1 10.1021/jm0502236
44338787 6815 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 469 8 0 6 5.6 Fc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1F 10.1016/s0960-894x(01)00745-4
CHEMBL108428 6815 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 469 8 0 6 5.6 Fc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1F 10.1016/s0960-894x(01)00745-4
44432719 86312 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 388 3 0 4 5.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccncc4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL231944 86312 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 388 3 0 4 5.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccncc4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
44409039 140749 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 460 3 1 4 6.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(NC(=O)C(C)(C)C)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL383216 140749 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 460 3 1 4 6.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(NC(=O)C(C)(C)C)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
44416654 80006 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 407 4 0 4 5.7 COc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)O[C@@H](OC)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2006.06.042
CHEMBL214575 80006 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 407 4 0 4 5.7 COc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)O[C@@H](OC)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2006.06.042
58045981 132775 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 455 8 2 9 3.0 Cc1c(OC(C)C)nn2c(=N)n(CC(=O)c3cc(OCCO)cc(C(C)(C)C)c3)nc2c1C nan
CHEMBL3704475 132775 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 455 8 2 9 3.0 Cc1c(OC(C)C)nn2c(=N)n(CC(=O)c3cc(OCCO)cc(C(C)(C)C)c3)nc2c1C nan
44409077 76249 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 480 4 1 4 6.5 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(NC(=O)c5ccccc5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL206325 76249 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 480 4 1 4 6.5 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(NC(=O)c5ccccc5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
23630913 92679 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 473 3 0 4 6.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CSCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
CHEMBL244290 92679 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 473 3 0 4 6.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CSCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
59110450 72896 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 393 4 0 3 5.8 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccccc2F)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012490 72896 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 393 4 0 3 5.8 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccccc2F)cn1 10.1016/j.bmcl.2012.01.138
44432718 86310 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 388 3 0 4 5.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccn4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL231942 86310 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 388 3 0 4 5.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccn4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
9908345 86311 0 None - 1 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 388 3 0 4 5.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccnc4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL231943 86311 0 None - 1 Human 7.7 pIC50 = 7.7 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 388 3 0 4 5.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccnc4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
9844209 72002 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 405 3 0 3 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4F)cn3)[C@H]12 10.1021/jm0502236
CHEMBL198473 72002 0 None - 0 Human 7.7 pIC50 = 7.7 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 405 3 0 3 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4F)cn3)[C@H]12 10.1021/jm0502236
90663360 106189 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 795 21 9 9 1.2 CC(=O)N(Oc1cccs1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143326 106189 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 795 21 9 9 1.2 CC(=O)N(Oc1cccs1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
72547306 103385 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 337 3 1 2 5.1 OC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091973 103385 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 337 3 1 2 5.1 OC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
9853816 96888 0 None - 1 Human 5.7 pIC50 = 5.7 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 789 18 6 7 5.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL269345 96888 0 None - 1 Human 5.7 pIC50 = 5.7 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 789 18 6 7 5.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
49766546 75448 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 358 6 2 2 5.3 CCCC(=O)Nc1cccc(NC(=O)c2cccc(-c3ccccc3)c2)c1 10.1021/ml2002696
CHEMBL2048430 75448 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 358 6 2 2 5.3 CCCC(=O)Nc1cccc(NC(=O)c2cccc(-c3ccccc3)c2)c1 10.1021/ml2002696
44280608 99641 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 731 18 9 8 1.8 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C(F)=C/c2ccccc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL287468 99641 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 731 18 9 8 1.8 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C(F)=C/c2ccccc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44309838 96104 0 None - 0 Human 4.7 pIC50 = 4.7 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 796 16 5 7 5.6 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1cccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c12)C(=O)NCCN1CCCC1 10.1016/s0960-894x(03)00325-1
CHEMBL262932 96104 0 None - 0 Human 4.7 pIC50 = 4.7 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 796 16 5 7 5.6 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1cccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c12)C(=O)NCCN1CCCC1 10.1016/s0960-894x(03)00325-1
44339001 109002 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 463 9 0 7 5.4 COc1ccccc1-c1cc(N(CCCN2CCCCCC2)Cc2ccc3c(c2)OCO3)on1 10.1016/s0960-894x(01)00745-4
CHEMBL322093 109002 0 None - 0 Human 5.7 pIC50 = 5.7 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 463 9 0 7 5.4 COc1ccccc1-c1cc(N(CCCN2CCCCCC2)Cc2ccc3c(c2)OCO3)on1 10.1016/s0960-894x(01)00745-4
23631554 92759 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 478 4 0 5 5.3 CCOC(=O)N1CCC[C@H]2[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]21 10.1021/jm070704k
CHEMBL244484 92759 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 478 4 0 5 5.3 CCOC(=O)N1CCC[C@H]2[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]21 10.1021/jm070704k
44432842 144780 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 399 3 0 4 5.2 COc1ccc2nc(/C=C/[C@@H]3c4ccccc4C[C@H]4C(=O)OC(C)(C)[C@@H]34)ccc2c1 10.1016/j.bmcl.2007.04.061
CHEMBL391324 144780 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 399 3 0 4 5.2 COc1ccc2nc(/C=C/[C@@H]3c4ccccc4C[C@H]4C(=O)OC(C)(C)[C@@H]34)ccc2c1 10.1016/j.bmcl.2007.04.061
44432771 154296 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 469 3 0 3 6.6 O=C1OC[C@H]2[C@@H]1Cc1c(Cl)cccc1[C@@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL400435 154296 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 469 3 0 3 6.6 O=C1OC[C@H]2[C@@H]1Cc1c(Cl)cccc1[C@@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2007.04.061
70687423 72893 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 445 5 0 3 6.6 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1CCc1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012487 72893 0 None - 0 Human 6.7 pIC50 = 6.7 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 445 5 0 3 6.6 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1CCc1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2012.01.138
53245483 75539 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 394 5 2 2 5.1 CCCC(=O)Nc1cccc(NC(=O)c2c(Cl)cccc2Br)c1 10.1021/ml2002696
CHEMBL2049116 75539 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 394 5 2 2 5.1 CCCC(=O)Nc1cccc(NC(=O)c2c(Cl)cccc2Br)c1 10.1021/ml2002696
90663338 106179 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 833 22 9 9 1.8 C=CC(=O)c1ccsc1N(C(C)=O)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143302 106179 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 833 22 9 9 1.8 C=CC(=O)c1ccsc1N(C(C)=O)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143246 209395 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC#Cc1ccccc1C(=O)N(C(C)=O)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143249 209397 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccc(F)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
9934461 136236 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
CHEMBL374106 136236 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
44309461 202114 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 795 15 5 7 6.8 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1cccs1 10.1016/s0960-894x(03)00325-1
CHEMBL68372 202114 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 795 15 5 7 6.8 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1cccs1 10.1016/s0960-894x(03)00325-1
76331784 103399 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 336 3 1 2 5.1 NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091987 103399 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 336 3 1 2 5.1 NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
76324547 103402 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 404 5 1 2 5.6 O=C(NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1)C1CC1 10.1021/ml400235c
CHEMBL3091990 103402 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 404 5 1 2 5.6 O=C(NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1)C1CC1 10.1021/ml400235c
44306903 101782 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 809 18 6 7 5.8 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL303157 101782 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 809 18 6 7 5.8 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
44280683 98946 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 593 15 8 7 0.7 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cccnc1N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL282733 98946 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 593 15 8 7 0.7 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cccnc1N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44281070 111856 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 633 15 7 6 2.9 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc2ccccc2s1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL32941 111856 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 633 15 7 6 2.9 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc2ccccc2s1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
90663339 106180 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 883 21 9 8 3.1 CC(=O)N(C(=O)c1cccc(C2CCCCC2)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143303 106180 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 883 21 9 8 3.1 CC(=O)N(C(=O)c1cccc(C2CCCCC2)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
58045960 132778 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 453 7 1 8 4.1 CCOc1nn2c(=N)n(CC(=O)c3cc(C(C)(C)C)cc(C(C)(C)OC)c3)nc2c(C)c1C nan
CHEMBL3704478 132778 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 453 7 1 8 4.1 CCOc1nn2c(=N)n(CC(=O)c3cc(C(C)(C)C)cc(C(C)(C)OC)c3)nc2c(C)c1C nan
46931633 126755 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 433 5 1 2 5.0 CCc1ccc(C2CC(NC(=O)N(C)c3ccccc3)CN(C(=O)C3CCCC3)C2)cc1 nan
CHEMBL3658408 126755 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 433 5 1 2 5.0 CCc1ccc(C2CC(NC(=O)N(C)c3ccccc3)CN(C(=O)C3CCCC3)C2)cc1 nan
10557086 106166 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 765 20 10 8 0.8 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1ccsc1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143276 106166 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 765 20 10 8 0.8 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1ccsc1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
10747898 106217 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 798 20 11 7 1.2 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc2ccccc2[nH]1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143683 106217 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 798 20 11 7 1.2 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc2ccccc2[nH]1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143311 209425 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143320 209431 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None C/C=C/C=C/CC(=O)N(C(C)=O)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
60003490 72894 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 443 4 0 3 6.6 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012488 72894 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 443 4 0 3 6.6 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2012.01.138
9804049 133040 2 None - 1 Human 7.6 pIC50 = 7.6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm0502236
CHEMBL371069 133040 2 None - 1 Human 7.6 pIC50 = 7.6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm0502236
44306697 102259 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 846 17 6 6 6.9 NC(=O)NCCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL304924 102259 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 846 17 6 6 6.9 NC(=O)NCCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
44280949 102241 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 651 15 7 5 3.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc2c(c1)-c1ccccc1-2)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL30484 102241 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 651 15 7 5 3.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc2c(c1)-c1ccccc1-2)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44281079 116717 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 612 15 7 6 1.8 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc(Cl)nc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33945 116717 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 612 15 7 6 1.8 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc(Cl)nc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
58045994 132758 0 None - 0 Human 4.6 pIC50 = 4.6 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 458 5 1 9 2.7 COc1c(N2CCOCC2)cc(C(=O)Cn2nc3ccc(Cl)nn3c2=N)cc1C(C)(C)C nan
CHEMBL3704458 132758 0 None - 0 Human 4.6 pIC50 = 4.6 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 458 5 1 9 2.7 COc1c(N2CCOCC2)cc(C(=O)Cn2nc3ccc(Cl)nn3c2=N)cc1C(C)(C)C nan
44290206 172970 0 None - 0 Human 4.6 pIC50 = 4.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 763 20 7 8 3.4 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(C)c2ccccc2)cs1 10.1016/s0960-894x(98)00292-3
CHEMBL45317 172970 0 None - 0 Human 4.6 pIC50 = 4.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 763 20 7 8 3.4 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(C)c2ccccc2)cs1 10.1016/s0960-894x(98)00292-3
44290207 172973 0 None - 0 Human 4.6 pIC50 = 4.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 729 19 7 8 2.1 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cs1 10.1016/s0960-894x(98)00292-3
CHEMBL45318 172973 0 None - 0 Human 4.6 pIC50 = 4.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 729 19 7 8 2.1 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cs1 10.1016/s0960-894x(98)00292-3
CHEMBL3143313 209426 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
46931630 126759 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 454 7 1 3 4.2 CCc1ccc(C2CC(NS(=O)(=O)Cc3ccccc3)CN(C(=O)C3CCCC3)C2)cc1 nan
CHEMBL3658411 126759 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 454 7 1 3 4.2 CCc1ccc(C2CC(NS(=O)(=O)Cc3ccccc3)CN(C(=O)C3CCCC3)C2)cc1 nan
9897054 102682 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 773 16 5 7 5.9 CSCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCCN 10.1016/s0960-894x(03)00325-1
CHEMBL308050 102682 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 773 16 5 7 5.9 CSCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCCN 10.1016/s0960-894x(03)00325-1
11803290 106167 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 765 20 10 8 0.8 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cccs1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143277 106167 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 765 20 10 8 0.8 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cccs1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
90663316 106168 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 1002 28 11 11 0.7 CC(=O)N(C(=O)/C=C/c1ccc(F)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN)C(=O)CC(N)=O 10.1021/jm960455s
CHEMBL3143278 106168 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 1002 28 11 11 0.7 CC(=O)N(C(=O)/C=C/c1ccc(F)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN)C(=O)CC(N)=O 10.1021/jm960455s
70854697 127012 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 476 3 1 4 3.4 Cc1cccc(C(=O)NC2CC(c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCOCC3)C2)n1 nan
CHEMBL3662513 127012 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 476 3 1 4 3.4 Cc1cccc(C(=O)NC2CC(c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCOCC3)C2)n1 nan
44409057 140667 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 510 6 1 5 6.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OCC(=O)Nc5ccccc5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL382830 140667 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 510 6 1 5 6.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OCC(=O)Nc5ccccc5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
23631105 141489 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 407 3 0 4 4.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3COCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4F)cn3)[C@H]12 10.1021/jm070704k
CHEMBL387603 141489 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 407 3 0 4 4.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3COCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4F)cn3)[C@H]12 10.1021/jm070704k
23631464 152394 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 590 5 0 5 7.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CN(C(=O)OCc4ccccc4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
CHEMBL397491 152394 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 590 5 0 5 7.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CN(C(=O)OCc4ccccc4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
59110475 72898 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 409 4 0 3 6.3 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccccc2Cl)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012492 72898 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 409 4 0 3 6.3 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccccc2Cl)cn1 10.1016/j.bmcl.2012.01.138
11583548 71971 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 465 3 0 3 6.5 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(Br)c4)cn3)[C@H]12 10.1021/jm0502236
CHEMBL198375 71971 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 465 3 0 3 6.5 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(Br)c4)cn3)[C@H]12 10.1021/jm0502236
11502485 168500 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 412 3 0 4 5.6 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C#N)c4)cn3)[C@H]12 10.1021/jm0502236
CHEMBL439681 168500 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 412 3 0 4 5.6 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C#N)c4)cn3)[C@H]12 10.1021/jm0502236
44339173 8140 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 463 9 0 7 5.4 COc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL109226 8140 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 463 9 0 7 5.4 COc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
11610042 133081 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 353 4 0 3 5.1 CCCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
CHEMBL371294 133081 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 353 4 0 3 5.1 CCCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
58045796 132764 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 485 11 1 10 2.9 CCOc1cc(C)c2nn(CC(=O)c3cc(OC(COC)COC)cc(C(C)(C)C)c3)c(=N)n2n1 nan
CHEMBL3704464 132764 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 485 11 1 10 2.9 CCOc1cc(C)c2nn(CC(=O)c3cc(OC(COC)COC)cc(C(C)(C)C)c3)c(=N)n2n1 nan
44306657 101789 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 861 19 6 8 6.2 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(OC(F)(F)F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL303187 101789 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 861 19 6 8 6.2 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(OC(F)(F)F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
44306403 201174 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 815 22 6 7 5.9 CCN(CC)Cc1cn(Cc2ccccc2C)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc3ccccc3)ccc12 10.1016/s0960-894x(01)00378-x
CHEMBL62584 201174 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 815 22 6 7 5.9 CCN(CC)Cc1cn(Cc2ccccc2C)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc3ccccc3)ccc12 10.1016/s0960-894x(01)00378-x
44280805 99315 0 None - 0 Human 4.6 pIC50 = 4.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 567 15 7 6 1.3 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccoc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL285186 99315 0 None - 0 Human 4.6 pIC50 = 4.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 567 15 7 6 1.3 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccoc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
58045925 132767 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 515 11 3 11 2.6 CCOc1cc(C(C)(C)O)c2nn(CC(=O)c3cc(OCCCO)c(OC)c(C(C)(C)C)c3)c(=N)n2n1 nan
CHEMBL3704468 132767 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 515 11 3 11 2.6 CCOc1cc(C(C)(C)O)c2nn(CC(=O)c3cc(OCCCO)c(OC)c(C(C)(C)C)c3)c(=N)n2n1 nan
11803426 106216 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 793 20 10 7 1.4 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1ccc(Cl)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143682 106216 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 793 20 10 7 1.4 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1ccc(Cl)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
10459564 514 34 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC nan
4048 514 34 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC nan
CHEMBL2103856 514 34 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC nan
DB12046 514 34 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC nan
23631104 92428 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 407 3 0 4 4.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3COCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm070704k
CHEMBL243913 92428 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 407 3 0 4 4.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3COCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm070704k
23631106 92518 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 425 3 0 4 4.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3COCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4F)cn3)[C@H]12 10.1021/jm070704k
CHEMBL244102 92518 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 425 3 0 4 4.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3COCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4F)cn3)[C@H]12 10.1021/jm070704k
72547552 103406 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 379 3 0 3 5.5 Fc1cccc(-c2ccc(/C=C/[C@@H]3[C@H]4CCCC[C@H]4CC34OCCO4)nc2)c1 10.1021/ml400235c
CHEMBL3091994 103406 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 379 3 0 3 5.5 Fc1cccc(-c2ccc(/C=C/[C@@H]3[C@H]4CCCC[C@H]4CC34OCCO4)nc2)c1 10.1021/ml400235c
127053982 145134 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 465 4 1 5 4.4 CC(=O)N[C@@]12CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)C1[C@@H](C)OC2=O nan
CHEMBL3915979 145134 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 465 4 1 5 4.4 CC(=O)N[C@@]12CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)C1[C@@H](C)OC2=O nan
11582568 140364 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 421 3 0 3 6.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4Cl)cn3)[C@H]12 10.1021/jm0502236
CHEMBL382104 140364 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 421 3 0 3 6.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4Cl)cn3)[C@H]12 10.1021/jm0502236
90663297 106158 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 779 20 9 8 1.4 CC(=O)N(c1cccs1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143256 106158 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 779 20 9 8 1.4 CC(=O)N(c1cccs1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
10276545 9057 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 463 9 0 7 5.4 COc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL110024 9057 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 463 9 0 7 5.4 COc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
1048267 32212 87 None - 0 Human 6.6 pIC50 = 6.6 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 360 5 2 2 4.4 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1021/ml2002696
CHEMBL1411333 32212 87 None - 0 Human 6.6 pIC50 = 6.6 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 360 5 2 2 4.4 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1021/ml2002696
44306540 201347 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 795 18 6 7 5.4 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL63402 201347 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 795 18 6 7 5.4 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
44306499 201654 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 815 22 6 7 5.9 CCN(CC)Cc1cn(Cc2cccc(C)c2)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc3ccccc3)ccc12 10.1016/s0960-894x(01)00378-x
CHEMBL65004 201654 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 815 22 6 7 5.9 CCN(CC)Cc1cn(Cc2cccc(C)c2)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc3ccccc3)ccc12 10.1016/s0960-894x(01)00378-x
44280905 99615 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 646 15 7 6 2.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cnc(Cl)c(Cl)c1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL287270 99615 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 646 15 7 6 2.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cnc(Cl)c(Cl)c1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44306066 100168 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 333 4 2 6 3.2 CCOc1ccc(Cn2ccc3c4c(N)nc(N)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
CHEMBL292032 100168 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 333 4 2 6 3.2 CCOc1ccc(Cn2ccc3c4c(N)nc(N)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
44432706 86309 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 339 3 0 3 4.7 CCc1ccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)nc1 10.1016/j.bmcl.2007.06.002
CHEMBL231938 86309 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 339 3 0 3 4.7 CCc1ccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)nc1 10.1016/j.bmcl.2007.06.002
50910549 75300 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 362 4 2 3 4.3 CCOC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1021/ml2002696
CHEMBL2047286 75300 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 362 4 2 3 4.3 CCOC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1021/ml2002696
59110483 72905 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 409 4 1 4 4.9 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012499 72905 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 409 4 1 4 4.9 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2012.01.138
9865055 70954 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 387 3 0 3 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL195729 70954 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 387 3 0 3 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
9865055 70954 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 387 3 0 3 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4)cn3)[C@H]12 10.1021/jm0502236
CHEMBL195729 70954 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 387 3 0 3 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4)cn3)[C@H]12 10.1021/jm0502236
CHEMBL3143248 209396 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)CCCN)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44290102 100838 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 820 21 8 9 2.5 CC(C)C(N)C(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cs1 10.1016/s0960-894x(98)00292-3
CHEMBL296565 100838 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 820 21 8 9 2.5 CC(C)C(N)C(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cs1 10.1016/s0960-894x(98)00292-3
44290300 177921 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 798 21 8 9 2.4 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2CCCCC2)C(N)=O)cs1 10.1016/s0960-894x(98)00292-3
CHEMBL46658 177921 0 None - 0 Human 5.6 pIC50 = 5.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 798 21 8 9 2.4 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2CCCCC2)C(N)=O)cs1 10.1016/s0960-894x(98)00292-3
44280835 99642 0 None - 0 Human 4.6 pIC50 = 4.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 573 15 10 9 -1.9 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1c[nH]cn1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL287469 99642 0 None - 0 Human 4.6 pIC50 = 4.6 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 573 15 10 9 -1.9 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1c[nH]cn1)C(N)=O 10.1016/s0960-894x(99)00197-3
44409228 140140 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 520 6 1 6 6.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OCCNC(=O)OC(C)(C)C)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL381506 140140 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 520 6 1 6 6.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OCCNC(=O)OC(C)(C)C)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
44182739 123960 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 510 9 1 10 3.6 CCC(CC)Oc1ccc2nn(CC(=O)c3cc(N4CCOCC4)c(OC)c(C(C)(C)C)c3)c(=N)n2n1 nan
CHEMBL3640033 123960 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 510 9 1 10 3.6 CCC(CC)Oc1ccc2nn(CC(=O)c3cc(N4CCOCC4)c(OC)c(C(C)(C)C)c3)c(=N)n2n1 nan
11432492 154026 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 526 9 2 7 4.4 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCNCC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3912154 154026 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 526 9 2 7 4.4 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCNCC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3991167 154026 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 526 9 2 7 4.4 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCNCC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3143271 209408 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143282 209413 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@H](CCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44409034 75054 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 446 5 1 4 6.0 CCCC(=O)Nc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2005.12.042
CHEMBL203992 75054 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 446 5 1 4 6.0 CCCC(=O)Nc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2005.12.042
44418854 82260 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 441 3 0 3 6.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CC(F)(F)CC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4F)cn3)[C@H]12 10.1021/jm061043e
CHEMBL217958 82260 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 441 3 0 3 6.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CC(F)(F)CC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4F)cn3)[C@H]12 10.1021/jm061043e
44418838 83008 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 421 3 1 4 4.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm061043e
CHEMBL219643 83008 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 421 3 1 4 4.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm061043e
16100352 136408 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@H]3[C@@H](CCC[C@H]3O)[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
CHEMBL374265 136408 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@H]3[C@@H](CCC[C@H]3O)[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
59110442 72899 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 409 4 0 3 6.3 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012493 72899 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 409 4 0 3 6.3 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2012.01.138
11661666 140041 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 417 4 0 4 5.8 COc1cccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc2)c1 10.1021/jm0502236
CHEMBL381226 140041 0 None - 0 Human 7.6 pIC50 = 7.6 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 417 4 0 4 5.8 COc1cccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc2)c1 10.1021/jm0502236
76317165 103386 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 427 6 0 2 7.3 Fc1cccc(-c2ccc(/C=C/[C@H]3C(OCc4ccccc4)C[C@@H]4CCCC[C@@H]43)nc2)c1 10.1021/ml400235c
CHEMBL3091974 103386 0 None - 0 Human 6.6 pIC50 = 6.6 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 427 6 0 2 7.3 Fc1cccc(-c2ccc(/C=C/[C@H]3C(OCc4ccccc4)C[C@@H]4CCCC[C@@H]43)nc2)c1 10.1021/ml400235c
44432705 86766 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 413 4 0 3 6.2 CCc1nc(/C=C/[C@H]2[C@@H]3CCCCC3=C[C@H]3C(=O)O[C@H](C)[C@@H]23)ccc1-c1ccccc1 10.1016/j.bmcl.2007.06.002
CHEMBL232726 86766 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 413 4 0 3 6.2 CCc1nc(/C=C/[C@H]2[C@@H]3CCCCC3=C[C@H]3C(=O)O[C@H](C)[C@@H]23)ccc1-c1ccccc1 10.1016/j.bmcl.2007.06.002
1047178 206418 4 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 490 6 2 6 5.6 CC(C)(C)c1cc(C(=O)Cn2c(=N)n(CCN3CCCCC3)c3ccccc32)cc(C(C)(C)C)c1O 10.1016/s0960-894x(01)00555-8
CHEMBL98231 206418 4 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 490 6 2 6 5.6 CC(C)(C)c1cc(C(=O)Cn2c(=N)n(CCN3CCCCC3)c3ccccc32)cc(C(C)(C)C)c1O 10.1016/s0960-894x(01)00555-8
10628873 106152 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 749 20 10 8 0.3 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1ccoc1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143247 106152 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 749 20 10 8 0.3 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1ccoc1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
66761216 126748 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 410 6 1 2 4.8 CCc1ccc(C2CC(C(=O)Nc3ccccc3)CN(C(=O)C(C)(C)CF)C2)cc1 nan
CHEMBL3658401 126748 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 410 6 1 2 4.8 CCc1ccc(C2CC(C(=O)Nc3ccccc3)CN(C(=O)C(C)(C)CF)C2)cc1 nan
11249717 153902 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 541 9 2 7 4.9 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCC(O)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3903962 153902 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 541 9 2 7 4.9 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCC(O)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3990074 153902 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 541 9 2 7 4.9 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCC(O)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
44432775 86601 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 419 3 0 3 5.7 O=C1OC[C@H]2[C@@H]1Cc1c(F)cccc1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL232536 86601 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 419 3 0 3 5.7 O=C1OC[C@H]2[C@@H]1Cc1c(F)cccc1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
11618945 140164 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 435 5 1 5 4.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OCC(=O)O)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL381593 140164 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 435 5 1 5 4.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OCC(=O)O)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
44432708 86958 0 None - 1 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 380 3 0 4 4.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(N4CCCC4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL233343 86958 0 None - 1 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 380 3 0 4 4.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(N4CCCC4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
44339002 9260 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 447 8 0 6 5.7 Cc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL111258 9260 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 447 8 0 6 5.7 Cc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
44409278 77283 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 474 6 1 5 4.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OCC(=O)NC5CC5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL208835 77283 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 474 6 1 5 4.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OCC(=O)NC5CC5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
50910548 75302 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 374 5 2 2 4.7 CC(C)CC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1021/ml2002696
CHEMBL2047299 75302 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 374 5 2 2 4.7 CC(C)CC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1 10.1021/ml2002696
44281080 99460 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 592 15 8 6 1.3 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc(N)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL286211 99460 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 592 15 8 6 1.3 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccc(N)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
90663332 106174 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 865 21 9 8 2.1 CC(=O)N(C(=O)Cc1ccc2ccccc2c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143295 106174 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 865 21 9 8 2.1 CC(=O)N(C(=O)Cc1ccc2ccccc2c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
23631640 168186 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 485 4 0 6 5.1 CCOC(=O)N1CCC[C@H]2[C@H](/C=C/c3ccc(-c4cccc(C#N)c4)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]21 10.1021/jm070704k
CHEMBL437171 168186 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 485 4 0 6 5.1 CCOC(=O)N1CCC[C@H]2[C@H](/C=C/c3ccc(-c4cccc(C#N)c4)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]21 10.1021/jm070704k
127053980 142863 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 517 6 1 7 4.7 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCc2nccn2C)CC1(F)F nan
CHEMBL3897916 142863 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 517 6 1 7 4.7 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCc2nccn2C)CC1(F)F nan
121335755 144449 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 562 5 1 6 5.7 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)c2ccc(Cl)nc2)CC1(F)F nan
CHEMBL3910807 144449 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 562 5 1 6 5.7 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)c2ccc(Cl)nc2)CC1(F)F nan
121335757 153680 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 545 5 1 5 5.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)c2cccc(F)c2)CC1(F)F nan
CHEMBL3985965 153680 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 545 5 1 5 5.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)c2cccc(F)c2)CC1(F)F nan
127053954 160160 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 515 5 1 6 5.6 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2ccccn2)CC1(F)F nan
CHEMBL4113629 160160 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 515 5 1 6 5.6 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2ccccn2)CC1(F)F nan
127053978 143970 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 514 6 1 6 5.4 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCc2ccccn2)CC1(F)F nan
CHEMBL3906932 143970 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 514 6 1 6 5.4 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCc2ccccn2)CC1(F)F nan
127053964 148909 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 476 4 0 8 3.9 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(n2cnnn2)CC1(F)F nan
CHEMBL3945945 148909 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 476 4 0 8 3.9 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(n2cnnn2)CC1(F)F nan
127053958 160311 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 505 5 1 7 5.2 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2ncco2)CC1(F)F nan
CHEMBL4114937 160311 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 505 5 1 7 5.2 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(O)c2ncco2)CC1(F)F nan
127053959 144295 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 456 4 0 4 6.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3Cl)cn2)C2[C@@H](C)OC(=O)[C@]2(CC#N)CC1(F)F nan
CHEMBL3909563 144295 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 456 4 0 4 6.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3Cl)cn2)C2[C@@H](C)OC(=O)[C@]2(CC#N)CC1(F)F nan
127053990 151962 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 437 3 1 5 4.5 Cc1cccc(-c2ccc(/C=C/[C@@H]3C4[C@@H](C)OC(=O)[C@]4(N)CC(F)(F)[C@H]3C)nc2)c1C#N nan
CHEMBL3971211 151962 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 437 3 1 5 4.5 Cc1cccc(-c2ccc(/C=C/[C@@H]3C4[C@@H](C)OC(=O)[C@]4(N)CC(F)(F)[C@H]3C)nc2)c1C#N nan
127053953 160253 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 505 5 1 5 5.1 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(=O)NC2CCC2)CC1(F)F nan
CHEMBL4114406 160253 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 505 5 1 5 5.1 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C(=O)NC2CCC2)CC1(F)F nan
121335756 152750 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 532 5 1 7 5.0 Cc1cc(C(=O)N[C@@]23CC(F)(F)[C@@H](C)[C@H](/C=C/c4ccc(-c5ccccc5C#N)cn4)[C@@H]2[C@@H](C)OC3=O)no1 nan
CHEMBL3977807 152750 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 532 5 1 7 5.0 Cc1cc(C(=O)N[C@@]23CC(F)(F)[C@@H](C)[C@H](/C=C/c4ccc(-c5ccccc5C#N)cn4)[C@@H]2[C@@H](C)OC3=O)no1 nan
127053946 153067 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 459 4 0 5 4.9 COC(=O)[C@@]12CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)C1[C@@H](C)OC2=O nan
CHEMBL3980639 153067 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 459 4 0 5 4.9 COC(=O)[C@@]12CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)C1[C@@H](C)OC2=O nan
121335541 142191 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 491 5 1 5 4.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)C2CC2)CC1(F)F nan
CHEMBL3892331 142191 0 None - 0 Human 8.5 pIC50 = 8.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 491 5 1 5 4.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)C2CC2)CC1(F)F nan
127053986 159392 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 531 5 1 7 4.4 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@@]2(NC(=O)c2ccn(C)n2)CC1(F)F nan
CHEMBL4107269 159392 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 531 5 1 7 4.4 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@@]2(NC(=O)c2ccn(C)n2)CC1(F)F nan
127053972 160350 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 514 6 1 6 5.4 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NCc2ccncc2)CC1(F)F nan
CHEMBL4115204 160350 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 514 6 1 6 5.4 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NCc2ccncc2)CC1(F)F nan
127050673 140247 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 506 6 1 5 4.5 CCN(C(=O)COC)C1CN(/C(=N\C#N)Nc2ccc(Cl)c(Cl)c2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
CHEMBL3818510 140247 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 506 6 1 5 4.5 CCN(C(=O)COC)C1CN(/C(=N\C#N)Nc2ccc(Cl)c(Cl)c2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
127050934 140277 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 404 7 2 5 1.8 CCCCN/C(=N/C#N)N1CC(N(CC)C(=O)CO)C(c2ccc(Cl)cc2)=N1 10.1021/acs.jmedchem.5b01890
CHEMBL3818898 140277 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 404 7 2 5 1.8 CCCCN/C(=N/C#N)N1CC(N(CC)C(=O)CO)C(c2ccc(Cl)cc2)=N1 10.1021/acs.jmedchem.5b01890
11432492 154026 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 526 9 2 7 4.4 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCNCC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3912154 154026 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 526 9 2 7 4.4 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCNCC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3991167 154026 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 526 9 2 7 4.4 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCNCC3)c(OC)c(C(C)(C)C)c1)C2 nan
44409232 75558 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 376 2 1 4 4.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(N)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL204955 75558 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 376 2 1 4 4.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(N)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
44305776 100173 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Antagonist activity at PAR1 (unknown origin) assessed as inhibition of thrombin-induced platelet aggregationAntagonist activity at PAR1 (unknown origin) assessed as inhibition of thrombin-induced platelet aggregation
ChEMBL 331 3 2 5 3.9 CC(C)c1ccc(Cn2ccc3c4c(N)nc(N)nc4ccc32)cc1 10.1039/c4md00485j
CHEMBL292089 100173 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Antagonist activity at PAR1 (unknown origin) assessed as inhibition of thrombin-induced platelet aggregationAntagonist activity at PAR1 (unknown origin) assessed as inhibition of thrombin-induced platelet aggregation
ChEMBL 331 3 2 5 3.9 CC(C)c1ccc(Cn2ccc3c4c(N)nc(N)nc4ccc32)cc1 10.1039/c4md00485j
11537143 71435 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 325 2 0 3 4.4 Cc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1016/j.bmcl.2006.06.042
CHEMBL196727 71435 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 325 2 0 3 4.4 Cc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1016/j.bmcl.2006.06.042
44409076 140021 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 443 3 0 4 7.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(-c5cccs5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL381121 140021 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 443 3 0 4 7.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(-c5cccs5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
44409033 140795 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 505 3 0 3 7.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(-c5cccc(C(F)(F)F)c5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL383479 140795 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 505 3 0 3 7.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(-c5cccc(C(F)(F)F)c5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
44306762 201411 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 817 17 5 6 7.5 NCCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL63966 201411 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 817 17 5 6 7.5 NCCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
11537143 71435 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 325 2 0 3 4.4 Cc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
CHEMBL196727 71435 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 325 2 0 3 4.4 Cc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
44305776 100173 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 331 3 2 5 3.9 CC(C)c1ccc(Cn2ccc3c4c(N)nc(N)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
CHEMBL292089 100173 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 331 3 2 5 3.9 CC(C)c1ccc(Cn2ccc3c4c(N)nc(N)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
50910530 75541 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 310 5 2 2 4.3 CCCC(=O)Nc1cccc(NC(=O)c2c(C)cccc2C)c1 10.1021/ml2002696
CHEMBL2049118 75541 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 310 5 2 2 4.3 CCCC(=O)Nc1cccc(NC(=O)c2c(C)cccc2C)c1 10.1021/ml2002696
44280660 99416 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 617 15 7 6 2.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc2ccccc2o1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL285915 99416 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 617 15 7 6 2.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc2ccccc2o1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280651 114934 0 None - 0 Human 4.5 pIC50 = 4.5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 781 18 9 8 2.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccc(C(F)(F)F)cc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33506 114934 0 None - 0 Human 4.5 pIC50 = 4.5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 781 18 9 8 2.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccc(C(F)(F)F)cc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
9831601 100017 0 None - 0 Human 4.5 pIC50 = 4.5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 704 17 6 7 3.5 CC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)c(C)o1 10.1016/s0960-894x(98)00292-3
CHEMBL290927 100017 0 None - 0 Human 4.5 pIC50 = 4.5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 704 17 6 7 3.5 CC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)c(C)o1 10.1016/s0960-894x(98)00292-3
10077130 3944 49 None - 1 Human 7.5 pIC50 = 7.5 Binding
Antagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in TRAP-stimulated platelet aggregation preincubated for 20 mins followed by TRAP stimulation measured after 5 mins by aggregometric analysisAntagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in TRAP-stimulated platelet aggregation preincubated for 20 mins followed by TRAP stimulation measured after 5 mins by aggregometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/acs.jmedchem.7b00951
4047 3944 49 None - 1 Human 7.5 pIC50 = 7.5 Binding
Antagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in TRAP-stimulated platelet aggregation preincubated for 20 mins followed by TRAP stimulation measured after 5 mins by aggregometric analysisAntagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in TRAP-stimulated platelet aggregation preincubated for 20 mins followed by TRAP stimulation measured after 5 mins by aggregometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/acs.jmedchem.7b00951
4870 3944 49 None - 1 Human 7.5 pIC50 = 7.5 Binding
Antagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in TRAP-stimulated platelet aggregation preincubated for 20 mins followed by TRAP stimulation measured after 5 mins by aggregometric analysisAntagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in TRAP-stimulated platelet aggregation preincubated for 20 mins followed by TRAP stimulation measured after 5 mins by aggregometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/acs.jmedchem.7b00951
CHEMBL493982 3944 49 None - 1 Human 7.5 pIC50 = 7.5 Binding
Antagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in TRAP-stimulated platelet aggregation preincubated for 20 mins followed by TRAP stimulation measured after 5 mins by aggregometric analysisAntagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in TRAP-stimulated platelet aggregation preincubated for 20 mins followed by TRAP stimulation measured after 5 mins by aggregometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/acs.jmedchem.7b00951
DB09030 3944 49 None - 1 Human 7.5 pIC50 = 7.5 Binding
Antagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in TRAP-stimulated platelet aggregation preincubated for 20 mins followed by TRAP stimulation measured after 5 mins by aggregometric analysisAntagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in TRAP-stimulated platelet aggregation preincubated for 20 mins followed by TRAP stimulation measured after 5 mins by aggregometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/acs.jmedchem.7b00951
44432767 86563 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 453 3 0 3 6.0 O=C1OC[C@H]2[C@@H]1Cc1ccc(F)cc1[C@@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL232372 86563 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 453 3 0 3 6.0 O=C1OC[C@H]2[C@@H]1Cc1ccc(F)cc1[C@@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2007.04.061
44309777 202612 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 810 17 5 7 6.0 NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCCN1CCCC1 10.1016/s0960-894x(03)00325-1
CHEMBL71444 202612 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 810 17 5 7 6.0 NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCCN1CCCC1 10.1016/s0960-894x(03)00325-1
90663340 106181 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 779 20 9 8 1.4 CC(=O)N(c1ccsc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143304 106181 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 779 20 9 8 1.4 CC(=O)N(c1ccsc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306660 202126 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 797 20 6 7 5.6 CCN(CC)Cc1cn(Cc2ccc(F)cc2)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC3CCCCC3)ccc12 10.1016/s0960-894x(01)00378-x
CHEMBL68458 202126 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 797 20 6 7 5.6 CCN(CC)Cc1cn(Cc2ccc(F)cc2)c2cc(NC(=O)N[C@@H](Cc3ccc(OC)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC3CCCCC3)ccc12 10.1016/s0960-894x(01)00378-x
9960837 115034 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 629 15 7 7 1.7 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cnc2ccccc2n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33532 115034 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 629 15 7 7 1.7 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cnc2ccccc2n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280607 167288 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 789 19 9 8 3.0 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C(=C/c2ccccc2)c2ccccc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL430930 167288 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 789 19 9 8 3.0 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C(=C/c2ccccc2)c2ccccc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280667 102473 0 None - 0 Human 4.5 pIC50 = 4.5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 738 18 9 9 1.4 N#Cc1ccc(/C=C/C(=O)Nc2nc(C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc3ccccc3)C(N)=O)n[nH]2)cc1 10.1016/s0960-894x(99)00197-3
CHEMBL30635 102473 0 None - 0 Human 4.5 pIC50 = 4.5 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 738 18 9 9 1.4 N#Cc1ccc(/C=C/C(=O)Nc2nc(C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc3ccccc3)C(N)=O)n[nH]2)cc1 10.1016/s0960-894x(99)00197-3
1361448 75540 7 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 350 5 2 2 5.0 CCCC(=O)Nc1cccc(NC(=O)c2cccc(Cl)c2Cl)c1 10.1021/ml2002696
CHEMBL2049117 75540 7 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 350 5 2 2 5.0 CCCC(=O)Nc1cccc(NC(=O)c2cccc(Cl)c2Cl)c1 10.1021/ml2002696
44432840 87718 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 385 3 0 4 4.8 COc1ccc2nc(/C=C/[C@@H]3c4ccccc4C[C@H]4C(=O)O[C@@H](C)[C@@H]34)ccc2c1 10.1016/j.bmcl.2007.04.061
CHEMBL234688 87718 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 385 3 0 4 4.8 COc1ccc2nc(/C=C/[C@@H]3c4ccccc4C[C@H]4C(=O)O[C@@H](C)[C@@H]34)ccc2c1 10.1016/j.bmcl.2007.04.061
CHEMBL3143270 209407 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@H](CCCN=C(N(C)C)N(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306894 102239 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 806 18 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4cccc(C)c4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL304829 102239 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 806 18 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4cccc(C)c4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
44305944 101767 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 373 5 1 5 4.9 CNc1nc(N(C)C)nc2ccc3c(ccn3Cc3ccc(C(C)C)cc3)c12 10.1016/s0960-894x(99)00339-x
CHEMBL303084 101767 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 373 5 1 5 4.9 CNc1nc(N(C)C)nc2ccc3c(ccn3Cc3ccc(C(C)C)cc3)c12 10.1016/s0960-894x(99)00339-x
11509594 69335 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 401 3 0 3 6.1 Cc1ccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc2)cc1 10.1021/jm0502236
CHEMBL193537 69335 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 401 3 0 3 6.1 Cc1ccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc2)cc1 10.1021/jm0502236
11702885 70050 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 341 3 0 4 4.1 COc1ccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)nc1 10.1021/jm0502236
CHEMBL194533 70050 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 341 3 0 4 4.1 COc1ccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)nc1 10.1021/jm0502236
44432778 145444 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 435 3 0 3 6.2 O=C1OC[C@H]2[C@@H]1Cc1c(Cl)cccc1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL391833 145444 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 435 3 0 3 6.2 O=C1OC[C@H]2[C@@H]1Cc1c(Cl)cccc1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
76328107 103404 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 351 3 1 2 5.5 CC1(O)C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091992 103404 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 351 3 1 2 5.5 CC1(O)C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
59110479 72907 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 405 4 1 4 5.0 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccccc2C)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012501 72907 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 405 4 1 4 5.0 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccccc2C)cn1 10.1016/j.bmcl.2012.01.138
2858257 112105 12 None - 0 Human 7.5 pIC50 = 7.5 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 483 5 2 5 6.5 Cc1ccc(Cn2c(=N)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c3ccccc32)cc1 10.1016/s0960-894x(01)00555-8
CHEMBL330204 112105 12 None - 0 Human 7.5 pIC50 = 7.5 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 483 5 2 5 6.5 Cc1ccc(Cn2c(=N)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c3ccccc32)cc1 10.1016/s0960-894x(01)00555-8
71736053 143342 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 532 5 1 7 5.0 Cc1oncc1C(=O)N[C@@]12CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@@H]1[C@@H](C)OC2=O nan
CHEMBL3901770 143342 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 532 5 1 7 5.0 Cc1oncc1C(=O)N[C@@]12CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@@H]1[C@@H](C)OC2=O nan
23631275 92682 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 461 4 0 6 4.4 CCOC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3ccccn3)cn2)C1 10.1021/jm070704k
CHEMBL244298 92682 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 461 4 0 6 4.4 CCOC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3ccccn3)cn2)C1 10.1021/jm070704k
66761314 127007 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 475 3 2 3 3.9 O=C(NC1CC(c2ccc(C(F)(F)F)cc2)CN(C(=O)N2CCC(O)CC2)C1)c1ccccc1 nan
CHEMBL3662508 127007 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 475 3 2 3 3.9 O=C(NC1CC(c2ccc(C(F)(F)F)cc2)CN(C(=O)N2CCC(O)CC2)C1)c1ccccc1 nan
44309751 102683 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccn1 10.1016/s0960-894x(03)00325-1
CHEMBL308052 102683 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccn1 10.1016/s0960-894x(03)00325-1
44432786 86270 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 419 3 0 3 5.7 O=C1OC[C@H]2[C@@H]1Cc1cccc(F)c1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL231732 86270 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 419 3 0 3 5.7 O=C1OC[C@H]2[C@@H]1Cc1cccc(F)c1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
44432710 154324 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 471 4 0 5 5.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(N4CCN(c5ccccc5)CC4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL400634 154324 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 471 4 0 5 5.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(N4CCN(c5ccccc5)CC4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
44306611 201908 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 775 18 6 7 4.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL66958 201908 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 775 18 6 7 4.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL3143266 209404 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccc(C)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143279 209411 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@H](CCN=C(N(C)C)N(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143315 209427 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1cccnc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
51003683 75301 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 346 6 2 2 4.9 CCCCNc1cccc(NC(=O)c2ccccc2Br)c1 10.1021/ml2002696
CHEMBL2047297 75301 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 346 6 2 2 4.9 CCCCNc1cccc(NC(=O)c2ccccc2Br)c1 10.1021/ml2002696
CHEMBL4227548 75301 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 346 6 2 2 4.9 CCCCNc1cccc(NC(=O)c2ccccc2Br)c1 10.1021/ml2002696
CHEMBL3143287 209415 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@H](Cc1cccnc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
127053992 150069 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 451 4 1 6 4.4 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3-c3nnn[nH]3)cn2)C2C(CC1(F)F)C(=O)O[C@@H]2C nan
CHEMBL3955189 150069 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 451 4 1 6 4.4 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3-c3nnn[nH]3)cn2)C2C(CC1(F)F)C(=O)O[C@@H]2C nan
44309958 202606 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 795 15 5 7 6.5 NCCNC(=O)[C@H](Cc1cccs1)NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1 10.1016/s0960-894x(03)00325-1
CHEMBL71411 202606 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 795 15 5 7 6.5 NCCNC(=O)[C@H](Cc1cccs1)NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1 10.1016/s0960-894x(03)00325-1
CHEMBL3143268 209405 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CCCCC/C=C/CC(=O)N(C(C)=O)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
70685280 72908 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 405 4 1 4 5.0 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(C)c2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012502 72908 0 None - 0 Human 7.5 pIC50 = 7.5 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 405 4 1 4 5.0 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(C)c2)cn1 10.1016/j.bmcl.2012.01.138
11697104 71799 1 None - 0 Human 7.5 pIC50 = 7.5 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 405 3 0 3 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm0502236
CHEMBL197903 71799 1 None - 0 Human 7.5 pIC50 = 7.5 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 405 3 0 3 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm0502236
90663341 106182 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 791 20 9 7 1.5 CC(=O)N(c1ccc(F)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143306 106182 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 791 20 9 7 1.5 CC(=O)N(c1ccc(F)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44432692 87810 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 323 2 0 3 4.3 Cc1cccc(/C=C/[C@H]2[C@@H]3CCCCC3=C[C@H]3C(=O)O[C@H](C)[C@@H]23)n1 10.1016/j.bmcl.2007.06.002
CHEMBL234804 87810 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 323 2 0 3 4.3 Cc1cccc(/C=C/[C@H]2[C@@H]3CCCCC3=C[C@H]3C(=O)O[C@H](C)[C@@H]23)n1 10.1016/j.bmcl.2007.06.002
44416563 137885 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 341 3 1 3 4.5 CCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)O[C@@H](O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1016/j.bmcl.2006.06.042
CHEMBL377378 137885 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 341 3 1 3 4.5 CCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)O[C@@H](O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1016/j.bmcl.2006.06.042
44306658 101725 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 835 19 6 9 5.0 COC(=O)c1ccc(Cn2cc(CN3CCCC3)c3ccc(NC(=O)N[C@@H](Cc4ccc(OC)cc4)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC4CCCCC4)cc32)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL302823 101725 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 835 19 6 9 5.0 COC(=O)c1ccc(Cn2cc(CN3CCCC3)c3ccc(NC(=O)N[C@@H](Cc4ccc(OC)cc4)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC4CCCCC4)cc32)cc1 10.1016/s0960-894x(01)00378-x
11703925 140593 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 395 7 0 3 6.2 CCCCCCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
CHEMBL382733 140593 0 None - 0 Human 5.5 pIC50 = 5.5 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 395 7 0 3 6.2 CCCCCCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
66701444 126753 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 384 4 1 2 4.3 CCc1ccc(C2CC(NC(=O)C(C)(C)C)CN(C(=O)C3CCCC3)C2)cc1 nan
CHEMBL3658406 126753 0 None - 0 Human 6.5 pIC50 = 6.5 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 384 4 1 2 4.3 CCc1ccc(C2CC(NC(=O)C(C)(C)C)CN(C(=O)C3CCCC3)C2)cc1 nan
3751851 206376 10 None - 0 Human 6.5 pIC50 = 6.5 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 435 6 2 5 5.9 CCCCn1c(=N)n(CC(=O)c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)c2ccccc21 10.1016/s0960-894x(01)00555-8
CHEMBL97952 206376 10 None - 0 Human 6.5 pIC50 = 6.5 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 435 6 2 5 5.9 CCCCn1c(=N)n(CC(=O)c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)c2ccccc21 10.1016/s0960-894x(01)00555-8
44432713 145447 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 427 3 0 4 6.5 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccc(Cl)s4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL391834 145447 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 427 3 0 4 6.5 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccc(Cl)s4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
76317166 103398 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 456 5 1 3 7.3 O=C(Nc1ccccc1)OC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091986 103398 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 456 5 1 3 7.3 O=C(Nc1ccccc1)OC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
44432691 87809 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 309 2 0 3 4.0 C[C@H]1OC(=O)[C@@H]2C=C3CCCC[C@H]3[C@H](/C=C/c3ccccn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL234803 87809 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 309 2 0 3 4.0 C[C@H]1OC(=O)[C@@H]2C=C3CCCC[C@H]3[C@H](/C=C/c3ccccn3)[C@H]12 10.1016/j.bmcl.2007.06.002
58136821 132766 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 455 8 1 9 2.6 CCOc1nn2/c(=N/C)n(CC(=O)c3cc(OCCO)cc(C(C)(C)C)c3)nc2c(C)c1C nan
CHEMBL3704467 132766 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 455 8 1 9 2.6 CCOc1nn2/c(=N/C)n(CC(=O)c3cc(OCCO)cc(C(C)(C)C)c3)nc2c(C)c1C nan
CHEMBL4115741 211164 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL None None None None nan
11718309 70237 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 401 4 0 3 5.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(Cc4ccccc4)cn3)[C@H]12 10.1021/jm0502236
CHEMBL194920 70237 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 401 4 0 3 5.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(Cc4ccccc4)cn3)[C@H]12 10.1021/jm0502236
16100350 136252 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 491 3 0 3 7.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CC(F)(F)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
CHEMBL374122 136252 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 491 3 0 3 7.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CC(F)(F)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
23631279 142922 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 524 4 0 4 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CN(C(=O)C4CC4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
CHEMBL389835 142922 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 524 4 0 4 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CN(C(=O)C4CC4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
90663302 106161 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 765 20 9 7 1.1 CC(=O)N(C1CCCC1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143262 106161 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 765 20 9 7 1.1 CC(=O)N(C1CCCC1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143259 209400 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
23630915 92758 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 489 3 0 4 5.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[S+]([O-])CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
CHEMBL244483 92758 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 489 3 0 4 5.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[S+]([O-])CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
44416717 80167 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 343 5 2 3 4.1 CCc1cccc(/C=C/[C@@H]2[C@H]([C@@H](C)O)[C@H](CO)C[C@@H]3CCCC[C@H]32)n1 10.1016/j.bmcl.2006.06.042
CHEMBL214956 80167 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 343 5 2 3 4.1 CCc1cccc(/C=C/[C@@H]2[C@H]([C@@H](C)O)[C@H](CO)C[C@@H]3CCCC[C@H]32)n1 10.1016/j.bmcl.2006.06.042
44418842 137357 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 437 3 1 4 5.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(Cl)c4)cn3)[C@H]12 10.1021/jm061043e
CHEMBL376285 137357 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 437 3 1 4 5.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(Cl)c4)cn3)[C@H]12 10.1021/jm061043e
127053952 160009 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 579 4 1 7 5.5 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C2(O)CN(C(=O)OC(C)(C)C)C2)CC1(F)F nan
CHEMBL4112571 160009 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 579 4 1 7 5.5 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C2(O)CN(C(=O)OC(C)(C)C)C2)CC1(F)F nan
44306500 167353 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 833 20 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccccc4Cl)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL431369 167353 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 833 20 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccccc4Cl)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
53245451 75538 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 394 5 2 2 5.1 CCCC(=O)Nc1cccc(NC(=O)c2cc(Cl)ccc2Br)c1 10.1021/ml2002696
CHEMBL2049115 75538 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 394 5 2 2 5.1 CCCC(=O)Nc1cccc(NC(=O)c2cc(Cl)ccc2Br)c1 10.1021/ml2002696
CHEMBL3143290 209418 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44408711 75065 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 375 2 0 3 5.6 Cc1cccc2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc12 10.1016/j.bmcl.2005.12.042
CHEMBL204064 75065 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 375 2 0 3 5.6 Cc1cccc2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc12 10.1016/j.bmcl.2005.12.042
53245435 75536 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 378 5 2 2 4.6 CCCC(=O)Nc1cccc(NC(=O)c2ccc(F)cc2Br)c1 10.1021/ml2002696
CHEMBL2049113 75536 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 378 5 2 2 4.6 CCCC(=O)Nc1cccc(NC(=O)c2ccc(F)cc2Br)c1 10.1021/ml2002696
72547554 103401 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 414 5 1 3 4.6 CS(=O)(=O)NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091989 103401 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 414 5 1 3 4.6 CS(=O)(=O)NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
56671606 62861 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 834 22 8 9 2.9 CC[C@@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cs1 10.1016/s0960-894x(98)00292-3
CHEMBL1790240 62861 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 834 22 8 9 2.9 CC[C@@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cs1 10.1016/s0960-894x(98)00292-3
90663313 106164 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 982 27 12 10 -0.3 C#CC(=O)c1cccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)c1 10.1021/jm960455s
CHEMBL3143273 106164 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 982 27 12 10 -0.3 C#CC(=O)c1cccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)c1 10.1021/jm960455s
127053969 152024 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 477 5 1 5 5.4 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NC2CCC2)CC1(F)F nan
CHEMBL3971706 152024 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 477 5 1 5 5.4 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NC2CCC2)CC1(F)F nan
117826532 149751 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 515 7 2 6 4.4 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCC(O)CCl)CC1(F)F nan
CHEMBL3952681 149751 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 515 7 2 6 4.4 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCC(O)CCl)CC1(F)F nan
127053968 150168 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 439 4 2 6 4.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NO)CC1(F)F nan
CHEMBL3956004 150168 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 439 4 2 6 4.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NO)CC1(F)F nan
127053977 153061 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 515 6 1 7 4.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCc2cnccn2)CC1(F)F nan
CHEMBL3980605 153061 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 515 6 1 7 4.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCc2cnccn2)CC1(F)F nan
127053944 151733 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 483 4 1 5 5.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3OC(F)(F)F)cn2)C2[C@@H](C)OC(=O)[C@]2(O)CC1(F)F nan
CHEMBL3969151 151733 0 None - 0 Human 8.4 pIC50 = 8.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 483 4 1 5 5.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3OC(F)(F)F)cn2)C2[C@@H](C)OC(=O)[C@]2(O)CC1(F)F nan
57404484 72914 0 None - 0 Human 8.3 pIC50 = 8.3 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 397 4 1 5 4.8 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccsc2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012509 72914 0 None - 0 Human 8.3 pIC50 = 8.3 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 397 4 1 5 4.8 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccsc2)cn1 10.1016/j.bmcl.2012.01.138
127053941 151293 0 None - 0 Human 8.3 pIC50 = 8.3 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 467 4 0 4 6.1 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3OC(F)(F)F)cn2)C2C(CC1(F)F)C(=O)O[C@@H]2C nan
CHEMBL3965348 151293 0 None - 0 Human 8.3 pIC50 = 8.3 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 467 4 0 4 6.1 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3OC(F)(F)F)cn2)C2C(CC1(F)F)C(=O)O[C@@H]2C nan
127053970 159585 0 None - 0 Human 8.3 pIC50 = 8.3 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 514 6 1 6 5.4 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NCc2cccnc2)CC1(F)F nan
CHEMBL4108966 159585 0 None - 0 Human 8.3 pIC50 = 8.3 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 514 6 1 6 5.4 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NCc2cccnc2)CC1(F)F nan
127053989 150710 0 None - 0 Human 8.3 pIC50 = 8.3 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 486 3 0 4 5.6 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(Br)CC1(F)F nan
CHEMBL3960140 150710 0 None - 0 Human 8.3 pIC50 = 8.3 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 486 3 0 4 5.6 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(Br)CC1(F)F nan
127050971 140297 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 416 7 2 5 1.8 CCN(C(=O)CO)C1CN(/C(=N\C#N)NCCC2CC2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
CHEMBL3819204 140297 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 416 7 2 5 1.8 CCN(C(=O)CO)C1CN(/C(=N\C#N)NCCC2CC2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
90663292 106155 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 857 22 9 9 1.4 COc1ccc(/C=C/C(=O)N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)cc1 10.1021/jm960455s
CHEMBL3143251 106155 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 857 22 9 9 1.4 COc1ccc(/C=C/C(=O)N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)cc1 10.1021/jm960455s
71735886 143557 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 479 4 2 6 3.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(C2(O)CNC2)CC1(F)F nan
CHEMBL3903446 143557 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 479 4 2 6 3.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(C2(O)CNC2)CC1(F)F nan
44403839 71065 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 339 3 0 3 4.7 CCc1cccc(/C=C/[C@@H]2[C@H]3CCCC[C@@H]3C[C@@H]3C(=O)O[C@@H](C)[C@@H]32)n1 10.1021/jm0502236
CHEMBL195909 71065 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 339 3 0 3 4.7 CCc1cccc(/C=C/[C@@H]2[C@H]3CCCC[C@@H]3C[C@@H]3C(=O)O[C@@H](C)[C@@H]32)n1 10.1021/jm0502236
11645276 71422 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 311 2 0 3 4.1 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccccn3)[C@H]12 10.1021/jm0502236
CHEMBL196683 71422 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 311 2 0 3 4.1 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccccn3)[C@H]12 10.1021/jm0502236
44280649 112160 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 743 19 8 9 1.3 COc1ccc(/C=C/C(=O)Nc2n[nH]c(C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc3ccccc3)C(N)=O)n2)cc1 10.1016/s0960-894x(99)00197-3
CHEMBL33033 112160 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 743 19 8 9 1.3 COc1ccc(/C=C/C(=O)Nc2n[nH]c(C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc3ccccc3)C(N)=O)n2)cc1 10.1016/s0960-894x(99)00197-3
44281172 99213 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 589 15 9 9 -0.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1cccs1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL284474 99213 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 589 15 9 9 -0.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1cccs1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280955 118787 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 611 15 8 6 0.9 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccc2[nH]cnc2c1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL34387 118787 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 611 15 8 6 0.9 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccc2[nH]cnc2c1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
10459564 514 34 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC nan
4048 514 34 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC nan
CHEMBL2103856 514 34 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC nan
DB12046 514 34 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 527 9 1 7 4.8 CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC nan
90663298 106159 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 861 21 9 8 2.1 CC(=O)N(C(=O)/C=C/c1cccc(Cl)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143257 106159 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 861 21 9 8 2.1 CC(=O)N(C(=O)/C=C/c1cccc(Cl)c1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
16100342 82836 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3[C@@H](O)CCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
CHEMBL218726 82836 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3[C@@H](O)CCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
72547552 103406 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 379 3 0 3 5.5 Fc1cccc(-c2ccc(/C=C/[C@@H]3[C@H]4CCCC[C@H]4CC34OCCO4)nc2)c1 10.1021/ml400235c
CHEMBL3091994 103406 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 379 3 0 3 5.5 Fc1cccc(-c2ccc(/C=C/[C@@H]3[C@H]4CCCC[C@H]4CC34OCCO4)nc2)c1 10.1021/ml400235c
72547552 103406 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 379 3 0 3 5.5 Fc1cccc(-c2ccc(/C=C/[C@@H]3[C@H]4CCCC[C@H]4CC34OCCO4)nc2)c1 10.1021/ml400235c
CHEMBL3091994 103406 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 379 3 0 3 5.5 Fc1cccc(-c2ccc(/C=C/[C@@H]3[C@H]4CCCC[C@H]4CC34OCCO4)nc2)c1 10.1021/ml400235c
44290166 169187 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 808 21 9 10 1.4 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(N)=O)cs1 10.1016/s0960-894x(98)00292-3
CHEMBL44387 169187 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 808 21 9 10 1.4 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(N)=O)cs1 10.1016/s0960-894x(98)00292-3
58046052 132777 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 457 9 1 8 3.9 CCOc1nn2c(=N)n(CC(=O)c3cc(OCCCF)cc(C(C)(C)C)c3)nc2c(C)c1C nan
CHEMBL3704477 132777 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 457 9 1 8 3.9 CCOc1nn2c(=N)n(CC(=O)c3cc(OCCCF)cc(C(C)(C)C)c3)nc2c(C)c1C nan
90663563 106218 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 829 22 9 8 2.0 CCC(=O)c1cccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)c1 10.1021/jm960455s
CHEMBL3143684 106218 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 829 22 9 8 2.0 CCC(=O)c1cccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)c1 10.1021/jm960455s
CHEMBL3143288 209416 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@H](Cc1cccs1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44280585 116478 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 727 18 8 8 1.7 C/C(=C\c1ccccc1)C(=O)Nc1n[nH]c(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)n1 10.1016/s0960-894x(99)00197-3
CHEMBL33873 116478 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 727 18 8 8 1.7 C/C(=C\c1ccccc1)C(=O)Nc1n[nH]c(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)n1 10.1016/s0960-894x(99)00197-3
44416466 140984 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 441 3 0 2 7.3 C[C@H]1OC[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@@H]21 10.1016/j.bmcl.2006.06.042
CHEMBL384562 140984 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 441 3 0 2 7.3 C[C@H]1OC[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@@H]21 10.1016/j.bmcl.2006.06.042
CHEMBL3143266 209404 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccc(C)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
72547555 103394 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 365 4 0 2 6.1 COC1(C)C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091982 103394 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 365 4 0 2 6.1 COC1(C)C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
44432693 145168 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 385 3 0 3 5.7 C[C@H]1OC(=O)[C@@H]2C=C3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL391624 145168 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 385 3 0 3 5.7 C[C@H]1OC(=O)[C@@H]2C=C3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
44309776 102655 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 754 16 6 7 5.3 NCCCNC(=O)[C@H](CCN)NC(=O)[C@H](Cc1ccc(Cl)cc1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1 10.1016/s0960-894x(03)00325-1
CHEMBL307831 102655 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 754 16 6 7 5.3 NCCCNC(=O)[C@H](CCN)NC(=O)[C@H](Cc1ccc(Cl)cc1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1 10.1016/s0960-894x(03)00325-1
90663337 106178 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 869 20 9 10 1.1 CC(=O)N(C(=O)c1cc2ccccc2oc1=O)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143301 106178 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 869 20 9 10 1.1 CC(=O)N(C(=O)c1cc2ccccc2oc1=O)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
90663294 106157 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 827 22 8 9 2.1 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN)C(=O)CC(N)=O 10.1021/jm960455s
CHEMBL3143253 106157 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 827 22 8 9 2.1 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN)C(=O)CC(N)=O 10.1021/jm960455s
9804049 133040 2 None - 1 Human 7.4 pIC50 = 7.4 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm0502236
CHEMBL371069 133040 2 None - 1 Human 7.4 pIC50 = 7.4 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm0502236
11691128 140818 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 459 5 0 5 5.9 CCOC(=O)c1ccccc1-c1ccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)nc1 10.1021/jm0502236
CHEMBL383606 140818 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 459 5 0 5 5.9 CCOC(=O)c1ccccc1-c1ccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)nc1 10.1021/jm0502236
3525 3367 8 None - 0 Human 6.4 pIC50 = 6.4 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 789 15 5 6 6.8 NCC[C@@H](C(=O)NCc1ccccc1)NC(=O)[C@H](Cc1ccc(c(c1)F)F)NC(=O)Nc1ccc2c(c1)n(Cc1c(Cl)cccc1Cl)cc2CN1CCCC1 10.1016/s0960-894x(03)00325-1
9853822 3367 8 None - 0 Human 6.4 pIC50 = 6.4 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 789 15 5 6 6.8 NCC[C@@H](C(=O)NCc1ccccc1)NC(=O)[C@H](Cc1ccc(c(c1)F)F)NC(=O)Nc1ccc2c(c1)n(Cc1c(Cl)cccc1Cl)cc2CN1CCCC1 10.1016/s0960-894x(03)00325-1
CHEMBL311626 3367 8 None - 0 Human 6.4 pIC50 = 6.4 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 789 15 5 6 6.8 NCC[C@@H](C(=O)NCc1ccccc1)NC(=O)[C@H](Cc1ccc(c(c1)F)F)NC(=O)Nc1ccc2c(c1)n(Cc1c(Cl)cccc1Cl)cc2CN1CCCC1 10.1016/s0960-894x(03)00325-1
44432756 86316 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 396 3 0 5 3.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(N4CCOCC4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL231971 86316 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 396 3 0 5 3.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(N4CCOCC4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
44306761 168343 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 789 15 5 6 6.8 NCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL438551 168343 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 789 15 5 6 6.8 NCCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
9810477 98321 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 719 18 9 9 1.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccs2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL278216 98321 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 719 18 9 9 1.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccs2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280899 114287 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 578 15 7 6 1.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccccn1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33394 114287 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 578 15 7 6 1.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccccn1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
11284457 153988 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 565 10 1 8 4.6 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCN(CC#N)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3939315 153988 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 565 10 1 8 4.6 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCN(CC#N)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3990814 153988 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting methodDisplacement of [3H] Ala-(4fluoro)Phe-Arg-(cy- clohexyl)Ala-(homo)Arg-Tyr-NH2 from thrombin receptor in human platelet membranes after 1 hr by liquid scintillation counting method
ChEMBL 565 10 1 8 4.6 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCN(CC#N)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
70693686 72901 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 389 4 0 3 5.9 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(C)c2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012495 72901 0 None - 0 Human 7.4 pIC50 = 7.4 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 389 4 0 3 5.9 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccc(C)c2)cn1 10.1016/j.bmcl.2012.01.138
44305939 201700 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 317 3 2 5 3.4 CCc1ccc(Cn2ccc3c4c(N)nc(N)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
CHEMBL65425 201700 0 None - 0 Human 5.4 pIC50 = 5.4 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 317 3 2 5 3.4 CCc1ccc(Cn2ccc3c4c(N)nc(N)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
70695800 72912 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 421 5 1 5 4.7 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccc(OC)cc2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012507 72912 0 None - 0 Human 6.4 pIC50 = 6.4 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 421 5 1 5 4.7 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccc(OC)cc2)cn1 10.1016/j.bmcl.2012.01.138
90663291 106154 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 877 21 9 8 2.7 CC(=O)N(C(=O)c1ccc(-c2ccccc2)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143250 106154 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 877 21 9 8 2.7 CC(=O)N(C(=O)c1ccc(-c2ccccc2)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
11503433 135024 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4C(F)(F)F)cn3)[C@H]12 10.1021/jm0502236
CHEMBL372886 135024 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4C(F)(F)F)cn3)[C@H]12 10.1021/jm0502236
44432772 86516 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 437 3 0 3 5.8 O=C1OC[C@H]2[C@@H]1Cc1c(F)cc(F)cc1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL232333 86516 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 437 3 0 3 5.8 O=C1OC[C@H]2[C@@H]1Cc1c(F)cc(F)cc1[C@@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1016/j.bmcl.2007.04.061
44280878 99600 0 None - 0 Human 4.3 pIC50 = 4.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 501 13 8 8 -2.7 C[C@H](NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL287156 99600 0 None - 0 Human 4.3 pIC50 = 4.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 501 13 8 8 -2.7 C[C@H](NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
11682882 72186 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 405 3 0 3 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccc(F)cc4)cn3)[C@H]12 10.1021/jm0502236
CHEMBL199101 72186 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 405 3 0 3 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4ccc(F)cc4)cn3)[C@H]12 10.1021/jm0502236
44432715 86268 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 394 3 0 5 5.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4nccs4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL231728 86268 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 394 3 0 5 5.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4nccs4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL3143260 209401 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44338791 9236 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 559 8 0 6 5.9 Ic1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL111106 9236 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 559 8 0 6 5.9 Ic1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
76335370 103383 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 379 3 0 3 5.5 Fc1cccc(-c2ccc(/C=C/[C@@H]3[C@H]4CCCC[C@@H]4CC34OCCO4)nc2)c1 10.1021/ml400235c
CHEMBL3091971 103383 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 379 3 0 3 5.5 Fc1cccc(-c2ccc(/C=C/[C@@H]3[C@H]4CCCC[C@@H]4CC34OCCO4)nc2)c1 10.1021/ml400235c
CHEMBL3143318 209430 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(Cl)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44309730 202258 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 819 16 5 7 6.8 COc1ccc(CNC(=O)[C@H](CCN)NC(=O)[C@H](Cc2ccc(F)c(F)c2)NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)cc1 10.1016/s0960-894x(03)00325-1
CHEMBL69359 202258 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 819 16 5 7 6.8 COc1ccc(CNC(=O)[C@H](CCN)NC(=O)[C@H](Cc2ccc(F)c(F)c2)NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)cc1 10.1016/s0960-894x(03)00325-1
53245434 75535 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 374 5 2 2 4.7 CCCC(=O)Nc1cccc(NC(=O)c2cc(C)ccc2Br)c1 10.1021/ml2002696
CHEMBL2049112 75535 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 374 5 2 2 4.7 CCCC(=O)Nc1cccc(NC(=O)c2cc(C)ccc2Br)c1 10.1021/ml2002696
16100353 82639 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CC[C@@H](O)C[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
CHEMBL218168 82639 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CC[C@@H](O)C[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
68058674 126750 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 420 6 1 3 4.2 CCc1ccc(C2CC(C(=O)Nc3ccccc3)CN(C(=O)C3(CC)COC3)C2)cc1 nan
CHEMBL3658403 126750 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 420 6 1 3 4.2 CCc1ccc(C2CC(C(=O)Nc3ccccc3)CN(C(=O)C3(CC)COC3)C2)cc1 nan
58046031 132781 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 485 10 2 10 3.1 CC(C)Oc1cc(OC(C)C)c2nn(CC(=O)c3cc(OCCO)cc(C(C)(C)C)c3)c(=N)n2n1 nan
CHEMBL3704481 132781 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 485 10 2 10 3.1 CC(C)Oc1cc(OC(C)C)c2nn(CC(=O)c3cc(OCCO)cc(C(C)(C)C)c3)c(=N)n2n1 nan
70685282 72913 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 392 4 1 5 4.1 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccnc2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012508 72913 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 392 4 1 5 4.1 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cccnc2)cn1 10.1016/j.bmcl.2012.01.138
44305953 101629 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 375 6 3 6 3.7 CC(C)c1ccc(Cn2ccc3c4c(N)nc(NCCO)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
CHEMBL302226 101629 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 375 6 3 6 3.7 CC(C)c1ccc(Cn2ccc3c4c(N)nc(NCCO)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
127053939 153667 0 None - 1 Human 8.3 pIC50 = 8.3 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 401 3 0 3 5.4 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)C2C(CC1(F)F)C(=O)O[C@@H]2C nan
CHEMBL3985900 153667 0 None - 1 Human 8.3 pIC50 = 8.3 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 401 3 0 3 5.4 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)C2C(CC1(F)F)C(=O)O[C@@H]2C nan
127053949 142227 0 None - 0 Human 8.3 pIC50 = 8.3 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 447 4 0 5 5.4 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(CC#N)CC1(F)F nan
CHEMBL3892564 142227 0 None - 0 Human 8.3 pIC50 = 8.3 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 447 4 0 5 5.4 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(CC#N)CC1(F)F nan
127053998 159329 0 None - 0 Human 8.3 pIC50 = 8.3 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 451 4 0 5 4.8 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(N(C)C)CC1(F)F nan
CHEMBL4106780 159329 0 None - 0 Human 8.3 pIC50 = 8.3 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 451 4 0 5 4.8 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(N(C)C)CC1(F)F nan
72547308 103403 0 None - 0 Human 8.3 pIC50 = 8.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 392 4 0 2 5.6 CC(=O)N(C)C1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091991 103403 0 None - 0 Human 8.3 pIC50 = 8.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 392 4 0 2 5.6 CC(=O)N(C)C1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
127053979 151727 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 515 6 1 7 4.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCc2cncnc2)CC1(F)F nan
CHEMBL3969105 151727 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 515 6 1 7 4.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NCc2cncnc2)CC1(F)F nan
127053996 152004 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 423 3 2 4 3.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)NC(=O)[C@]2(O)CC1(F)F nan
CHEMBL3971586 152004 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 423 3 2 4 3.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)NC(=O)[C@]2(O)CC1(F)F nan
127050658 140239 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 458 7 2 5 2.3 CCN(C(=O)CO)C1CN(/C(=N\C#N)NCCCC(F)(F)F)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
CHEMBL3818421 140239 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 458 7 2 5 2.3 CCN(C(=O)CO)C1CN(/C(=N\C#N)NCCCC(F)(F)F)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
11684648 140303 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 492 5 2 5 3.8 CCN(C(=O)CO)C1CN(/C(=N\C#N)Nc2ccc(Cl)c(Cl)c2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
CHEMBL3819237 140303 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 492 5 2 5 3.8 CCN(C(=O)CO)C1CN(/C(=N\C#N)Nc2ccc(Cl)c(Cl)c2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
44409074 75078 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 443 3 0 4 7.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(-c5ccsc5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL204157 75078 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 443 3 0 4 7.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(-c5ccsc5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
44409248 76795 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 421 4 0 5 5.3 COc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1OC 10.1016/j.bmcl.2005.12.042
CHEMBL207791 76795 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 421 4 0 5 5.3 COc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1OC 10.1016/j.bmcl.2005.12.042
72547554 103401 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 414 5 1 3 4.6 CS(=O)(=O)NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091989 103401 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 414 5 1 3 4.6 CS(=O)(=O)NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
44309472 202552 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 804 16 5 7 6.2 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCCc1ccccn1 10.1016/s0960-894x(03)00325-1
CHEMBL71140 202552 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 804 16 5 7 6.2 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCCc1ccccn1 10.1016/s0960-894x(03)00325-1
90663299 106160 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 812 20 10 7 1.9 CC(=O)N(c1c[nH]c2ccccc12)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143258 106160 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 812 20 10 7 1.9 CC(=O)N(c1c[nH]c2ccccc12)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44409029 76137 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 504 5 0 6 4.5 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OCC(=O)N5CCOCC5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL205987 76137 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 504 5 0 6 4.5 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OCC(=O)N5CCOCC5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
44409062 168425 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 538 6 1 5 7.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OC(C)(C)C(=O)Nc5ccccc5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL439157 168425 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 538 6 1 5 7.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OC(C)(C)C(=O)Nc5ccccc5)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
44306599 201958 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 803 16 5 6 7.1 NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL67308 201958 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 803 16 5 6 7.1 NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
44416724 80140 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 379 3 1 3 4.7 C[C@H]1O[C@H](Cc2ccc3ccccc3n2)C2[C@H]1[C@H](C(=O)O)C[C@@H]1CCCC[C@@H]21 10.1016/j.bmcl.2006.06.042
CHEMBL214862 80140 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 379 3 1 3 4.7 C[C@H]1O[C@H](Cc2ccc3ccccc3n2)C2[C@H]1[C@H](C(=O)O)C[C@@H]1CCCC[C@@H]21 10.1016/j.bmcl.2006.06.042
9831828 165847 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 733 19 7 8 2.7 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)c(C)o1 10.1016/s0960-894x(98)00292-3
CHEMBL42769 165847 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 733 19 7 8 2.7 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)c(C)o1 10.1016/s0960-894x(98)00292-3
44290181 172723 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 806 22 8 9 2.1 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCCN=C(N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cs1 10.1016/s0960-894x(98)00292-3
CHEMBL45259 172723 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 806 22 8 9 2.1 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCCN=C(N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cs1 10.1016/s0960-894x(98)00292-3
44281263 99380 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 603 16 7 5 2.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)/C=C/c1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL285685 99380 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 603 16 7 5 2.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)/C=C/c1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
70687425 72904 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 443 4 0 3 6.9 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cc(Cl)ccc2Cl)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012498 72904 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 443 4 0 3 6.9 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2cc(Cl)ccc2Cl)cn1 10.1016/j.bmcl.2012.01.138
10000177 201704 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Antagonist activity at PAR1 in human platelet membranes assessed as inhibition of interaction of PAR1 with [Ala-Phe(p-F)-Arg-Cha-HArg-Tyr-NH2] by Chronolog aggregometryAntagonist activity at PAR1 in human platelet membranes assessed as inhibition of interaction of PAR1 with [Ala-Phe(p-F)-Arg-Cha-HArg-Tyr-NH2] by Chronolog aggregometry
ChEMBL 385 5 1 5 4.9 CC(C)c1ccc(Cn2ccc3c4c(N)nc(N(C)C5CC5)nc4ccc32)cc1 10.1039/c4md00485j
CHEMBL65476 201704 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Antagonist activity at PAR1 in human platelet membranes assessed as inhibition of interaction of PAR1 with [Ala-Phe(p-F)-Arg-Cha-HArg-Tyr-NH2] by Chronolog aggregometryAntagonist activity at PAR1 in human platelet membranes assessed as inhibition of interaction of PAR1 with [Ala-Phe(p-F)-Arg-Cha-HArg-Tyr-NH2] by Chronolog aggregometry
ChEMBL 385 5 1 5 4.9 CC(C)c1ccc(Cn2ccc3c4c(N)nc(N(C)C5CC5)nc4ccc32)cc1 10.1039/c4md00485j
10000177 201704 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 385 5 1 5 4.9 CC(C)c1ccc(Cn2ccc3c4c(N)nc(N(C)C5CC5)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
CHEMBL65476 201704 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 385 5 1 5 4.9 CC(C)c1ccc(Cn2ccc3c4c(N)nc(N(C)C5CC5)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
44338929 5768 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 493 10 0 8 5.4 COc1cc(OC)cc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL107919 5768 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 493 10 0 8 5.4 COc1cc(OC)cc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
49766539 59274 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 386 4 2 2 4.8 O=C(Nc1cccc(NC(=O)C2CCCC2)c1)c1ccccc1Br 10.1021/ml2002696
CHEMBL1718628 59274 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 386 4 2 2 4.8 O=C(Nc1cccc(NC(=O)C2CCCC2)c1)c1ccccc1Br 10.1021/ml2002696
50910534 75445 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 310 6 2 2 4.2 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2CC)c1 10.1021/ml2002696
CHEMBL2048423 75445 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 310 6 2 2 4.2 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2CC)c1 10.1021/ml2002696
44305897 102365 2 None - 0 Human 6.3 pIC50 = 6.3 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 359 5 2 5 4.8 CCNc1nc(N)c2c(ccc3c2ccn3Cc2ccc(C(C)C)cc2)n1 10.1016/s0960-894x(99)00339-x
CHEMBL305557 102365 2 None - 0 Human 6.3 pIC50 = 6.3 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 359 5 2 5 4.8 CCNc1nc(N)c2c(ccc3c2ccn3Cc2ccc(C(C)C)cc2)n1 10.1016/s0960-894x(99)00339-x
16100351 82379 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 491 3 0 3 7.0 C[C@H]1OC(=O)[C@@H]2C[C@H]3[C@@H](CCCC3(F)F)[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
CHEMBL218000 82379 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 491 3 0 3 7.0 C[C@H]1OC(=O)[C@@H]2C[C@H]3[C@@H](CCCC3(F)F)[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
76328106 103391 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 378 4 1 2 5.2 CC(=O)NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091979 103391 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 378 4 1 2 5.2 CC(=O)NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
66761604 127010 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 474 3 2 3 2.8 O=C1CN(C(=O)N2CC(NC(=O)c3ccccc3)CC(c3ccc(C(F)(F)F)cc3)C2)CCN1 nan
CHEMBL3662511 127010 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 474 3 2 3 2.8 O=C1CN(C(=O)N2CC(NC(=O)c3ccccc3)CC(c3ccc(C(F)(F)F)cc3)C2)CCN1 nan
44306501 102218 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 834 17 7 7 6.3 N#Cc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL304683 102218 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 834 17 7 7 6.3 N#Cc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
44290276 164347 0 None - 0 Human 4.3 pIC50 = 4.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 748 19 8 9 1.7 Cc1oc([C@H](Cc2ccc(F)cc2)NC(=O)C(N)CN)nc1C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc1ccccc1 10.1016/s0960-894x(98)00292-3
CHEMBL42224 164347 0 None - 0 Human 4.3 pIC50 = 4.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 748 19 8 9 1.7 Cc1oc([C@H](Cc2ccc(F)cc2)NC(=O)C(N)CN)nc1C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc1ccccc1 10.1016/s0960-894x(98)00292-3
44290058 178419 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 705 18 7 8 2.1 NCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)co1 10.1016/s0960-894x(98)00292-3
CHEMBL47090 178419 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 705 18 7 8 2.1 NCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)co1 10.1016/s0960-894x(98)00292-3
9937578 99495 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 555 15 7 8 0.3 NCCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL286430 99495 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 555 15 7 8 0.3 NCCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
23631278 92522 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 498 3 0 4 5.5 CC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(C(F)(F)F)c3)cn2)C1 10.1021/jm070704k
CHEMBL244108 92522 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 498 3 0 4 5.5 CC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(C(F)(F)F)c3)cn2)C1 10.1021/jm070704k
11639231 71992 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 367 4 0 3 5.3 CC(C)Cc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
CHEMBL198451 71992 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 367 4 0 3 5.3 CC(C)Cc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
CHEMBL33473 209654 18 None - 0 Human 6.3 pIC50 = 6.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O 10.1016/s0960-894x(99)00197-3
44281237 116229 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 604 16 7 6 1.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)/C=C/c1cccnc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33742 116229 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 604 16 7 6 1.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)/C=C/c1cccnc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL4764659 212285 0 None - 0 Human 7.3 pIC50 = 7.3 Binding
Affinity Biochemical interaction (Binding assay (platelet membranes)) EUB0000291b F2RAffinity Biochemical interaction (Binding assay (platelet membranes)) EUB0000291b F2R
ChEMBL None None None O=C(N1CCS(=O)(=O)CC1)N1C[C@@](S)(c2ccc(OC(F)(F)F)cc2)C[C@@](S)(c2nc(C3CC3)no2)C1 nan
10971 3502 24 None - 0 Human 7.3 pIC50 = 7.3 Binding
Antagonist activity at PAR1 in human platelet membranes assessed as inhibition of interaction of PAR1 with [Ala-Phe(p-F)-Arg-Cha-HArg-Tyr-NH2] by Chronolog aggregometryAntagonist activity at PAR1 in human platelet membranes assessed as inhibition of interaction of PAR1 with [Ala-Phe(p-F)-Arg-Cha-HArg-Tyr-NH2] by Chronolog aggregometry
ChEMBL 371 5 2 5 4.9 CC(c1ccc(cc1)Cn1ccc2c1ccc1c2c(N)nc(n1)NC1CC1)C 10.1039/c4md00485j
4259181 3502 24 None - 0 Human 7.3 pIC50 = 7.3 Binding
Antagonist activity at PAR1 in human platelet membranes assessed as inhibition of interaction of PAR1 with [Ala-Phe(p-F)-Arg-Cha-HArg-Tyr-NH2] by Chronolog aggregometryAntagonist activity at PAR1 in human platelet membranes assessed as inhibition of interaction of PAR1 with [Ala-Phe(p-F)-Arg-Cha-HArg-Tyr-NH2] by Chronolog aggregometry
ChEMBL 371 5 2 5 4.9 CC(c1ccc(cc1)Cn1ccc2c1ccc1c2c(N)nc(n1)NC1CC1)C 10.1039/c4md00485j
CHEMBL63426 3502 24 None - 0 Human 7.3 pIC50 = 7.3 Binding
Antagonist activity at PAR1 in human platelet membranes assessed as inhibition of interaction of PAR1 with [Ala-Phe(p-F)-Arg-Cha-HArg-Tyr-NH2] by Chronolog aggregometryAntagonist activity at PAR1 in human platelet membranes assessed as inhibition of interaction of PAR1 with [Ala-Phe(p-F)-Arg-Cha-HArg-Tyr-NH2] by Chronolog aggregometry
ChEMBL 371 5 2 5 4.9 CC(c1ccc(cc1)Cn1ccc2c1ccc1c2c(N)nc(n1)NC1CC1)C 10.1039/c4md00485j
10971 3502 24 None - 0 Human 7.3 pIC50 = 7.3 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 371 5 2 5 4.9 CC(c1ccc(cc1)Cn1ccc2c1ccc1c2c(N)nc(n1)NC1CC1)C 10.1016/s0960-894x(99)00339-x
4259181 3502 24 None - 0 Human 7.3 pIC50 = 7.3 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 371 5 2 5 4.9 CC(c1ccc(cc1)Cn1ccc2c1ccc1c2c(N)nc(n1)NC1CC1)C 10.1016/s0960-894x(99)00339-x
CHEMBL63426 3502 24 None - 0 Human 7.3 pIC50 = 7.3 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 371 5 2 5 4.9 CC(c1ccc(cc1)Cn1ccc2c1ccc1c2c(N)nc(n1)NC1CC1)C 10.1016/s0960-894x(99)00339-x
90663354 106186 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 791 20 9 7 1.5 CC(=O)N(c1ccccc1F)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143319 106186 0 None - 0 Human 6.3 pIC50 = 6.3 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 791 20 9 7 1.5 CC(=O)N(c1ccccc1F)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306612 101690 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 875 19 6 8 6.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccc(OC(F)(F)F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL302603 101690 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 875 19 6 8 6.6 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccc(OC(F)(F)F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2CCCCC2)cc1 10.1016/s0960-894x(01)00378-x
9831948 178350 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 749 20 7 8 2.9 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCc2ccccc2)cs1 10.1016/s0960-894x(98)00292-3
CHEMBL47023 178350 0 None - 0 Human 5.3 pIC50 = 5.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 749 20 7 8 2.9 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCc2ccccc2)cs1 10.1016/s0960-894x(98)00292-3
44281264 114770 0 None - 0 Human 4.3 pIC50 = 4.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 616 15 8 5 2.2 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc2ccccc2[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33487 114770 0 None - 0 Human 4.3 pIC50 = 4.3 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 616 15 8 5 2.2 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc2ccccc2[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
11284457 153988 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 565 10 1 8 4.6 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCN(CC#N)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3939315 153988 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 565 10 1 8 4.6 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCN(CC#N)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3990814 153988 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 565 10 1 8 4.6 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCN(CC#N)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
44290231 99810 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 792 21 8 9 1.7 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cs1 10.1016/s0960-894x(98)00292-3
CHEMBL288976 99810 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 792 21 8 9 1.7 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cs1 10.1016/s0960-894x(98)00292-3
44432833 86257 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 385 3 0 4 4.8 COc1ccc2nc(/C=C/[C@@H]3c4ccccc4C[C@H]4C(=O)O[C@H](C)[C@@H]34)ccc2c1 10.1016/j.bmcl.2007.04.061
CHEMBL231695 86257 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 385 3 0 4 4.8 COc1ccc2nc(/C=C/[C@@H]3c4ccccc4C[C@H]4C(=O)O[C@H](C)[C@@H]34)ccc2c1 10.1016/j.bmcl.2007.04.061
72547553 103387 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 415 5 0 4 5.1 CS(=O)(=O)OC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091975 103387 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 415 5 0 4 5.1 CS(=O)(=O)OC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
121335735 152025 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 521 5 1 5 5.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)CC(C)(C)C)CC1(F)F nan
CHEMBL3971708 152025 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 521 5 1 5 5.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(NC(=O)CC(C)(C)C)CC1(F)F nan
9951647 140046 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 377 2 1 4 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(O)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL381265 140046 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 377 2 1 4 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(O)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
127053984 160221 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 522 5 2 5 4.9 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@@]2(NC(=S)NC2CC2)CC1(F)F nan
CHEMBL4114149 160221 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 522 5 2 5 4.9 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@@]2(NC(=S)NC2CC2)CC1(F)F nan
72547553 103387 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 415 5 0 4 5.1 CS(=O)(=O)OC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091975 103387 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 415 5 0 4 5.1 CS(=O)(=O)OC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
57404504 72906 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 391 4 1 4 4.7 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccccc2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012500 72906 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 391 4 1 4 4.7 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccccc2)cn1 10.1016/j.bmcl.2012.01.138
127053964 148909 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 476 4 0 8 3.9 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(n2cnnn2)CC1(F)F nan
CHEMBL3945945 148909 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 476 4 0 8 3.9 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(n2cnnn2)CC1(F)F nan
127053967 159651 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 490 4 0 8 4.2 Cc1nnnn1[C@@]12CC(F)(F)C(C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)C1[C@@H](C)OC2=O nan
CHEMBL4109515 159651 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 490 4 0 8 4.2 Cc1nnnn1[C@@]12CC(F)(F)C(C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)C1[C@@H](C)OC2=O nan
127053973 159610 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 504 6 1 7 5.0 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NCc2ncco2)CC1(F)F nan
CHEMBL4109166 159610 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 504 6 1 7 5.0 CC1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NCc2ncco2)CC1(F)F nan
CHEMBL3143275 209410 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN)C(N)=O 10.1021/jm960455s
44310308 167324 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 759 15 5 7 5.5 CSC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCCN 10.1016/s0960-894x(03)00325-1
CHEMBL431164 167324 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 759 15 5 7 5.5 CSC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCCN 10.1016/s0960-894x(03)00325-1
127051545 140202 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 476 5 2 5 3.3 CCN(C(=O)CO)C1CN(/C(=N\C#N)Nc2ccc(F)c(Cl)c2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
CHEMBL3817930 140202 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 476 5 2 5 3.3 CCN(C(=O)CO)C1CN(/C(=N\C#N)Nc2ccc(F)c(Cl)c2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
127050656 140310 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 490 7 2 6 3.1 CCN(C(=O)CO)C1CN(/C(=N\C#N)Nc2ccc(OC(F)F)cc2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
CHEMBL3819343 140310 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 490 7 2 6 3.1 CCN(C(=O)CO)C1CN(/C(=N\C#N)Nc2ccc(OC(F)F)cc2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
44408851 75057 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 361 2 0 3 5.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@H]12 10.1016/j.bmcl.2006.06.042
CHEMBL204009 75057 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 361 2 0 3 5.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@H]12 10.1016/j.bmcl.2006.06.042
44408851 75057 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 361 2 0 3 5.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL204009 75057 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 361 2 0 3 5.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
10161572 5476 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 458 8 0 7 5.2 N#Cc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL107667 5476 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 458 8 0 7 5.2 N#Cc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
23631809 92761 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 456 3 1 4 5.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CNCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
CHEMBL244487 92761 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 456 3 1 4 5.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CNCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
23631900 142381 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 474 4 0 5 5.5 CCOC(=O)N1CCC[C@H]2[C@H](/C=C/c3ccc(-c4ccccc4C)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]21 10.1021/jm070704k
CHEMBL389382 142381 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 474 4 0 5 5.5 CCOC(=O)N1CCC[C@H]2[C@H](/C=C/c3ccc(-c4ccccc4C)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]21 10.1021/jm070704k
53245432 75537 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 378 5 2 2 4.6 CCCC(=O)Nc1cccc(NC(=O)c2cc(F)ccc2Br)c1 10.1021/ml2002696
CHEMBL2049114 75537 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 378 5 2 2 4.6 CCCC(=O)Nc1cccc(NC(=O)c2cc(F)ccc2Br)c1 10.1021/ml2002696
44281289 118057 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 599 15 10 9 -0.9 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL34156 118057 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 599 15 10 9 -0.9 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44290110 100775 0 None - 0 Human 4.2 pIC50 = 4.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 715 19 7 8 2.5 CNCC(=O)N[C@@H](Cc1ccccc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)c(C)o1 10.1016/s0960-894x(98)00292-3
CHEMBL296147 100775 0 None - 0 Human 4.2 pIC50 = 4.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 715 19 7 8 2.5 CNCC(=O)N[C@@H](Cc1ccccc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)c(C)o1 10.1016/s0960-894x(98)00292-3
44187102 124621 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 404 8 1 7 2.7 CCC(CC)Oc1ccc2n(n1)c(N)n[n+]2CC(=O)c1cc(Cl)cc(OC)c1 nan
CHEMBL3644437 124621 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 404 8 1 7 2.7 CCC(CC)Oc1ccc2n(n1)c(N)n[n+]2CC(=O)c1cc(Cl)cc(OC)c1 nan
CHEMBL3143299 209420 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccc(N)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143321 209432 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccc(O)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44416691 80944 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 393 3 1 4 5.1 COc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)O[C@@H](O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2006.06.042
CHEMBL215924 80944 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 393 3 1 4 5.1 COc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)O[C@@H](O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2006.06.042
44408873 76357 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 391 3 0 4 5.3 COc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2005.12.042
CHEMBL206502 76357 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 391 3 0 4 5.3 COc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2005.12.042
44290059 100981 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 615 16 7 8 0.3 NCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)co1 10.1016/s0960-894x(98)00292-3
CHEMBL297640 100981 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 615 16 7 8 0.3 NCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)co1 10.1016/s0960-894x(98)00292-3
44416567 138111 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 377 3 0 3 5.7 COc1ccc2nc(/C=C/[C@@H]3[C@H]4[C@H](CO[C@@H]4C)C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2006.06.042
CHEMBL377594 138111 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 377 3 0 3 5.7 COc1ccc2nc(/C=C/[C@@H]3[C@H]4[C@H](CO[C@@H]4C)C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2006.06.042
66760951 127014 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 476 3 1 3 4.5 N#CC1CCN(C(=O)N2CC(NC(=O)C3CCCC3)CC(c3ccc(C(F)(F)F)cc3)C2)CC1 nan
CHEMBL3662515 127014 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 476 3 1 3 4.5 N#CC1CCN(C(=O)N2CC(NC(=O)C3CCCC3)CC(c3ccc(C(F)(F)F)cc3)C2)CC1 nan
44432795 86314 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 419 3 0 3 5.7 O=C1OC[C@H]2[C@@H]1Cc1c(Cl)cccc1[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL231957 86314 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 419 3 0 3 5.7 O=C1OC[C@H]2[C@@H]1Cc1c(Cl)cccc1[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL3143300 209421 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@H](CCc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44183746 132757 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 469 11 1 9 3.8 CCC(CC)Oc1ccc2nn(CC(=O)c3cc(OCCOC)cc(C(C)(C)C)c3)c(=N)n2n1 nan
CHEMBL3704457 132757 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 469 11 1 9 3.8 CCC(CC)Oc1ccc2nn(CC(=O)c3cc(OCCOC)cc(C(C)(C)C)c3)c(=N)n2n1 nan
70683207 72916 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 384 4 1 5 3.7 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(N2CCCC2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012511 72916 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 384 4 1 5 3.7 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(N2CCCC2)cn1 10.1016/j.bmcl.2012.01.138
44306336 201853 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 780 17 6 7 5.1 Cc1ccccc1Cn1cc(CN2CCCC2)c2ccc(NC(=O)N[C@@H](Cc3ccc(C#N)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc3ccccc3)cc21 10.1016/s0960-894x(01)00378-x
CHEMBL66585 201853 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 780 17 6 7 5.1 Cc1ccccc1Cn1cc(CN2CCCC2)c2ccc(NC(=O)N[C@@H](Cc3ccc(C#N)cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc3ccccc3)cc21 10.1016/s0960-894x(01)00378-x
9875040 113925 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 713 18 9 8 1.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccccc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33318 113925 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 713 18 9 8 1.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2ccccc2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44432763 86367 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 453 3 0 3 6.0 O=C1OC[C@H]2[C@@H]1Cc1c(F)cccc1[C@@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL232171 86367 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 453 3 0 3 6.0 O=C1OC[C@H]2[C@@H]1Cc1c(F)cccc1[C@@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1016/j.bmcl.2007.04.061
2858875 206514 10 None - 0 Human 7.2 pIC50 = 7.2 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 469 5 2 5 6.2 CC(C)(C)c1cc(C(=O)Cn2c(=N)n(Cc3ccccc3)c3ccccc32)cc(C(C)(C)C)c1O 10.1016/s0960-894x(01)00555-8
CHEMBL98805 206514 10 None - 0 Human 7.2 pIC50 = 7.2 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 469 5 2 5 6.2 CC(C)(C)c1cc(C(=O)Cn2c(=N)n(Cc3ccccc3)c3ccccc32)cc(C(C)(C)C)c1O 10.1016/s0960-894x(01)00555-8
137661486 158929 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Antagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in thrombin-stimulated platelet aggregation preincubated for 3 mins followed by thrombin stimulation measured after 5 mins by aggregometric analysisAntagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in thrombin-stimulated platelet aggregation preincubated for 3 mins followed by thrombin stimulation measured after 5 mins by aggregometric analysis
ChEMBL 407 3 1 2 6.8 C[C@H]1CC[C@@H]2C(C)(C)[C@H](O)CC[C@@]2(C)[C@@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
CHEMBL4101591 158929 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Antagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in thrombin-stimulated platelet aggregation preincubated for 3 mins followed by thrombin stimulation measured after 5 mins by aggregometric analysisAntagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in thrombin-stimulated platelet aggregation preincubated for 3 mins followed by thrombin stimulation measured after 5 mins by aggregometric analysis
ChEMBL 407 3 1 2 6.8 C[C@H]1CC[C@@H]2C(C)(C)[C@H](O)CC[C@@]2(C)[C@@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/acs.jmedchem.7b00951
10204371 205172 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Binding affinity against platelet thrombin receptorBinding affinity against platelet thrombin receptor
ChEMBL 451 6 3 3 4.9 CN(C[C@@H](O)c1ccc(Cl)c(Cl)c1)C(=O)Nc1ccc(CNC(=O)C(C)(C)C)cc1 10.1016/s0960-894x(01)00538-8
CHEMBL90864 205172 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Binding affinity against platelet thrombin receptorBinding affinity against platelet thrombin receptor
ChEMBL 451 6 3 3 4.9 CN(C[C@@H](O)c1ccc(Cl)c(Cl)c1)C(=O)Nc1ccc(CNC(=O)C(C)(C)C)cc1 10.1016/s0960-894x(01)00538-8
76313664 103396 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 351 4 0 2 5.7 COC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091984 103396 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 351 4 0 2 5.7 COC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
76335372 103397 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 379 4 0 3 5.7 CC(=O)OC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091985 103397 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 379 4 0 3 5.7 CC(=O)OC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
9810475 101068 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 719 19 7 8 2.5 NCCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)co1 10.1016/s0960-894x(98)00292-3
CHEMBL298273 101068 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 719 19 7 8 2.5 NCCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)co1 10.1016/s0960-894x(98)00292-3
44409259 140163 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 432 4 1 4 5.6 CCC(=O)Nc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2005.12.042
CHEMBL381569 140163 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 432 4 1 4 5.6 CCC(=O)Nc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2005.12.042
90663331 106173 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 773 20 9 7 1.4 CC(=O)N(c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143294 106173 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 773 20 9 7 1.4 CC(=O)N(c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44306076 201340 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 335 3 2 6 3.5 CSc1ccc(Cn2ccc3c4c(N)nc(N)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
CHEMBL63381 201340 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 335 3 2 6 3.5 CSc1ccc(Cn2ccc3c4c(N)nc(N)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
44432803 144477 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 421 3 0 3 5.3 O=C1OC[C@H]2[C@@H]1Cc1c(ccc(F)c1F)[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL391098 144477 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 421 3 0 3 5.3 O=C1OC[C@H]2[C@@H]1Cc1c(ccc(F)c1F)[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
127053987 143277 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 501 5 1 6 3.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NS(C)(=O)=O)CC1(F)F nan
CHEMBL3901289 143277 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 501 5 1 6 3.8 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NS(C)(=O)=O)CC1(F)F nan
66761456 126761 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 500 4 1 4 4.5 N#CC1CCN(C(=O)N2CC(NC(=O)c3ccccc3)CC(c3ccc(OC(F)(F)F)cc3)C2)CC1 nan
CHEMBL3658413 126761 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 500 4 1 4 4.5 N#CC1CCN(C(=O)N2CC(NC(=O)c3ccccc3)CC(c3ccc(OC(F)(F)F)cc3)C2)CC1 nan
127053983 148231 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 520 5 2 5 5.1 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NC(=O)NC2CCC2)CC1(F)F nan
CHEMBL3940503 148231 0 None - 0 Human 8.2 pIC50 = 8.2 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 520 5 2 5 5.1 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(NC(=O)NC2CCC2)CC1(F)F nan
72547551 103393 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 392 3 1 3 5.2 O=C1NCC2(C[C@@H]3CCCC[C@@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)O1 10.1021/ml400235c
CHEMBL3091981 103393 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Antagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in washed human platelets assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 392 3 1 3 5.2 O=C1NCC2(C[C@@H]3CCCC[C@@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)O1 10.1021/ml400235c
127053942 142896 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 423 3 1 5 4.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(N)CC1(F)F nan
CHEMBL3898141 142896 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 423 3 1 5 4.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(N)CC1(F)F nan
CHEMBL3143291 209419 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44432814 87588 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 385 3 0 3 5.0 O=C1OC[C@H]2[C@@H]1Cc1ccccc1[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL234397 87588 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 385 3 0 3 5.0 O=C1OC[C@H]2[C@@H]1Cc1ccccc1[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
127053961 151179 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 499 5 1 6 5.0 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3Cl)cn2)C2[C@@H](C)OC(=O)[C@]2(Cc2nn[nH]n2)CC1(F)F nan
CHEMBL3964337 151179 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 499 5 1 6 5.0 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3Cl)cn2)C2[C@@H](C)OC(=O)[C@]2(Cc2nn[nH]n2)CC1(F)F nan
10350886 178179 1 None - 0 Human 8.1 pIC50 = 8.1 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 942 27 13 9 -0.3 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1016/s0960-894x(98)00292-3
CHEMBL46869 178179 1 None - 0 Human 8.1 pIC50 = 8.1 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 942 27 13 9 -0.3 CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)/C=C/c1ccccc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1016/s0960-894x(98)00292-3
23628249 86817 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 403 3 0 3 5.2 O=C1OC[C@H]2[C@@H]1Cc1cc(F)ccc1[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL232955 86817 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 403 3 0 3 5.2 O=C1OC[C@H]2[C@@H]1Cc1cc(F)ccc1[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL3143272 209409 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44309471 101688 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 796 16 5 7 5.6 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCCN1CCCC1 10.1016/s0960-894x(03)00325-1
CHEMBL302594 101688 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 796 16 5 7 5.6 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCCN1CCCC1 10.1016/s0960-894x(03)00325-1
44309959 168644 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 772 15 5 7 5.7 NCCNC(=O)[C@H](Cc1ccncc1)NC(=O)[C@H](Cc1ccccc1F)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1 10.1016/s0960-894x(03)00325-1
CHEMBL440808 168644 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 772 15 5 7 5.7 NCCNC(=O)[C@H](Cc1ccncc1)NC(=O)[C@H](Cc1ccccc1F)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1 10.1016/s0960-894x(03)00325-1
127051546 140305 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 490 7 2 6 3.1 CCN(C(=O)CO)C1CN(/C(=N\C#N)Nc2cccc(OC(F)F)c2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
CHEMBL3819277 140305 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 490 7 2 6 3.1 CCN(C(=O)CO)C1CN(/C(=N\C#N)Nc2cccc(OC(F)F)c2)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
44418846 82823 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 417 3 1 4 5.0 Cc1ccccc1-c1ccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3C[C@H](O)CC[C@H]32)nc1 10.1021/jm061043e
CHEMBL218670 82823 0 None - 0 Human 7.2 pIC50 = 7.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 417 3 1 4 5.0 Cc1ccccc1-c1ccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3C[C@H](O)CC[C@H]32)nc1 10.1021/jm061043e
10246587 71762 0 None - 1 Human 7.2 pIC50 = 7.2 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 339 3 0 3 4.7 CCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
CHEMBL197791 71762 0 None - 1 Human 7.2 pIC50 = 7.2 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 339 3 0 3 4.7 CCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
44324193 105675 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Binding affinity against platelet thrombin receptorBinding affinity against platelet thrombin receptor
ChEMBL 479 7 3 3 5.6 CC(C)N(C[C@@H](O)c1ccc(Cl)c(Cl)c1)C(=O)Nc1ccc(CNC(=O)C(C)(C)C)cc1 10.1016/s0960-894x(01)00538-8
CHEMBL313645 105675 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Binding affinity against platelet thrombin receptorBinding affinity against platelet thrombin receptor
ChEMBL 479 7 3 3 5.6 CC(C)N(C[C@@H](O)c1ccc(Cl)c(Cl)c1)C(=O)Nc1ccc(CNC(=O)C(C)(C)C)cc1 10.1016/s0960-894x(01)00538-8
44408709 140846 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 391 3 0 4 5.3 COc1cccc2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc12 10.1016/j.bmcl.2005.12.042
CHEMBL383832 140846 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 391 3 0 4 5.3 COc1cccc2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)nc12 10.1016/j.bmcl.2005.12.042
44416634 80673 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 377 3 0 3 5.7 CO[C@@H]1O[C@H](C)[C@H]2[C@@H](/C=C/c3ccc4ccccc4n3)[C@@H]3CCCC[C@H]3C[C@H]21 10.1016/j.bmcl.2006.06.042
CHEMBL215524 80673 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 377 3 0 3 5.7 CO[C@@H]1O[C@H](C)[C@H]2[C@@H](/C=C/c3ccc4ccccc4n3)[C@@H]3CCCC[C@H]3C[C@H]21 10.1016/j.bmcl.2006.06.042
44416487 165456 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 321 3 0 2 5.9 COc1ccc2nc(/C=C/[C@@H]3CCC[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2006.06.042
CHEMBL425437 165456 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 321 3 0 2 5.9 COc1ccc2nc(/C=C/[C@@H]3CCC[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2006.06.042
44280703 116296 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 578 15 7 6 1.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccncc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33781 116296 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 578 15 7 6 1.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccncc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280768 116672 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 569 14 9 8 -0.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@H](C(N)=O)c1ccccc1 10.1016/s0960-894x(99)00197-3
CHEMBL33940 116672 0 None - 0 Human 5.2 pIC50 = 5.2 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 569 14 9 8 -0.5 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(N)n1)C(=O)N[C@H](C(N)=O)c1ccccc1 10.1016/s0960-894x(99)00197-3
50910535 75446 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 366 6 2 3 4.6 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2OC(F)(F)F)c1 10.1021/ml2002696
CHEMBL2048425 75446 0 None - 0 Human 6.2 pIC50 = 6.2 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 366 6 2 3 4.6 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2OC(F)(F)F)c1 10.1021/ml2002696
44418839 83013 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 421 3 1 4 4.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4F)cn3)[C@H]12 10.1021/jm061043e
CHEMBL219698 83013 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 421 3 1 4 4.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4F)cn3)[C@H]12 10.1021/jm061043e
11674764 71935 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 353 3 0 3 5.2 CC(C)c1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
CHEMBL198273 71935 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 353 3 0 3 5.2 CC(C)c1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
44408615 74080 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 379 2 0 3 5.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(F)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL202677 74080 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 379 2 0 3 5.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(F)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
44306402 167645 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 827 20 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccccc4C)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL433499 167645 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 827 20 6 7 6.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCCC4)cn(Cc4ccccc4C)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCc2ccccc2)cc1 10.1016/s0960-894x(01)00378-x
CHEMBL33473 209654 18 None - 0 Human 4.1 pIC50 = 4.1 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O 10.1016/s0960-894x(98)00292-3
44328647 112300 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 525 5 2 5 7.5 CC(C)(C)c1ccc(Cn2c(=N)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c3ccccc32)cc1 10.1016/s0960-894x(01)00555-8
CHEMBL330643 112300 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 525 5 2 5 7.5 CC(C)(C)c1ccc(Cn2c(=N)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c3ccccc32)cc1 10.1016/s0960-894x(01)00555-8
44416740 141462 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 395 5 2 4 4.7 COc1ccc2nc(/C=C/[C@@H]3[C@H]([C@@H](C)O)[C@H](CO)C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2006.06.042
CHEMBL387441 141462 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 395 5 2 4 4.7 COc1ccc2nc(/C=C/[C@@H]3[C@H]([C@@H](C)O)[C@H](CO)C[C@@H]4CCCC[C@H]43)ccc2c1 10.1016/j.bmcl.2006.06.042
CHEMBL3143316 209428 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc([N+](=O)[O-])cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44280522 98744 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 612 15 7 6 1.8 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cccnc1Cl)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL281443 98744 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 612 15 7 6 1.8 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cccnc1Cl)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
23631277 142917 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 470 3 0 4 5.5 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CN(C)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
CHEMBL389834 142917 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 470 3 0 4 5.5 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CN(C)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
12018762 109146 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 451 8 0 6 5.5 Fc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL322282 109146 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 451 8 0 6 5.5 Fc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
17187522 59337 2 None - 0 Human 6.1 pIC50 = 6.1 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 296 5 2 2 4.0 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2C)c1 10.1021/ml2002696
CHEMBL1721173 59337 2 None - 0 Human 6.1 pIC50 = 6.1 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 296 5 2 2 4.0 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2C)c1 10.1021/ml2002696
90663305 106162 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 558 11 5 5 2.3 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(N)=O 10.1021/jm960455s
CHEMBL3143265 106162 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 558 11 5 5 2.3 CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(N)=O 10.1021/jm960455s
76331783 103390 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 436 4 1 3 6.6 CC(C)(C)OC(=O)NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091978 103390 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 436 4 1 3 6.6 CC(C)(C)OC(=O)NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
66761321 127005 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 435 4 1 3 3.9 CC(C)c1cccc(C2CC(NC(=O)c3ccccc3)CN(C(=O)N3CCOCC3)C2)c1 nan
CHEMBL3662506 127005 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 435 4 1 3 3.9 CC(C)c1cccc(C2CC(NC(=O)c3ccccc3)CN(C(=O)N3CCOCC3)C2)c1 nan
23631188 92520 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 478 4 0 5 5.2 CCOC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3ccccc3F)cn2)C1 10.1021/jm070704k
CHEMBL244105 92520 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 478 4 0 5 5.2 CCOC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3ccccc3F)cn2)C1 10.1021/jm070704k
23631811 92683 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 474 4 0 4 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CN(C(=O)C4CC4)CC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4F)cn3)[C@H]12 10.1021/jm070704k
CHEMBL244299 92683 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 474 4 0 4 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CN(C(=O)C4CC4)CC[C@H]3[C@H](/C=C/c3ccc(-c4ccccc4F)cn3)[C@H]12 10.1021/jm070704k
127053951 149009 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 480 4 1 6 4.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C2(O)COC2)CC1(F)F nan
CHEMBL3946656 149009 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 480 4 1 6 4.2 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)C2[C@@H](C)OC(=O)[C@]2(C2(O)COC2)CC1(F)F nan
57404483 72910 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 421 5 1 5 4.7 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccccc2OC)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012505 72910 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 421 5 1 5 4.7 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccccc2OC)cn1 10.1016/j.bmcl.2012.01.138
127053945 143974 0 None - 1 Human 8.1 pIC50 = 8.1 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 417 3 1 4 4.5 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)C2[C@@H](C)OC(=O)[C@]2(O)CC1(F)F nan
CHEMBL3906979 143974 0 None - 1 Human 8.1 pIC50 = 8.1 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 417 3 1 4 4.5 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)C2[C@@H](C)OC(=O)[C@]2(O)CC1(F)F nan
72547551 103393 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 392 3 1 3 5.2 O=C1NCC2(C[C@@H]3CCCC[C@@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)O1 10.1021/ml400235c
CHEMBL3091981 103393 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 392 3 1 3 5.2 O=C1NCC2(C[C@@H]3CCCC[C@@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)O1 10.1021/ml400235c
70683205 72915 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 381 4 1 5 4.3 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccoc2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012510 72915 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 381 4 1 5 4.3 CC[C@@H]1[C@@H](C)C[C@@]2(O)C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccoc2)cn1 10.1016/j.bmcl.2012.01.138
70681077 72895 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 375 4 0 3 5.6 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccccc2)cn1 10.1016/j.bmcl.2012.01.138
CHEMBL2012489 72895 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Displacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation countingDisplacement of [3H]haTRAP from human PAR1 after 1 hr by TopCount scintillation counting
ChEMBL 375 4 0 3 5.6 CC[C@@H]1[C@@H](C)C[C@H]2C(=O)O[C@H](C)[C@H]2[C@H]1/C=C/c1ccc(-c2ccccc2)cn1 10.1016/j.bmcl.2012.01.138
127051547 140262 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 504 5 2 7 2.8 CCN(C(=O)CO)C1CN(/C(=N\C#N)Nc2ccc3c(c2)OC(F)(F)O3)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
CHEMBL3818750 140262 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Antagonist activity at PAR1 (unknown origin)Antagonist activity at PAR1 (unknown origin)
ChEMBL 504 5 2 7 2.8 CCN(C(=O)CO)C1CN(/C(=N\C#N)Nc2ccc3c(c2)OC(F)(F)O3)N=C1c1ccc(Cl)cc1 10.1021/acs.jmedchem.5b01890
23630915 92758 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 489 3 0 4 5.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[S+]([O-])CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
CHEMBL244483 92758 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 489 3 0 4 5.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[S+]([O-])CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm070704k
44418837 141050 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 437 3 0 3 6.3 Cc1cccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CC(F)(F)CC[C@H]43)nc2)c1 10.1021/jm061043e
CHEMBL384982 141050 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 437 3 0 3 6.3 Cc1cccc(-c2ccc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CC(F)(F)CC[C@H]43)nc2)c1 10.1021/jm061043e
44409289 74296 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 425 3 0 4 5.9 COc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1Cl 10.1016/j.bmcl.2005.12.042
CHEMBL203012 74296 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 425 3 0 4 5.9 COc1ccc2nc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@@H]4CCCC[C@H]43)ccc2c1Cl 10.1016/j.bmcl.2005.12.042
44409050 140549 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 462 5 1 5 4.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OC(C)(C)C(N)=O)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
CHEMBL382581 140549 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 462 5 1 5 4.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4cc(OC(C)(C)C(N)=O)ccc4n3)[C@H]12 10.1016/j.bmcl.2005.12.042
44306337 96389 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 800 18 6 8 5.1 Cc1ccccc1Cn1cc(CN2CCCC2)c2ccc(NC(=O)N[C@@H](Cc3ccc([N+](=O)[O-])cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc3ccccc3)cc21 10.1016/s0960-894x(01)00378-x
CHEMBL265227 96389 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 800 18 6 8 5.1 Cc1ccccc1Cn1cc(CN2CCCC2)c2ccc(NC(=O)N[C@@H](Cc3ccc([N+](=O)[O-])cc3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc3ccccc3)cc21 10.1016/s0960-894x(01)00378-x
44416672 165901 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 347 2 0 2 5.7 C[C@H]1OC[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@@H]21 10.1016/j.bmcl.2006.06.042
CHEMBL427783 165901 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 347 2 0 2 5.7 C[C@H]1OC[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc4ccccc4n3)[C@@H]21 10.1016/j.bmcl.2006.06.042
44289954 100901 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 721 18 7 8 2.3 NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1CCCCC1)NC(=O)c1csc([C@@H](N)Cc2ccc(F)cc2)n1 10.1016/s0960-894x(98)00292-3
CHEMBL297091 100901 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 721 18 7 8 2.3 NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1CCCCC1)NC(=O)c1csc([C@@H](N)Cc2ccc(F)cc2)n1 10.1016/s0960-894x(98)00292-3
10077130 3944 49 None - 1 Human 7.1 pIC50 = 7.1 Binding
Antagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in thrombin-stimulated platelet aggregation preincubated for 3 mins followed by thrombin stimulation measured after 5 mins by aggregometric analysisAntagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in thrombin-stimulated platelet aggregation preincubated for 3 mins followed by thrombin stimulation measured after 5 mins by aggregometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/acs.jmedchem.7b00951
4047 3944 49 None - 1 Human 7.1 pIC50 = 7.1 Binding
Antagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in thrombin-stimulated platelet aggregation preincubated for 3 mins followed by thrombin stimulation measured after 5 mins by aggregometric analysisAntagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in thrombin-stimulated platelet aggregation preincubated for 3 mins followed by thrombin stimulation measured after 5 mins by aggregometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/acs.jmedchem.7b00951
4870 3944 49 None - 1 Human 7.1 pIC50 = 7.1 Binding
Antagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in thrombin-stimulated platelet aggregation preincubated for 3 mins followed by thrombin stimulation measured after 5 mins by aggregometric analysisAntagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in thrombin-stimulated platelet aggregation preincubated for 3 mins followed by thrombin stimulation measured after 5 mins by aggregometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/acs.jmedchem.7b00951
CHEMBL493982 3944 49 None - 1 Human 7.1 pIC50 = 7.1 Binding
Antagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in thrombin-stimulated platelet aggregation preincubated for 3 mins followed by thrombin stimulation measured after 5 mins by aggregometric analysisAntagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in thrombin-stimulated platelet aggregation preincubated for 3 mins followed by thrombin stimulation measured after 5 mins by aggregometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/acs.jmedchem.7b00951
DB09030 3944 49 None - 1 Human 7.1 pIC50 = 7.1 Binding
Antagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in thrombin-stimulated platelet aggregation preincubated for 3 mins followed by thrombin stimulation measured after 5 mins by aggregometric analysisAntagonist activity at PAR1 in human platelet-rich plasma assessed as reduction in thrombin-stimulated platelet aggregation preincubated for 3 mins followed by thrombin stimulation measured after 5 mins by aggregometric analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/acs.jmedchem.7b00951
46931416 127013 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 467 3 2 3 3.7 O=C(NC1CC(c2ccc(C(F)(F)F)cc2)CN(C(=O)N2CCC(O)CC2)C1)C1CCCC1 nan
CHEMBL3662514 127013 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 467 3 2 3 3.7 O=C(NC1CC(c2ccc(C(F)(F)F)cc2)CN(C(=O)N2CCC(O)CC2)C1)C1CCCC1 nan
9919038 166175 0 None - 1 Human 6.1 pIC50 = 6.1 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 845 17 7 6 6.7 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL428311 166175 0 None - 1 Human 6.1 pIC50 = 6.1 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 845 17 7 6 6.7 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
44290234 177940 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 832 22 8 10 2.4 COc1ccc(C[C@H](NC(=O)C(N)C(C)C)c2nc(C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc3ccccc3)C(N)=O)cs2)cc1 10.1016/s0960-894x(98)00292-3
CHEMBL46670 177940 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 832 22 8 10 2.4 COc1ccc(C[C@H](NC(=O)C(N)C(C)C)c2nc(C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc3ccccc3)C(N)=O)cs2)cc1 10.1016/s0960-894x(98)00292-3
58045917 132765 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 496 8 1 10 3.0 CCOc1nn2c(=N)n(CC(=O)c3cc(N4CCOCC4)c(OC)c(C(C)(C)C)c3)nc2cc1CC nan
CHEMBL3704465 132765 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 496 8 1 10 3.0 CCOc1nn2c(=N)n(CC(=O)c3cc(N4CCOCC4)c(OC)c(C(C)(C)C)c3)nc2cc1CC nan
44418840 83014 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 421 3 1 4 4.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4ccc(F)cc4)cn3)[C@H]12 10.1021/jm061043e
CHEMBL219699 83014 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 421 3 1 4 4.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4ccc(F)cc4)cn3)[C@H]12 10.1021/jm061043e
11249717 153902 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 541 9 2 7 4.9 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCC(O)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3903962 153902 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 541 9 2 7 4.9 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCC(O)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
CHEMBL3990074 153902 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Antagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometerAntagonist activity at thrombin receptor in human platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins followed by thrombin addition measured after 6 mins by aggregometer
ChEMBL 541 9 2 7 4.9 CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCC(O)CC3)c(OC)c(C(C)(C)C)c1)C2 nan
58137009 124628 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 486 11 2 9 2.5 CCOc1nn2c(N)n[n+](CC(=O)c3cc(OCCCO)c(OC)c(C(C)(C)C)c3)c2cc1CC nan
CHEMBL3644444 124628 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 486 11 2 9 2.5 CCOc1nn2c(N)n[n+](CC(=O)c3cc(OCCCO)c(OC)c(C(C)(C)C)c3)c2cc1CC nan
16100343 137629 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CC[C@H](O)C[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
CHEMBL376890 137629 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CC[C@H](O)C[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
44187647 124624 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 470 11 1 8 3.4 CCC(CC)Oc1ccc2n(n1)c(N)n[n+]2CC(=O)c1cc(OCCOC)cc(C(C)(C)C)c1 nan
CHEMBL3644440 124624 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997).The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at RT for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB microtiter filtration.
ChEMBL 470 11 1 8 3.4 CCC(CC)Oc1ccc2n(n1)c(N)n[n+]2CC(=O)c1cc(OCCOC)cc(C(C)(C)C)c1 nan
10246587 71762 0 None - 1 Human 7.1 pIC50 = 7.1 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 339 3 0 3 4.7 CCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1016/j.bmcl.2006.06.042
CHEMBL197791 71762 0 None - 1 Human 7.1 pIC50 = 7.1 Binding
Binding affinity to PAR1 in human platelet membraneBinding affinity to PAR1 in human platelet membrane
ChEMBL 339 3 0 3 4.7 CCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1016/j.bmcl.2006.06.042
10246587 71762 0 None - 1 Human 7.1 pIC50 = 7.1 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 339 3 0 3 4.7 CCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
CHEMBL197791 71762 0 None - 1 Human 7.1 pIC50 = 7.1 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 339 3 0 3 4.7 CCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
44432806 86857 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 403 3 0 3 5.2 O=C1OC[C@H]2[C@@H]1Cc1cccc(F)c1[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
CHEMBL233163 86857 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 403 3 0 3 5.2 O=C1OC[C@H]2[C@@H]1Cc1cccc(F)c1[C@@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1016/j.bmcl.2007.04.061
11508687 71551 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 355 4 0 4 4.2 COCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
CHEMBL197133 71551 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 355 4 0 4 4.2 COCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
44826172 99526 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 758 19 9 10 1.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccc([N+](=O)[O-])c2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL286648 99526 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to Thrombin receptor 1 (PAR-1) on membranes from CHRF cells
ChEMBL 758 19 9 10 1.4 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1n[nH]c(NC(=O)/C=C/c2cccc([N+](=O)[O-])c2)n1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44280822 116045 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 594 15 8 8 0.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1nccnc1N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33629 116045 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 594 15 8 8 0.1 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1nccnc1N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL3143255 209399 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CCCN)C(N)=O 10.1021/jm960455s
44305896 102324 3 None - 0 Human 6.1 pIC50 = 6.1 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 345 4 2 5 4.4 CNc1nc(N)c2c(ccc3c2ccn3Cc2ccc(C(C)C)cc2)n1 10.1016/s0960-894x(99)00339-x
CHEMBL305329 102324 3 None - 0 Human 6.1 pIC50 = 6.1 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 345 4 2 5 4.4 CNc1nc(N)c2c(ccc3c2ccn3Cc2ccc(C(C)C)cc2)n1 10.1016/s0960-894x(99)00339-x
127053991 143139 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 466 4 2 7 3.5 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3-c3nnn[nH]3)cn2)C2[C@@H](C)OC(=O)[C@]2(N)CC1(F)F nan
CHEMBL3900057 143139 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 466 4 2 7 3.5 C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3-c3nnn[nH]3)cn2)C2[C@@H](C)OC(=O)[C@]2(N)CC1(F)F nan
44432721 86355 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 389 3 0 5 4.6 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cnccn4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
CHEMBL232140 86355 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Displacement of [3H]haTRAP from human PAR1 receptor in platelet membraneDisplacement of [3H]haTRAP from human PAR1 receptor in platelet membrane
ChEMBL 389 3 0 5 4.6 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cnccn4)cn3)[C@H]12 10.1016/j.bmcl.2007.06.002
44339029 109204 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 447 8 0 6 5.7 Cc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
CHEMBL322763 109204 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 447 8 0 6 5.7 Cc1cccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)c1 10.1016/s0960-894x(01)00745-4
72547308 103403 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 392 4 0 2 5.6 CC(=O)N(C)C1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091991 103403 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 392 4 0 2 5.6 CC(=O)N(C)C1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3143305 209422 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(NC(=N)N)cc1)NC(=O)[C@H](Cc1ccc(F)cc1)NS(=O)(=O)c1cccs1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
90663318 106169 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 986 28 12 10 0.5 CCC(=O)c1cccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)c1 10.1021/jm960455s
CHEMBL3143280 106169 0 None - 0 Human 8.1 pIC50 = 8.1 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 986 28 12 10 0.5 CCC(=O)c1cccc(N(C(C)=O)[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(NC(=N)N)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)c1 10.1021/jm960455s
127053966 160387 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 580 6 1 8 6.2 CNc1ccc(-c2cn([C@@]34CC(F)(F)C(C)[C@H](/C=C/c5ccc(-c6ccccc6C#N)cn5)C3[C@@H](C)OC4=O)nn2)cc1 nan
CHEMBL4115431 160387 0 None - 0 Human 8.0 pIC50 = 8.0 Binding
FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.FLIPR Assay: HEK 293 Cells were grown in media containing DMEM, 10% FBS pen/strep/L-Glutamine and non-essential amino acids. The cells were plated in 384-well PDL coated plates at 12000 cells/well and incubated overnight at 37° C./5% CO2. Media was then removed from the cells, which were then incubated with buffer (Hank's containing HEPES and Chaps) containing FLIPR calcium-5 dye, made with buffer containing probenecid, for 60 minutes at 37° C. Varying concentrations of compound in a final concentration of 5% DMSO were then added to the cells and incubated at 25° C. for 30 minutes. The plates were then added to the FLIPR Tetra and the device added a concentration of a PAR1 selective receptor-activating peptide with the sequence Ala-parafluoroPhe-Arg-Cha-Cit-Try-Nh2 (prepared in water) at a concentration equal to the effective concentration that achieves 80% activation of signaling on the day of the experiment.
ChEMBL 580 6 1 8 6.2 CNc1ccc(-c2cn([C@@]34CC(F)(F)C(C)[C@H](/C=C/c5ccc(-c6ccccc6C#N)cn5)C3[C@@H](C)OC4=O)nn2)cc1 nan
44310191 202839 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 770 17 6 7 5.2 CCNCCNC(=O)[C@H](CCN)NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1 10.1016/s0960-894x(03)00325-1
CHEMBL72854 202839 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Ability to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cellsAbility to inhibit the binding of [3H]S-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2 to thrombin receptor on the membranes of CHRF-288-11 cells
ChEMBL 770 17 6 7 5.2 CCNCCNC(=O)[C@H](CCN)NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1 10.1016/s0960-894x(03)00325-1
44432836 87611 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 385 3 0 4 4.8 COc1ccc2nc(/C=C/[C@H]3c4ccccc4C[C@@H]4C(=O)O[C@H](C)[C@@H]43)ccc2c1 10.1016/j.bmcl.2007.04.061
CHEMBL234483 87611 0 None - 0 Human 7.1 pIC50 = 7.1 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 385 3 0 4 4.8 COc1ccc2nc(/C=C/[C@H]3c4ccccc4C[C@@H]4C(=O)O[C@H](C)[C@@H]43)ccc2c1 10.1016/j.bmcl.2007.04.061
11516923 71590 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 401 4 0 3 5.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3cccc(Cc4ccccc4)n3)[C@H]12 10.1021/jm0502236
CHEMBL197248 71590 0 None - 0 Human 6.1 pIC50 = 6.1 Binding
In vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligandIn vitro inhibitory concentration against human protease activated receptor 1 using [3H]-haTRAP as radioligand
ChEMBL 401 4 0 3 5.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3cccc(Cc4ccccc4)n3)[C@H]12 10.1021/jm0502236
1047175 206334 12 None - 0 Human 6.1 pIC50 = 6.1 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 393 3 2 5 4.6 Cn1c(=N)n(CC(=O)c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)c2ccccc21 10.1016/s0960-894x(01)00555-8
CHEMBL97706 206334 12 None - 0 Human 6.1 pIC50 = 6.1 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 393 3 2 5 4.6 Cn1c(=N)n(CC(=O)c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)c2ccccc21 10.1016/s0960-894x(01)00555-8
44281173 114774 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 544 16 7 6 -0.5 NCCC(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL33489 114774 0 None - 0 Human 5.1 pIC50 = 5.1 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 544 16 7 6 -0.5 NCCC(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44432839 144777 0 None - 0 Human 5.0 pIC50 = 5.0 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 385 3 0 4 4.8 COc1ccc2nc(/C=C/[C@H]3c4ccccc4C[C@@H]4C(=O)O[C@@H](C)[C@@H]43)ccc2c1 10.1016/j.bmcl.2007.04.061
CHEMBL391323 144777 0 None - 0 Human 5.0 pIC50 = 5.0 Binding
Displacement of [3H]haTRAP from PAR1Displacement of [3H]haTRAP from PAR1
ChEMBL 385 3 0 4 4.8 COc1ccc2nc(/C=C/[C@H]3c4ccccc4C[C@@H]4C(=O)O[C@@H](C)[C@@H]43)ccc2c1 10.1016/j.bmcl.2007.04.061
44306732 102131 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 775 14 5 6 6.4 NCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL304128 102131 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
In vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cellsIn vitro displacement of [3H]S-(p-F-Phe)-homoarginine-K Y-NH2 (at a concentration of 10 uM) from thrombin receptor (PAR-1) on the membranes of CHRF-288-11 cells
ChEMBL 775 14 5 6 6.4 NCC(NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1016/s0960-894x(01)00378-x
CHEMBL3143289 209417 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL None None None CC(=O)N(C(=O)/C=C/c1ccccc1)[C@H](CC1CCCCC1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
44280685 99290 0 None - 0 Human 5.0 pIC50 = 5.0 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 585 15 7 8 0.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1csnn1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
CHEMBL285018 99290 0 None - 0 Human 5.0 pIC50 = 5.0 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cellsInhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to thrombin receptor (PAR-1) on membranes from CHRF cells
ChEMBL 585 15 7 8 0.6 N=C(N)NCCC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1csnn1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O 10.1016/s0960-894x(99)00197-3
44290251 100738 0 None - 0 Human 4.0 pIC50 = 4.0 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 792 21 8 9 1.7 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cs1 10.1016/s0960-894x(98)00292-3
CHEMBL295849 100738 0 None - 0 Human 4.0 pIC50 = 4.0 Binding
Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.Inhibition of [3H]S-(p-F-Phe)-Har-L-Har-KY-NH2 binding to a thrombin receptor (PAR-1) membrane preparation.
ChEMBL 792 21 8 9 1.7 CNCC(=O)N[C@@H](Cc1ccc(F)cc1)c1nc(C(=O)N[C@H](CC2CCCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cs1 10.1016/s0960-894x(98)00292-3
90663329 106171 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 774 20 9 8 0.8 CC(=O)N(c1cccnc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143292 106171 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 774 20 9 8 0.8 CC(=O)N(c1cccnc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
58045928 132759 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 439 8 1 8 4.1 CCC(CC)Oc1nn2c(=N)n(CC(=O)c3cc(OC)cc(C(C)(C)C)c3)nc2cc1C nan
CHEMBL3704459 132759 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 439 8 1 8 4.1 CCC(CC)Oc1nn2c(=N)n(CC(=O)c3cc(OC)cc(C(C)(C)C)c3)nc2cc1C nan
44305955 100558 0 None - 0 Human 5.0 pIC50 = 5.0 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 315 3 2 5 3.4 C=Cc1ccc(Cn2ccc3c4c(N)nc(N)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
CHEMBL294544 100558 0 None - 0 Human 5.0 pIC50 = 5.0 Binding
Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)Inhibitory activity against binding to Thrombin receptor 1 (PAR-1)
ChEMBL 315 3 2 5 3.4 C=Cc1ccc(Cn2ccc3c4c(N)nc(N)nc4ccc32)cc1 10.1016/s0960-894x(99)00339-x
4314709 205936 1 None - 0 Human 6.0 pIC50 = 6.0 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 477 9 2 5 7.1 CCCCCCCn1c(=N)n(CC(=O)c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)c2ccccc21 10.1016/s0960-894x(01)00555-8
CHEMBL95359 205936 1 None - 0 Human 6.0 pIC50 = 6.0 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 477 9 2 5 7.1 CCCCCCCn1c(=N)n(CC(=O)c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)c2ccccc21 10.1016/s0960-894x(01)00555-8
72547307 103392 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 428 5 0 3 5.0 CN(C1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1)S(C)(=O)=O 10.1021/ml400235c
CHEMBL3091980 103392 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Antagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysisAntagonist activity at PAR1 in human platelet rich plasma assessed as inhibition of haTRAP-induced platelet aggregation preincubated for 1 hr followed by haTRAP addition measured for 10 mins by spectrophotometric analysis
ChEMBL 428 5 0 3 5.0 CN(C1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1)S(C)(=O)=O 10.1021/ml400235c
44418848 82781 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 6.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cc(Cl)ccc4Cl)cn3)[C@H]12 10.1021/jm061043e
CHEMBL218449 82781 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 6.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cc(Cl)ccc4Cl)cn3)[C@H]12 10.1021/jm061043e
17187609 59561 2 None - 0 Human 6.0 pIC50 = 6.0 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 300 5 2 2 3.8 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2F)c1 10.1021/ml2002696
CHEMBL1729550 59561 2 None - 0 Human 6.0 pIC50 = 6.0 Binding
Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometryInhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin after 20 mins by flow cytometry
ChEMBL 300 5 2 2 3.8 CCCC(=O)Nc1cccc(NC(=O)c2ccccc2F)c1 10.1021/ml2002696
58046023 132763 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 499 11 2 10 3.4 CCC(CC)Oc1cc(C)c2nn(CC(=O)c3cc(OCCO)c(OC)c(C(C)(C)C)c3)c(=N)n2n1 nan
CHEMBL3704463 132763 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL 499 11 2 10 3.4 CCC(CC)Oc1cc(C)c2nn(CC(=O)c3cc(OCCO)c(OC)c(C(C)(C)C)c3)c(=N)n2n1 nan
1047179 205982 5 None - 0 Human 7.0 pIC50 = 7.0 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 492 6 2 7 4.4 CC(C)(C)c1cc(C(=O)Cn2c(=N)n(CCN3CCOCC3)c3ccccc32)cc(C(C)(C)C)c1O 10.1016/s0960-894x(01)00555-8
CHEMBL95632 205982 5 None - 0 Human 7.0 pIC50 = 7.0 Binding
Inhibitory concentration against potent thrombin receptor-1 (PAR-1) on human plateletsInhibitory concentration against potent thrombin receptor-1 (PAR-1) on human platelets
ChEMBL 492 6 2 7 4.4 CC(C)(C)c1cc(C(=O)Cn2c(=N)n(CCN3CCOCC3)c3ccccc32)cc(C(C)(C)C)c1O 10.1016/s0960-894x(01)00555-8
68058705 126751 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 433 5 1 4 4.9 CCc1ccc(C2CC(C(=O)Nc3ccccc3)CN(C(=O)c3scnc3C)C2)cc1 nan
CHEMBL3658404 126751 0 None - 0 Human 7.0 pIC50 = 7.0 Binding
Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.Binding Assay: Platelet membranes are incubated with 12 nM [3H]haTRAP and test substance in different concentrations in a buffer (50 mM Tris pH 7.5, 10 mM magnesium chloride, 1 mM EGTA, 0.1% BSA) at room temperature for 80 min. Then the mixture is transferred to a filter plate and washed twice with buffer. After addition of scintillation liquid, the radioactivity on the filter is measured in a beta counter.
ChEMBL 433 5 1 4 4.9 CCc1ccc(C2CC(C(=O)Nc3ccccc3)CN(C(=O)c3scnc3C)C2)cc1 nan
76335371 103389 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 394 4 1 3 5.5 COC(=O)NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL3091977 103389 0 None - 0 Human 6.0 pIC50 = 6.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysisDisplacement of [3H]haTRAP from PAR1 in human platelet membranes after 60 mins by scintillation counting analysis
ChEMBL 394 4 1 3 5.5 COC(=O)NC1C[C@@H]2CCCC[C@@H]2[C@H]1/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400235c
CHEMBL4115732 211159 0 None - 0 Human 5.0 pIC50 = 5.0 Binding
Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.Binding Assay: The synthesized substances were examined in a PAR1 binding test. This tested whether the substances can inhibit the binding of a radioactively labeled PAR1 agonist known from the literature at the PAR1 receptor (Ho-Sam Ahn, Mol Pharm, 51:350-356, 1997). The human PAR1 receptor was expressed transiently in High Five insect cells. From these cells, after 48 hours, a membrane preparation was produced by standard methods, aliquoted into 10 mM Tris-HCl; 0.3 mM EDTA; 1 mM EGTA; 250 mM sucrose pH 7.5, and stored at -80 C.The substances were preincubated with the membrane at room temperature for 15 minutes, then the radioligand (ALA-(para-F-Phe)-Arg-ChA-homoArg-(3,4-3H-Tyr)-NH2; approx. 40 Ci/mMol) was added. The end concentration of the radioligand in the test buffer (50 mM Tris-HCl; 10 mM MgCl2; 1 mM EGTA; 0.1% BSA; 2% DMSO) was 20 nM, that of the membrane 1 mg/ml. After an incubation time of 60 minutes, 25 uL of the mixture were transferred to a 96-well MultiScreenHTS FB.
ChEMBL None None None None nan
90663307 106163 0 None - 0 Human 7.0 pIC50 = 7 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 861 21 9 8 2.1 CC(=O)N(C(=O)/C=C/c1ccc(Cl)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
CHEMBL3143267 106163 0 None - 0 Human 7.0 pIC50 = 7 Binding
Antagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assayAntagonistic activity against tritiated agonist (SFFLRR-NH2, at 25 nM) binding to human platelet membranes measured by the GTPase assay
ChEMBL 861 21 9 8 2.1 CC(=O)N(C(=O)/C=C/c1ccc(Cl)cc1)[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O 10.1021/jm960455s
12018759 110711 0 None - 0 Human 6.0 pIC50 = 6 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 467 8 0 6 6.0 Clc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
CHEMBL326456 110711 0 None - 0 Human 6.0 pIC50 = 6 Binding
Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1Displacement of [3H]SFFLRR-NH2 from human thrombin receptor PAR-1
ChEMBL 467 8 0 6 6.0 Clc1ccc(-c2cc(N(CCCN3CCCCCC3)Cc3ccc4c(c3)OCO4)on2)cc1 10.1016/s0960-894x(01)00745-4
44264856 96607 0 None - 1 Human 10.4 pKd = 10.4 Binding
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 846 17 7 7 6.1 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccncc1 10.1021/jm000506s
CHEMBL267059 96607 0 None - 1 Human 10.4 pKd = 10.4 Binding
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 846 17 7 7 6.1 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccncc1 10.1021/jm000506s
9832212 203241 4 None - 1 Human 9.8 pKd = 9.8 Binding
Binding Affinity of ligand against Protease-activated Receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding Affinity of ligand against Protease-activated Receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1021/jm000506s
CHEMBL4226137 203241 4 None - 1 Human 9.8 pKd = 9.8 Binding
Binding Affinity of ligand against Protease-activated Receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding Affinity of ligand against Protease-activated Receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1021/jm000506s
CHEMBL7642 203241 4 None - 1 Human 9.8 pKd = 9.8 Binding
Binding Affinity of ligand against Protease-activated Receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding Affinity of ligand against Protease-activated Receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 790 15 5 7 6.1 NCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)nn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1021/jm000506s
10509332 98032 0 None - 1 Human 9.2 pKd = 9.2 Binding
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 759 17 7 6 5.2 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3ccc(F)cc3)c2c1)C(=O)NCc1ccccc1 10.1021/jm000506s
CHEMBL275946 98032 0 None - 1 Human 9.2 pKd = 9.2 Binding
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 759 17 7 6 5.2 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3ccc(F)cc3)c2c1)C(=O)NCc1ccccc1 10.1021/jm000506s
9919038 166175 0 None - 1 Human 9.1 pKd = 9.1 Binding
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 845 17 7 6 6.7 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1021/jm000506s
CHEMBL428311 166175 0 None - 1 Human 9.1 pKd = 9.1 Binding
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 845 17 7 6 6.7 N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)Nc1ccc2c(CN3CCCC3)cn(Cc3c(Cl)cccc3Cl)c2c1)C(=O)NCc1ccccc1 10.1021/jm000506s
10819322 203205 0 None - 1 Human 8.9 pKd = 8.9 Binding
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 839 18 7 7 6.4 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCc2ccccc2)cc1 10.1021/jm000506s
CHEMBL7610 203205 0 None - 1 Human 8.9 pKd = 8.9 Binding
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 839 18 7 7 6.4 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4c(Cl)cccc4Cl)c3c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCc2ccccc2)cc1 10.1021/jm000506s
10747940 203221 0 None - 1 Human 8.0 pKd = 8.0 Binding
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 803 19 7 7 5.5 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CNC4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1021/jm000506s
CHEMBL7627 203221 0 None - 1 Human 8.0 pKd = 8.0 Binding
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 803 19 7 7 5.5 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CNC4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1021/jm000506s
9853816 96888 0 None - 1 Human 8.7 pKd = 8.7 Binding
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 789 18 6 7 5.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1021/jm000506s
CHEMBL269345 96888 0 None - 1 Human 8.7 pKd = 8.7 Binding
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 789 18 6 7 5.0 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1021/jm000506s
10724264 96743 0 None - 1 Human 8.6 pKd = 8.6 Binding
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 855 19 6 8 5.8 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(OC(F)(F)F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1021/jm000506s
CHEMBL268328 96743 0 None - 1 Human 8.6 pKd = 8.6 Binding
Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)Binding affinity against Protease-activated receptor (PAR-1) using [3H]-s-(p-F-Phe)-homoarginine-L-homoarginine-KY-NH2, 10 nM (Kd= 15 nM)
ChEMBL 855 19 6 8 5.8 COc1ccc(C[C@H](NC(=O)Nc2ccc3c(CN4CCCC4)cn(Cc4ccc(OC(F)(F)F)cc4)c3c2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCc2ccccc2)cc1 10.1021/jm000506s
24879036 168873 0 None - 1 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 499 5 1 6 5.4 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C#N)c2)cn1 10.1021/jm800180e
CHEMBL442649 168873 0 None - 1 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 499 5 1 6 5.4 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C#N)c2)cn1 10.1021/jm800180e
24878928 171887 0 None - 1 Human 8.0 pKi = 8 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 548 5 1 5 5.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](NS(C)(=O)=O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm800180e
CHEMBL447996 171887 0 None - 1 Human 8.0 pKi = 8 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 548 5 1 5 5.3 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](NS(C)(=O)=O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm800180e
9890926 82875 0 None - 1 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
CHEMBL218933 82875 0 None - 1 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 471 3 1 4 5.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm061043e
24878927 186875 0 None - 1 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 498 5 1 5 4.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](NS(C)(=O)=O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm800180e
CHEMBL493975 186875 0 None - 1 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 498 5 1 5 4.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](NS(C)(=O)=O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm800180e
24878984 187149 0 None - 1 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccc2F)cn1 10.1021/jm800180e
CHEMBL495422 187149 0 None - 1 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccc2F)cn1 10.1021/jm800180e
24879079 188321 0 None - 1 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 506 5 1 5 5.9 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C)c2F)cn1 10.1021/jm800180e
CHEMBL507697 188321 0 None - 1 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 506 5 1 5 5.9 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C)c2F)cn1 10.1021/jm800180e
24879037 192005 0 None - 1 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 508 5 1 5 6.1 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1021/jm800180e
CHEMBL521531 192005 0 None - 1 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 508 5 1 5 6.1 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(Cl)c2)cn1 10.1021/jm800180e
76310288 104330 0 None - 1 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 476 5 1 4 5.3 CC(=O)NC[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
CHEMBL3109583 104330 0 None - 1 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 476 5 1 4 5.3 CC(=O)NC[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
52947767 18119 0 None - 1 Human 7.9 pKi = 7.9 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 504 6 1 6 5.5 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccc2OC)cn1 10.1016/j.bmcl.2010.09.009
CHEMBL1270636 18119 0 None - 1 Human 7.9 pKi = 7.9 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 504 6 1 6 5.5 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccc2OC)cn1 10.1016/j.bmcl.2010.09.009
10246587 71762 0 None - 1 Human 7.9 pKi = 7.9 Binding
Inhibitory constant against Protease-activated receptor 1Inhibitory constant against Protease-activated receptor 1
ChEMBL 339 3 0 3 4.7 CCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
CHEMBL197791 71762 0 None - 1 Human 7.9 pKi = 7.9 Binding
Inhibitory constant against Protease-activated receptor 1Inhibitory constant against Protease-activated receptor 1
ChEMBL 339 3 0 3 4.7 CCc1cccc(/C=C/[C@@H]2[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]3CCCC[C@H]32)n1 10.1021/jm0502236
76317514 104331 0 None - 1 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 490 6 1 4 5.7 CCC(=O)NC[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
CHEMBL3109584 104331 0 None - 1 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 490 6 1 4 5.7 CCC(=O)NC[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
76335713 104337 0 None - 1 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 505 6 2 4 5.5 CCNC(=O)NC[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
CHEMBL3109590 104337 0 None - 1 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 505 6 2 4 5.5 CCNC(=O)NC[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
24878827 172063 0 None - 1 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 542 5 1 5 6.5 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1021/jm800180e
CHEMBL449425 172063 0 None - 1 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 542 5 1 5 6.5 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1021/jm800180e
76324857 104334 0 None - 1 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 545 6 2 5 5.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](CNC(=O)C4CCNCC4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/ml400452v
CHEMBL3109587 104334 0 None - 1 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 545 6 2 5 5.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](CNC(=O)C4CCNCC4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/ml400452v
58939091 104329 0 None - 1 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 506 6 1 5 5.9 CCOC(=O)NC[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
CHEMBL3109582 104329 0 None - 1 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 506 6 1 5 5.9 CCOC(=O)NC[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
76328415 104336 0 None - 1 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 526 7 1 5 5.1 CCS(=O)(=O)NC[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
CHEMBL3109589 104336 0 None - 1 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 526 7 1 5 5.1 CCS(=O)(=O)NC[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
76335711 104321 0 None - 1 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 575 5 1 5 7.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](C(=O)Nc4ccncc4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/ml400452v
CHEMBL3109574 104321 0 None - 1 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 575 5 1 5 7.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](C(=O)Nc4ccncc4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/ml400452v
44264660 203384 0 None - 1 Human 4.9 pKi = 4.9 Binding
Inhibitory activity against factor XaInhibitory activity against factor Xa
ChEMBL 519 8 2 5 4.4 CNc1ccc(C#CC[C@H](NS(=O)(=O)c2ccc3cc(OC)ccc3c2)C(=O)N(C)C2CCCC2)cc1 10.1016/s0960-894x(99)00125-0
CHEMBL7758 203384 0 None - 1 Human 4.9 pKi = 4.9 Binding
Inhibitory activity against factor XaInhibitory activity against factor Xa
ChEMBL 519 8 2 5 4.4 CNc1ccc(C#CC[C@H](NS(=O)(=O)c2ccc3cc(OC)ccc3c2)C(=O)N(C)C2CCCC2)cc1 10.1016/s0960-894x(99)00125-0
52940892 18184 0 None - 1 Human 6.8 pKi = 6.8 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 489 5 1 6 5.2 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccc(C)cn2)cn1 10.1016/j.bmcl.2010.09.009
CHEMBL1271149 18184 0 None - 1 Human 6.8 pKi = 6.8 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 489 5 1 6 5.2 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccc(C)cn2)cn1 10.1016/j.bmcl.2010.09.009
76332097 104335 0 None - 1 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 512 6 1 5 4.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](CNS(C)(=O)=O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/ml400452v
CHEMBL3109588 104335 0 None - 1 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 512 6 1 5 4.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](CNS(C)(=O)=O)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/ml400452v
52949514 18107 0 None - 1 Human 7.8 pKi = 7.8 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 499 5 1 6 5.4 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccc2C#N)cn1 10.1016/j.bmcl.2010.09.009
CHEMBL1270537 18107 0 None - 1 Human 7.8 pKi = 7.8 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 499 5 1 6 5.4 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccc2C#N)cn1 10.1016/j.bmcl.2010.09.009
90644637 111483 0 None - 1 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 476 3 1 5 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(F)c5)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
CHEMBL3288436 111483 0 None - 1 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 476 3 1 5 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(F)c5)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
24830436 187032 0 None - 1 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 506 6 1 5 6.0 CCCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/jm800180e
CHEMBL494816 187032 0 None - 1 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 506 6 1 5 6.0 CCCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/jm800180e
76335712 104323 0 None - 1 Human 6.8 pKi = 6.8 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 568 4 1 5 5.6 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](C(=O)N4CC[C@@H](O)C4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/ml400452v
CHEMBL3109576 104323 0 None - 1 Human 6.8 pKi = 6.8 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 568 4 1 5 5.6 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](C(=O)N4CC[C@@H](O)C4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/ml400452v
16214871 18134 3 None - 1 Human 7.7 pKi = 7.7 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 475 5 1 6 4.9 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccn2)cn1 10.1016/j.bmcl.2010.09.009
CHEMBL1270738 18134 3 None - 1 Human 7.7 pKi = 7.7 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 475 5 1 6 4.9 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccn2)cn1 10.1016/j.bmcl.2010.09.009
59016155 104325 0 None - 1 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 508 5 2 6 4.7 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@]1(O)C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
CHEMBL3109578 104325 0 None - 1 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 508 5 2 6 4.7 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@]1(O)C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
10345602 203179 0 None - 1 Human 5.7 pKi = 5.7 Binding
Inhibitory activity against factor XaInhibitory activity against factor Xa
ChEMBL 493 7 2 4 4.1 CNc1ccc(C#CC[C@H](NS(=O)(=O)c2ccc3c(c2)CCCC3)C(=O)N(C)C2CCCC2)cc1 10.1016/s0960-894x(99)00125-0
CHEMBL7587 203179 0 None - 1 Human 5.7 pKi = 5.7 Binding
Inhibitory activity against factor XaInhibitory activity against factor Xa
ChEMBL 493 7 2 4 4.1 CNc1ccc(C#CC[C@H](NS(=O)(=O)c2ccc3c(c2)CCCC3)C(=O)N(C)C2CCCC2)cc1 10.1016/s0960-894x(99)00125-0
9804049 133040 2 None - 1 Human 8.6 pKi = 8.6 Binding
Inhibitory constant against Protease-activated receptor 1Inhibitory constant against Protease-activated receptor 1
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm0502236
CHEMBL371069 133040 2 None - 1 Human 8.6 pKi = 8.6 Binding
Inhibitory constant against Protease-activated receptor 1Inhibitory constant against Protease-activated receptor 1
ChEMBL 455 3 0 3 6.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3CCCC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/jm0502236
59016136 104327 0 None - 1 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 434 4 1 4 5.1 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](CN)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/ml400452v
CHEMBL3109580 104327 0 None - 1 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 434 4 1 4 5.1 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](CN)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/ml400452v
24878828 187600 3 None - 1 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 420 3 1 4 4.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](N)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm800180e
CHEMBL498785 187600 3 None - 1 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 420 3 1 4 4.8 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](N)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm800180e
90644636 111482 0 None - 1 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 526 3 1 5 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(C(F)(F)F)c5)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
CHEMBL3288435 111482 0 None - 1 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 526 3 1 5 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(C(F)(F)F)c5)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
90644643 111492 0 None - 1 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 459 3 1 6 4.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5ccccn5)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
CHEMBL3288444 111492 0 None - 1 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 459 3 1 6 4.2 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5ccccn5)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
76310287 104322 0 None - 1 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 575 5 1 5 7.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](C(=O)Nc4cccnc4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/ml400452v
CHEMBL3109575 104322 0 None - 1 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 575 5 1 5 7.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](C(=O)Nc4cccnc4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/ml400452v
76310289 104333 0 None - 1 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 531 6 2 5 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](CNC(=O)[C@@H]4CCCN4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/ml400452v
CHEMBL3109586 104333 0 None - 1 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 531 6 2 5 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](CNC(=O)[C@@H]4CCCN4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/ml400452v
52942074 18149 0 None - 1 Human 6.6 pKi = 6.6 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 475 5 1 6 4.9 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccnc2)cn1 10.1016/j.bmcl.2010.09.009
CHEMBL1270840 18149 0 None - 1 Human 6.6 pKi = 6.6 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 475 5 1 6 4.9 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccnc2)cn1 10.1016/j.bmcl.2010.09.009
76310290 104338 0 None - 1 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 512 4 1 4 5.8 CNC(=O)[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1021/ml400452v
CHEMBL3109591 104338 0 None - 1 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 512 4 1 4 5.8 CNC(=O)[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1021/ml400452v
90644642 111491 0 None - 1 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 476 3 1 5 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5ccccc5F)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
CHEMBL3288443 111491 0 None - 1 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 476 3 1 5 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5ccccc5F)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
52946929 18163 0 None - 1 Human 6.6 pKi = 6.6 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 475 5 1 6 4.9 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccncc2)cn1 10.1016/j.bmcl.2010.09.009
CHEMBL1270942 18163 0 None - 1 Human 6.6 pKi = 6.6 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 475 5 1 6 4.9 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccncc2)cn1 10.1016/j.bmcl.2010.09.009
90644639 111486 0 None - 1 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 526 3 1 5 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(C(F)(F)F)c5)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
CHEMBL3288439 111486 0 None - 1 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 526 3 1 5 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(C(F)(F)F)c5)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
90644638 111485 0 None - 1 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 483 3 1 6 4.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(C#N)c5)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
CHEMBL3288438 111485 0 None - 1 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 483 3 1 6 4.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(C#N)c5)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
90644640 111488 0 None - 1 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 476 3 1 5 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(F)c5)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
CHEMBL3288440 111488 0 None - 1 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 476 3 1 5 5.0 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(F)c5)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
127053945 143974 0 None - 1 Human 8.5 pKi = 8.5 Binding
High Throughput Thrombin Receptor Radioligand Binding Assay: Thrombin receptor antagonists were screened using a modification of the thrombin receptor radioligand binding assay of Ahn et al. (Ahn et al., Mol. Pharmacol., 51:350-356 (1997)). The assay was performed in 96 well Nunc plates (Cat. No. 269620) at a final assay volume of 200 μl. Platelet membranes and [3H]haTRAP were diluted to 0.4 mg/ml and 22.2 nM, respectively, in binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.1% BSA). Stock solutions (10 mM in 100% DMSO) of test compounds were further diluted in 100% DMSO. Unless otherwise indicated, 10 μl of diluted compound solutions and 90 μL of radioligand (a final concentration of 10 nM in 5% DMSO) were added to each well, and the reaction was started by the addition of 100 μl of membranes (40 μg protein/well).High Throughput Thrombin Receptor Radioligand Binding Assay: Thrombin receptor antagonists were screened using a modification of the thrombin receptor radioligand binding assay of Ahn et al. (Ahn et al., Mol. Pharmacol., 51:350-356 (1997)). The assay was performed in 96 well Nunc plates (Cat. No. 269620) at a final assay volume of 200 μl. Platelet membranes and [3H]haTRAP were diluted to 0.4 mg/ml and 22.2 nM, respectively, in binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.1% BSA). Stock solutions (10 mM in 100% DMSO) of test compounds were further diluted in 100% DMSO. Unless otherwise indicated, 10 μl of diluted compound solutions and 90 μL of radioligand (a final concentration of 10 nM in 5% DMSO) were added to each well, and the reaction was started by the addition of 100 μl of membranes (40 μg protein/well).
ChEMBL 417 3 1 4 4.5 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)C2[C@@H](C)OC(=O)[C@]2(O)CC1(F)F nan
CHEMBL3906979 143974 0 None - 1 Human 8.5 pKi = 8.5 Binding
High Throughput Thrombin Receptor Radioligand Binding Assay: Thrombin receptor antagonists were screened using a modification of the thrombin receptor radioligand binding assay of Ahn et al. (Ahn et al., Mol. Pharmacol., 51:350-356 (1997)). The assay was performed in 96 well Nunc plates (Cat. No. 269620) at a final assay volume of 200 μl. Platelet membranes and [3H]haTRAP were diluted to 0.4 mg/ml and 22.2 nM, respectively, in binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.1% BSA). Stock solutions (10 mM in 100% DMSO) of test compounds were further diluted in 100% DMSO. Unless otherwise indicated, 10 μl of diluted compound solutions and 90 μL of radioligand (a final concentration of 10 nM in 5% DMSO) were added to each well, and the reaction was started by the addition of 100 μl of membranes (40 μg protein/well).High Throughput Thrombin Receptor Radioligand Binding Assay: Thrombin receptor antagonists were screened using a modification of the thrombin receptor radioligand binding assay of Ahn et al. (Ahn et al., Mol. Pharmacol., 51:350-356 (1997)). The assay was performed in 96 well Nunc plates (Cat. No. 269620) at a final assay volume of 200 μl. Platelet membranes and [3H]haTRAP were diluted to 0.4 mg/ml and 22.2 nM, respectively, in binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.1% BSA). Stock solutions (10 mM in 100% DMSO) of test compounds were further diluted in 100% DMSO. Unless otherwise indicated, 10 μl of diluted compound solutions and 90 μL of radioligand (a final concentration of 10 nM in 5% DMSO) were added to each well, and the reaction was started by the addition of 100 μl of membranes (40 μg protein/well).
ChEMBL 417 3 1 4 4.5 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)C2[C@@H](C)OC(=O)[C@]2(O)CC1(F)F nan
127053948 146306 0 None - 1 Human 8.5 pKi = 8.5 Binding
High Throughput Thrombin Receptor Radioligand Binding Assay: Thrombin receptor antagonists were screened using a modification of the thrombin receptor radioligand binding assay of Ahn et al. (Ahn et al., Mol. Pharmacol., 51:350-356 (1997)). The assay was performed in 96 well Nunc plates (Cat. No. 269620) at a final assay volume of 200 μl. Platelet membranes and [3H]haTRAP were diluted to 0.4 mg/ml and 22.2 nM, respectively, in binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.1% BSA). Stock solutions (10 mM in 100% DMSO) of test compounds were further diluted in 100% DMSO. Unless otherwise indicated, 10 μl of diluted compound solutions and 90 μL of radioligand (a final concentration of 10 nM in 5% DMSO) were added to each well, and the reaction was started by the addition of 100 μl of membranes (40 μg protein/well).High Throughput Thrombin Receptor Radioligand Binding Assay: Thrombin receptor antagonists were screened using a modification of the thrombin receptor radioligand binding assay of Ahn et al. (Ahn et al., Mol. Pharmacol., 51:350-356 (1997)). The assay was performed in 96 well Nunc plates (Cat. No. 269620) at a final assay volume of 200 μl. Platelet membranes and [3H]haTRAP were diluted to 0.4 mg/ml and 22.2 nM, respectively, in binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.1% BSA). Stock solutions (10 mM in 100% DMSO) of test compounds were further diluted in 100% DMSO. Unless otherwise indicated, 10 μl of diluted compound solutions and 90 μL of radioligand (a final concentration of 10 nM in 5% DMSO) were added to each well, and the reaction was started by the addition of 100 μl of membranes (40 μg protein/well).
ChEMBL 488 6 2 5 3.8 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)C2[C@@H](C)OC(=O)[C@]2(C(=O)NCCO)CC1(F)F nan
CHEMBL3925032 146306 0 None - 1 Human 8.5 pKi = 8.5 Binding
High Throughput Thrombin Receptor Radioligand Binding Assay: Thrombin receptor antagonists were screened using a modification of the thrombin receptor radioligand binding assay of Ahn et al. (Ahn et al., Mol. Pharmacol., 51:350-356 (1997)). The assay was performed in 96 well Nunc plates (Cat. No. 269620) at a final assay volume of 200 μl. Platelet membranes and [3H]haTRAP were diluted to 0.4 mg/ml and 22.2 nM, respectively, in binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.1% BSA). Stock solutions (10 mM in 100% DMSO) of test compounds were further diluted in 100% DMSO. Unless otherwise indicated, 10 μl of diluted compound solutions and 90 μL of radioligand (a final concentration of 10 nM in 5% DMSO) were added to each well, and the reaction was started by the addition of 100 μl of membranes (40 μg protein/well).High Throughput Thrombin Receptor Radioligand Binding Assay: Thrombin receptor antagonists were screened using a modification of the thrombin receptor radioligand binding assay of Ahn et al. (Ahn et al., Mol. Pharmacol., 51:350-356 (1997)). The assay was performed in 96 well Nunc plates (Cat. No. 269620) at a final assay volume of 200 μl. Platelet membranes and [3H]haTRAP were diluted to 0.4 mg/ml and 22.2 nM, respectively, in binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.1% BSA). Stock solutions (10 mM in 100% DMSO) of test compounds were further diluted in 100% DMSO. Unless otherwise indicated, 10 μl of diluted compound solutions and 90 μL of radioligand (a final concentration of 10 nM in 5% DMSO) were added to each well, and the reaction was started by the addition of 100 μl of membranes (40 μg protein/well).
ChEMBL 488 6 2 5 3.8 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)C2[C@@H](C)OC(=O)[C@]2(C(=O)NCCO)CC1(F)F nan
127053939 153667 0 None - 1 Human 8.5 pKi = 8.5 Binding
High Throughput Thrombin Receptor Radioligand Binding Assay: Thrombin receptor antagonists were screened using a modification of the thrombin receptor radioligand binding assay of Ahn et al. (Ahn et al., Mol. Pharmacol., 51:350-356 (1997)). The assay was performed in 96 well Nunc plates (Cat. No. 269620) at a final assay volume of 200 μl. Platelet membranes and [3H]haTRAP were diluted to 0.4 mg/ml and 22.2 nM, respectively, in binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.1% BSA). Stock solutions (10 mM in 100% DMSO) of test compounds were further diluted in 100% DMSO. Unless otherwise indicated, 10 μl of diluted compound solutions and 90 μL of radioligand (a final concentration of 10 nM in 5% DMSO) were added to each well, and the reaction was started by the addition of 100 μl of membranes (40 μg protein/well).High Throughput Thrombin Receptor Radioligand Binding Assay: Thrombin receptor antagonists were screened using a modification of the thrombin receptor radioligand binding assay of Ahn et al. (Ahn et al., Mol. Pharmacol., 51:350-356 (1997)). The assay was performed in 96 well Nunc plates (Cat. No. 269620) at a final assay volume of 200 μl. Platelet membranes and [3H]haTRAP were diluted to 0.4 mg/ml and 22.2 nM, respectively, in binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.1% BSA). Stock solutions (10 mM in 100% DMSO) of test compounds were further diluted in 100% DMSO. Unless otherwise indicated, 10 μl of diluted compound solutions and 90 μL of radioligand (a final concentration of 10 nM in 5% DMSO) were added to each well, and the reaction was started by the addition of 100 μl of membranes (40 μg protein/well).
ChEMBL 401 3 0 3 5.4 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)C2C(CC1(F)F)C(=O)O[C@@H]2C nan
CHEMBL3985900 153667 0 None - 1 Human 8.5 pKi = 8.5 Binding
High Throughput Thrombin Receptor Radioligand Binding Assay: Thrombin receptor antagonists were screened using a modification of the thrombin receptor radioligand binding assay of Ahn et al. (Ahn et al., Mol. Pharmacol., 51:350-356 (1997)). The assay was performed in 96 well Nunc plates (Cat. No. 269620) at a final assay volume of 200 μl. Platelet membranes and [3H]haTRAP were diluted to 0.4 mg/ml and 22.2 nM, respectively, in binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.1% BSA). Stock solutions (10 mM in 100% DMSO) of test compounds were further diluted in 100% DMSO. Unless otherwise indicated, 10 μl of diluted compound solutions and 90 μL of radioligand (a final concentration of 10 nM in 5% DMSO) were added to each well, and the reaction was started by the addition of 100 μl of membranes (40 μg protein/well).High Throughput Thrombin Receptor Radioligand Binding Assay: Thrombin receptor antagonists were screened using a modification of the thrombin receptor radioligand binding assay of Ahn et al. (Ahn et al., Mol. Pharmacol., 51:350-356 (1997)). The assay was performed in 96 well Nunc plates (Cat. No. 269620) at a final assay volume of 200 μl. Platelet membranes and [3H]haTRAP were diluted to 0.4 mg/ml and 22.2 nM, respectively, in binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.1% BSA). Stock solutions (10 mM in 100% DMSO) of test compounds were further diluted in 100% DMSO. Unless otherwise indicated, 10 μl of diluted compound solutions and 90 μL of radioligand (a final concentration of 10 nM in 5% DMSO) were added to each well, and the reaction was started by the addition of 100 μl of membranes (40 μg protein/well).
ChEMBL 401 3 0 3 5.4 C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)C2C(CC1(F)F)C(=O)O[C@@H]2C nan
24878982 173002 0 None - 1 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 556 5 0 5 6.9 CCOC(=O)N(C)[C@@H]1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(C(F)(F)F)c3)cn2)C1 10.1021/jm800180e
CHEMBL453277 173002 0 None - 1 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 556 5 0 5 6.9 CCOC(=O)N(C)[C@@H]1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(C(F)(F)F)c3)cn2)C1 10.1021/jm800180e
24878829 171880 0 None - 1 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 512 4 1 4 5.9 CC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1021/jm800180e
CHEMBL447913 171880 0 None - 1 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 512 4 1 4 5.9 CC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1021/jm800180e
76317512 104319 0 None - 1 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 540 5 1 4 6.5 CC(C)NC(=O)[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1021/ml400452v
CHEMBL3109572 104319 0 None - 1 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 540 5 1 4 6.5 CC(C)NC(=O)[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1021/ml400452v
90644644 111493 0 None - 1 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 526 3 1 5 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(C(F)(F)F)c5)cn3)[C@H]12)CNC(=O)O4 10.1021/ml500008w
CHEMBL3288445 111493 0 None - 1 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 526 3 1 5 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(C(F)(F)F)c5)cn3)[C@H]12)CNC(=O)O4 10.1021/ml500008w
76332096 104332 0 None - 1 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 505 6 2 5 4.6 C[C@H](N)C(=O)NC[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
CHEMBL3109585 104332 0 None - 1 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 505 6 2 5 4.6 C[C@H](N)C(=O)NC[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
52940897 18196 0 None - 1 Human 6.5 pKi = 6.5 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 476 5 1 7 4.3 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cncnc2)cn1 10.1016/j.bmcl.2010.09.009
CHEMBL1271252 18196 0 None - 1 Human 6.5 pKi = 6.5 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 476 5 1 7 4.3 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cncnc2)cn1 10.1016/j.bmcl.2010.09.009
58187662 104318 0 None - 1 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 526 5 1 4 6.1 CCNC(=O)[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1021/ml400452v
CHEMBL3109571 104318 0 None - 1 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 526 5 1 4 6.1 CCNC(=O)[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C(F)(F)F)c2)cn1 10.1021/ml400452v
24879035 176207 0 None - 1 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 517 6 2 6 4.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C(N)=O)c2)cn1 10.1021/jm800180e
CHEMBL460583 176207 0 None - 1 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 517 6 2 6 4.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(C(N)=O)c2)cn1 10.1021/jm800180e
76317513 104324 0 None - 1 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 568 4 1 5 5.6 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](C(=O)N4CC[C@H](O)C4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/ml400452v
CHEMBL3109577 104324 0 None - 1 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 568 4 1 5 5.6 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](C(=O)N4CC[C@H](O)C4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/ml400452v
90644645 111494 0 None - 1 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 526 3 1 5 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(C(F)(F)F)c5)cn3)[C@H]12)CNC(=O)O4 10.1021/ml500008w
CHEMBL3288446 111494 0 None - 1 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 526 3 1 5 5.9 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(C(F)(F)F)c5)cn3)[C@H]12)CNC(=O)O4 10.1021/ml500008w
24878930 187727 0 None - 1 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 506 5 0 5 6.0 CCOC(=O)N(C)[C@@H]1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)C1 10.1021/jm800180e
CHEMBL500551 187727 0 None - 1 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 506 5 0 5 6.0 CCOC(=O)N(C)[C@@H]1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)C1 10.1021/jm800180e
44428104 143890 0 None - 1 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 478 4 0 5 5.2 CCOC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)C1 10.1021/jm070704k
CHEMBL390630 143890 0 None - 1 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]haTRAP from PAR1 in human platelet membraneDisplacement of [3H]haTRAP from PAR1 in human platelet membrane
ChEMBL 478 4 0 5 5.2 CCOC(=O)N1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)C1 10.1021/jm070704k
24878874 186816 0 None - 1 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 477 4 2 4 4.8 CNC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/jm800180e
CHEMBL493633 186816 0 None - 1 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 477 4 2 4 4.8 CNC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/jm800180e
24878875 192661 0 None - 1 Human 8.3 pKi = 8.3 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 491 5 2 4 5.2 CCNC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/jm800180e
CHEMBL523854 192661 0 None - 1 Human 8.3 pKi = 8.3 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 491 5 2 4 5.2 CCNC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/jm800180e
52942093 18173 0 None - 1 Human 7.4 pKi = 7.4 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 489 5 1 6 5.2 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cc(C)ccn2)cn1 10.1016/j.bmcl.2010.09.009
CHEMBL1271045 18173 0 None - 1 Human 7.4 pKi = 7.4 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 489 5 1 6 5.2 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cc(C)ccn2)cn1 10.1016/j.bmcl.2010.09.009
90644641 111490 0 None - 1 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 483 3 1 6 4.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(C#N)c5)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
CHEMBL3288442 111490 0 None - 1 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 483 3 1 6 4.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5cccc(C#N)c5)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
24878929 173733 0 None - 1 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 527 4 1 6 6.1 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](NC(=O)OC(C)(C)C)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C#N)c4)cn3)[C@H]12 10.1021/jm800180e
CHEMBL455020 173733 0 None - 1 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 527 4 1 6 6.1 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](NC(=O)OC(C)(C)C)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C#N)c4)cn3)[C@H]12 10.1021/jm800180e
52946957 18205 0 None - 1 Human 7.3 pKi = 7.3 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 505 6 1 7 4.9 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccc(OC)cn2)cn1 10.1016/j.bmcl.2010.09.009
CHEMBL1271353 18205 0 None - 1 Human 7.3 pKi = 7.3 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 505 6 1 7 4.9 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccc(OC)cn2)cn1 10.1016/j.bmcl.2010.09.009
76285459 104328 0 None - 1 Human 8.3 pKi = 8.3 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 492 5 1 5 5.5 COC(=O)NC[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
CHEMBL3109581 104328 0 None - 1 Human 8.3 pKi = 8.3 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 492 5 1 5 5.5 COC(=O)NC[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/ml400452v
86302495 111484 0 None - 1 Human 8.3 pKi = 8.3 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 483 3 1 6 4.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5ccccc5C#N)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
CHEMBL3288437 111484 0 None - 1 Human 8.3 pKi = 8.3 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 483 3 1 6 4.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5ccccc5C#N)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
24878983 170900 0 None - 1 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 504 6 1 6 5.5 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(OC)c2)cn1 10.1021/jm800180e
CHEMBL446344 170900 0 None - 1 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 504 6 1 6 5.5 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(OC)c2)cn1 10.1021/jm800180e
24879038 175151 0 None - 1 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 510 5 1 5 5.8 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cc(F)cc(F)c2)cn1 10.1021/jm800180e
CHEMBL458264 175151 0 None - 1 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 510 5 1 5 5.8 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cc(F)cc(F)c2)cn1 10.1021/jm800180e
24830595 186878 0 None - 1 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 478 4 1 5 5.2 COC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/jm800180e
CHEMBL493983 186878 0 None - 1 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 478 4 1 5 5.2 COC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/jm800180e
24878873 186815 0 None - 1 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 462 4 1 4 5.0 CC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/jm800180e
CHEMBL493632 186815 0 None - 1 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 462 4 1 4 5.0 CC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/jm800180e
24878871 186846 0 None - 1 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 476 5 1 4 5.4 CCC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/jm800180e
CHEMBL493792 186846 0 None - 1 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 476 5 1 4 5.4 CCC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 10.1021/jm800180e
24878872 186991 0 None - 1 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 488 5 1 4 5.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](NC(=O)C4CC4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm800180e
CHEMBL494618 186991 0 None - 1 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 488 5 1 4 5.4 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](NC(=O)C4CC4)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/jm800180e
52949425 18212 0 None - 1 Human 7.2 pKi = 7.2 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 464 5 1 6 5.1 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccoc2)cn1 10.1016/j.bmcl.2010.09.009
CHEMBL1271461 18212 0 None - 1 Human 7.2 pKi = 7.2 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 464 5 1 6 5.1 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccoc2)cn1 10.1016/j.bmcl.2010.09.009
10390481 193816 0 None - 1 Human 5.2 pKi = 5.2 Binding
Inhibitory activity against factor XaInhibitory activity against factor Xa
ChEMBL 481 9 2 4 4.2 CCCc1ccc(S(=O)(=O)N[C@@H](CC#Cc2ccc(NC)cc2)C(=O)N(C)C2CCCC2)cc1 10.1016/s0960-894x(99)00125-0
CHEMBL553108 193816 0 None - 1 Human 5.2 pKi = 5.2 Binding
Inhibitory activity against factor XaInhibitory activity against factor Xa
ChEMBL 481 9 2 4 4.2 CCCc1ccc(S(=O)(=O)N[C@@H](CC#Cc2ccc(NC)cc2)C(=O)N(C)C2CCCC2)cc1 10.1016/s0960-894x(99)00125-0
52948306 17998 0 None - 1 Human 7.1 pKi = 7.1 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 481 5 1 7 4.9 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2nccs2)cn1 10.1016/j.bmcl.2010.09.009
CHEMBL1269815 17998 0 None - 1 Human 7.1 pKi = 7.1 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 481 5 1 7 4.9 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2nccs2)cn1 10.1016/j.bmcl.2010.09.009
59016133 104326 0 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 435 4 1 4 5.1 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](CO)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/ml400452v
CHEMBL3109579 104326 0 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 435 4 1 4 5.1 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](CO)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12 10.1021/ml400452v
10077130 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1016/j.bmcl.2010.09.009
4047 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1016/j.bmcl.2010.09.009
4870 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1016/j.bmcl.2010.09.009
CHEMBL493982 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1016/j.bmcl.2010.09.009
DB09030 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of high affinity TRAP form human platelet PAR1Displacement of high affinity TRAP form human platelet PAR1
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1016/j.bmcl.2010.09.009
10077130 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
4047 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
4870 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
CHEMBL493982 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
DB09030 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/jm800180e
10077130 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400452v
4047 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400452v
4870 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400452v
CHEMBL493982 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400452v
DB09030 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 10.1021/ml400452v
86302515 111489 0 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 483 3 1 6 4.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5ccccc5C#N)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
CHEMBL3288441 111489 0 None - 1 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 receptor in human platelet membranes after 1 hr by scintillation counting analysis
ChEMBL 483 3 1 6 4.7 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@@]4(CC[C@H]3[C@H](/C=C/c3ccc(-c5ccccc5C#N)cn3)[C@H]12)COC(=O)N4 10.1021/ml500008w
24878981 188268 0 None - 1 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 534 7 0 5 6.8 CCCN(C(=O)OCC)[C@@H]1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)C1 10.1021/jm800180e
CHEMBL506808 188268 0 None - 1 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]haTRAP from PAR1 in human plateletsDisplacement of [3H]haTRAP from PAR1 in human platelets
ChEMBL 534 7 0 5 6.8 CCCN(C(=O)OCC)[C@@H]1CC[C@@H]2[C@H](C[C@H]3C(=O)O[C@H](C)[C@H]3[C@H]2/C=C/c2ccc(-c3cccc(F)c3)cn2)C1 10.1021/jm800180e
76332095 104320 0 None - 1 Human 7.0 pKi = 7.0 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 542 6 2 5 5.1 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](C(=O)NCCO)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/ml400452v
CHEMBL3109573 104320 0 None - 1 Human 7.0 pKi = 7.0 Binding
Displacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysisDisplacement of [3H]haTRAP from PAR-1 isolated from human platelets by liquid scintillation counting analysis
ChEMBL 542 6 2 5 5.1 C[C@H]1OC(=O)[C@@H]2C[C@@H]3C[C@H](C(=O)NCCO)CC[C@H]3[C@H](/C=C/c3ccc(-c4cccc(C(F)(F)F)c4)cn3)[C@H]12 10.1021/ml400452v
10077130 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
antagonistantagonist
Drug Central 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C None
4047 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
antagonistantagonist
Drug Central 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C None
4870 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
antagonistantagonist
Drug Central 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C None
CHEMBL493982 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
antagonistantagonist
Drug Central 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C None
DB09030 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
antagonistantagonist
Drug Central 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C None
10077130 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
UnclassifiedUnclassified
Guide to Pharmacology 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 18447380
4047 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
UnclassifiedUnclassified
Guide to Pharmacology 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 18447380
4870 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
UnclassifiedUnclassified
Guide to Pharmacology 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 18447380
CHEMBL493982 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
UnclassifiedUnclassified
Guide to Pharmacology 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 18447380
DB09030 3944 49 None - 1 Human 8.1 pKi = 8.1 Binding
UnclassifiedUnclassified
Guide to Pharmacology 492 5 1 5 5.6 CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C 18447380